var title_f37_24_38272="Tacrolimus: Patient drug information";
var content_f37_24_38272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tacrolimus: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/14/40165?source=see_link\">",
"       Tacrolimus (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/21/341?source=see_link\">",
"       Tacrolimus (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11066 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-880E22D557-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38272=[""].join("\n");
var outline_f37_24_38272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/14/40165?source=related_link\">",
"      Tacrolimus (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/21/341?source=related_link\">",
"      Tacrolimus (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38273="Child humeral fracture";
var content_f37_24_38273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child humeral fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Diaphyseal humeral shaft fracture in 12-year-old boy treated in coaptation splint. B) Union at 2 months with mild varus angulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Beaty JH. Fractures of the proximal humerus and shaft in children, in Eilert RE (ed): Instructional Course Lectures 41. Rosemont, IL, American Academy of Orthopaedic Surgeons, 1992, pp 369-372.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38273=[""].join("\n");
var outline_f37_24_38273=null;
var title_f37_24_38274="Alcaftadine: Drug information";
var content_f37_24_38274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alcaftadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/14/41187?source=see_link\">",
"    see \"Alcaftadine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11392625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lastacaft&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10494066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Mast Cell Stabilizer",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10587133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop into each eye once daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10587132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10587134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11384150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lastacaft&trade;: 0.25% (3 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10587031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10587135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only. Contact lenses should be removed prior to application, and may be reinserted 10 minutes after administration. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip with affected eye(s).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10494068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of itching associated with allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10587039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Ocular reactions (&lt;4%; includes burning, pruritus, irritation, redness, stinging)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Nasopharyngitis (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Influenza (&lt;3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10587035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10587036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses prior to administration and wait 10 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For topical ophthalmic use only. Not for the treatment of contact lens irritation; do not wear contact lens if eye is red. To avoid contamination, do not touch dropper tip to any surface.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10571712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10587032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10587033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no well-controlled studies in pregnant women. Animal studies showed no evidence of teratogenicity or harm to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10587034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lastacaft Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (3 mL): $138.31",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10587105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist and inhibitor of histamine release from mast cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10587125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimal systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~40%; Carboxylic acid (metabolite): ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Non-CYP450 cytosolic enzymes to the active metabolite carboxylic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Carboxylic acid: ~2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15587 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38274=[""].join("\n");
var outline_f37_24_38274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392625\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494066\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587133\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587132\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587134\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671338\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671339\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11384150\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587031\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587135\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587039\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587035\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587036\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298695\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571712\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587032\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587034\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322862\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587105\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10587125\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/14/41187?source=related_link\">",
"      Alcaftadine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38275="Proximal subungual onychomycosis - fingernails";
var content_f37_24_38275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitish discoloration originating under the surface of the proximal nail plate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38275=[""].join("\n");
var outline_f37_24_38275=null;
var title_f37_24_38276="Ileal J pouch construction with inversion of the pouch";
var content_f37_24_38276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Ileal J pouch construction with inversion of the pouch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the completion of the construction of the ileal pouch. The mucosal surface has been inverted back into its normal position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38276=[""].join("\n");
var outline_f37_24_38276=null;
var title_f37_24_38277="Polycystic kidney disease";
var content_f37_24_38277=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Polycystic kidney disease (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/24/38277/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38277/contributors\" id=\"au6973\">",
"       William M Bennett, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38277/contributors\" id=\"au1302\">",
"       Frederic F Rahbari-Oskoui, MD, MSCR",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38277/contributors\" id=\"au1085\">",
"       Arlene B Chapman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/24/38277/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38277/contributors\" id=\"se801\">",
"       Ronald D Perrone, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/24/38277/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38277/contributors\" id=\"de1856\">",
"       Alice M Sheridan, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/24/38277?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      POLYCYSTIC KIDNEY DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Normally, the kidneys filter out excess toxic and waste substances and fluid from the blood. In people with polycystic kidney disease, the kidneys become enlarged with multiple cysts that interfere with normal kidney function. This can sometimes lead to kidney (renal) failure and the need for dialysis or kidney transplantation.",
"    </p>",
"    <p>",
"     There are two major forms of polycystic kidney disease: autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, occurring in approximately 1 in every 400 to 1000 people. Autosomal dominant means that each child of an affected parent has a 50 percent chance of inheriting the disease. In addition, autosomal dominant means that it does not skip generations (ie, if a patient with the disease does not pass it along to one of his or her children, then the disease disappears from that family and grandchildren cannot inherit the disease). However, some patients with ADPKD are not diagnosed during the person's lifetime due to very few symptoms. This means that a family member may have the disease without knowing it.",
"      </li>",
"      <li>",
"       Autosomal recessive polycystic kidney disease (ARPKD) is uncommon and is typically diagnosed in infancy or in utero, although less severe forms may be diagnosed later in childhood or adolescence. The estimated incidence is approximately 1 in 20,000 people. Autosomal recessive means that the mutated gene must be present in both parents, who, because they carry one abnormal gene, are considered carriers. When both parents are carriers (each having one abnormal and one normal gene), then there is a 25 percent chance that each child will inherit an abnormal gene from both parents and have the disease.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The following is a discussion of autosomal dominant polycystic kidney disease, the most common cystic kidney disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GENETICS OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     Approximately 85 percent of families with ADPKD have a mutation in the PKD1 gene located on chromosome 16; these people have PKD1 disease. The remaining 15 percent have a mutation in the PKD2 gene on chromosome 4; this is called PKD2 disease. In some cases, it is not possible to detect which gene is mutated. PKD2 disease is milder; therefore, it often presents later in life, and is sometimes not diagnosed at all. Thus, it is likely that more than 15 percent of all people with ADPKD have PKD2 disease.",
"    </p>",
"    <p>",
"     Kidney failure occurs at an earlier age in PKD1 patients; the average age of end-stage renal disease (that is, needing dialysis or a transplant) is approximately 55 years in PKD1 versus 74 years in PKD2 patients.",
"    </p>",
"    <p>",
"     In approximately 15 percent of cases, ADPKD occurs in people without a family history of the disease (ie, family members have been evaluated and have no evidence for PKD). This is due to the patient having a new (de novo) genetic mutation that was not present in either parent.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CYST FORMATION",
"     </span>",
"    </p>",
"    <p>",
"     ADPKD appears to cause abnormal cell growth that leads to cysts on the kidneys. The basic unit of the kidney is the nephron, with each kidney containing approximately one million nephrons (",
"     <a class=\"graphic graphic_figure graphicRef82497 \" href=\"mobipreview.htm?5/10/5286\">",
"      figure 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_figure graphicRef80336 \" href=\"mobipreview.htm?3/35/3634\">",
"      figure 2",
"     </a>",
"     ). Each nephron consists of a glomerulus, which is a collection of very small arteries intermingled among a series of tubules. The glomeruli and tubules work together to filter waste products from the bloodstream and dispose of them in the urine.",
"    </p>",
"    <p>",
"     In ADPKD, cyst formation begins as an expansion, or ballooning, of a tubule in a small proportion of nephrons. The cyst subsequently enlarges, usually due to fluid secretion into the cyst. The cells making up the cysts multiply, causing the cyst to grow even larger. Cysts may also grow in other organs, including the liver, pancreas, thyroid gland,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     spleen.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      EFFECTS ON THE KIDNEY",
"     </span>",
"    </p>",
"    <p>",
"     ADPKD often leads to progressive kidney (renal) failure, due in large part to continued enlargement of the cysts and replacement of normal kidney tissue. Other problems involving the kidney can occur, including high blood pressure, kidney infection, blood in the urine (hematuria), and kidney stones. Flank and abdominal pain are also common",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Kidney failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Kidney (renal) failure severe enough to require dialysis or kidney transplantation is called end-stage renal disease (ESRD). ADPKD rarely leads to ESRD in early childhood; it most commonly occurs in middle age or later in life. The likelihood of requiring dialysis in people with ADPKD is estimated at less than 2 percent in people under age of 40, increasing to 50 to 75 percent by age 70 to 75. Not all patients with ADPKD develop kidney failure, particularly those with PKD2. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of developing kidney failure in ADPKD depends upon a number of factors. As an example, having enlarged kidneys is the most reliable predictor for developing renal failure in patients with ADPKD. In addition, factors that increase the risk of developing kidney failure include being male, having PKD1 disease, having episodes of visible blood or detectable protein in the urine, or having high blood pressure (particularly before age 35). Enlarged kidneys or a high cyst burden is associated with all of these complications and is the most important risk factor for progression to renal failure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      High blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;High blood pressure is a common feature of ADPKD, occurring in 60 to 70 percent of patients with normal kidney function by the age of 29. Over 90 percent of patients will have high blood pressure by the time they reach end-stage renal failure. Men have higher blood pressures than women, and high blood pressure is associated with bigger kidneys and faster rates of kidney growth. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Kidney infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 30 to 50 percent of people with ADPKD will have at least one cyst infection during their lifetime. The primary symptoms of a kidney infection in people with ADPKD are fever and flank pain. The infection may be of the kidney or of a cyst. Not all antibiotics work well if the infection is in the cyst. Since it is not easy to tell where the infection is, most physicians will use an oral antibiotic that can penetrate into the cyst cavity. Some people with high fevers or severe symptoms need to be treated with intravenous antibiotics. The duration of treatment for a cyst or kidney infection is typically longer than with a routine kidney infection in someone without ADPKD. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Blood in the urine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hematuria (blood in the urine) occurs in 35 to 50 percent of people with ADPKD and may be the first sign of the disease. With hematuria, the urine may be a pink or red color. Repeated episodes of hematuria are common. Hematuria is associated with increased kidney size and a faster rate of kidney growth. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Hematuria is usually caused by bleeding into a cyst that communicates with the urinary tract and bladder. This can occur as a result of strenuous activity, and bleeding can cause pain in the side of the low back (called flank pain). Patients with ADPKD can also develop kidney stones, which can cause hematuria and flank pain.",
"    </p>",
"    <p>",
"     Hematuria related to bleeding cysts generally stops within two to seven days. The usual treatment includes bed rest and increasing fluids until the bleeding stops. If bleeding does not stop with bed rest and increased fluids, a procedure to stop the bleeding may be required. Bleeding into a cyst that does not communicate with the urinary system may not produce visible blood; in this setting, patients typically have localized flank pain and, in some cases, a low grade fever.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Kidney stones",
"     </span>",
"     &nbsp;&mdash;&nbsp;Kidney stones occur in up to 25 percent of people with ADPKD. Kidney stones may cause pain, or sometimes they can block the flow of urine without symptoms.",
"    </p>",
"    <p>",
"     Treating kidney stones that block urine flow is extremely important in patients with ADPKD. If the blockage is not relieved, the function in that kidney may be lost. Relieving the blockage may require the help of a urologist. The cysts make it harder to surgically remove the stone or use shock waves to break up the stone (extracorporeal shock-wave lithotripsy or ESWL). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Flank and abdominal pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with ADPKD often develop flank and abdominal pain that is not related to infection, bleeding into a cyst, or a kidney stone. The pain is often dull and persistent and is thought to be caused by stretching of the wall of a cyst or pressure on other organs when the kidneys",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     liver are very large. This is the most common symptom in ADPKD patients. In contrast, pain that begins suddenly is more likely to be caused by bleeding into or infection of a cyst, twisting of the kidney, or a kidney stone.",
"    </p>",
"    <p>",
"     No specific treatment is required in most people with dull or persistent flank and abdominal pain; pain medications such as acetaminophen are often recommended. The use of nonsteroidal antiinflammatory drugs (NSAIDs), such as ibuprofen or naproxen, is",
"     <strong>",
"      not",
"     </strong>",
"     recommended, although people with ADPKD may, on occasion, benefit from these medications and should speak to their healthcare provider about the risks and benefits of NSAIDs before using them. NSAIDs are",
"     <strong>",
"      not",
"     </strong>",
"     recommended for patients with ADPKD when kidney function is reduced or when they need to be used on a long-term basis to treat chronic pain basis.",
"    </p>",
"    <p>",
"     Some people have persistent pain that is severe enough to limit their daily activities. Severe pain is usually evaluated with renal imaging to see if a large cyst is present in the area of pain. If so, a needle through the skin can be used for drainage of the cyst. This needs to be done with appropriate imaging and a radiologist who is trained in this type of technique. Most people have significant relief of pain after drainage. However, pain can recur and surgery is sometimes required to relieve chronic pain that interferes with quality of life.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      COMPLICATIONS OUTSIDE OF THE KIDNEY",
"     </span>",
"    </p>",
"    <p>",
"     A variety of complications outside the kidney can occur in people with ADPKD. These complications can involve a number of systems, including the liver, vascular system, and the connective tissue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Intracranial aneurysm",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most serious possible complication of polycystic kidney disease is a cerebral or brain aneurysm (a bulging blood vessel due to weakening of the blood vessel wall). Aneurysms can rupture, causing bleeding into the brain (subarachnoid hemorrhage). If not treated before the aneurysm ruptures, this can lead to irreversible brain damage or death. Aneurysm rupture occurs most often in people with larger aneurysms (&gt;10 mm). The most common symptom of subarachnoid hemorrhage is a severe headache that begins suddenly, often with a pop, frequently with nausea and vomiting. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=see_link\">",
"      \"Patient information: Hemorrhagic stroke treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Approximately 5 to 7 percent of young adults with ADPKD may have brain aneurysms, and the frequency increases to 12 to 15 percent if someone else in the patient&rsquo;s family has had an intracranial aneurysm. Compared with the general population, the risk of developing an aneurysm in ADPKD is approximately fivefold greater. People with a first degree relative with a history of intracranial aneurysm or subarachnoid hemorrhage are at the highest risk of forming an aneurysm.",
"    </p>",
"    <p>",
"     Early detection (before symptoms occur) of intracranial aneurysms is recommended in people who are at high-risk. Screening (looking for an aneurysm before it ruptures) is generally performed with magnetic resonance angiography (MRA) or if not available, a CT scan.",
"    </p>",
"    <p>",
"     At present, routine screening is recommended",
"     <strong>",
"      only",
"     </strong>",
"     for high-risk patients, such as those with a previous rupture, a positive family history of a brain hemorrhage or stroke, warning symptoms (eg, unusual headaches), or a person with a high-risk occupation (eg, airline pilot), in whom a loss of consciousness would place the patient or others at extreme risk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Liver cysts",
"     </span>",
"     &nbsp;&mdash;&nbsp;Liver cysts occur commonly in people with ADPKD. More than 85 percent of patients will have liver cysts by age 30.",
"    </p>",
"    <p>",
"     Liver cysts become larger and more numerous as patients age. In addition, women have larger liver cysts than men, particularly women who have had multiple pregnancies or who have taken oral contraceptive pills or hormone replacement therapy for prolonged periods of time.",
"    </p>",
"    <p>",
"     Most people with liver cysts have no symptoms and have normal or near-normal liver function. However, some people develop abdominal fullness, early satiety, difficulty breathing, or less commonly, pain (which may require drainage of the cyst if it is persistent and severe)",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     cyst infection (which requires antibiotic therapy and, in some cases, drainage).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Heart valve disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Abnormalities of the heart valves are detected in up to 25 percent of patients with ADPKD. Most patients with heart valve disease have no symptoms and require no treatment. However, in very rare cases, the valve disease may progress over time and become severe enough to require valve replacement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Abdominal wall hernias",
"     </span>",
"     &nbsp;&mdash;&nbsp;A hernia is an area of weakness in a muscle. The area may protrude if the organs behind the muscle press against the area of weakness, especially as a person increases the pressure in their abdomen (such as during a cough or while carrying a heavy package). Abdominal wall hernias are relatively frequent, affecting approximately 45 percent of people with ADPKD. Abdominal wall hernias are usually located on the midline just above the belly button (ventral) or in the groin (inguinal) areas.",
"    </p>",
"    <p>",
"     Surgery is the best treatment for abdominal wall hernias, but not all hernias require surgical repair. Small hernias may be monitored over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      POLYCYSTIC KIDNEY DISEASE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     It is usually easy to diagnose autosomal dominant polycystic kidney disease (ADPKD) in people who develop flank or abdominal pain and in those who have a family history of ADPKD. An imaging study, such as an ultrasound, is recommended as the first diagnostic test and may reveal multiple cysts on both kidneys. Cysts may also be seen in the liver, pancreas, and spleen.",
"    </p>",
"    <p>",
"     In people without a family history, ADPKD may be more difficult to diagnose. The diagnosis of polycystic kidney disease may first be suspected based on an imaging test, such as an ultrasound, performed for some other reason. The family history may be negative either because family members developed symptoms at a later age and died of other causes before ADPKD was diagnosed, or because a new mutation has occurred (which is the case in 15 percent of patients with ADPKD). If the family history is negative, the diagnosis of ADPKD can be made using information on the number of cysts present in the kidneys in relation to the patient&rsquo;s age (as described above), and the presence of other clinical findings (such as liver cysts). Rarely, in cases where the imaging diagnosis is not straightforward, genetic testing would need to be performed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      POLYCYSTIC KIDNEY DISEASE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Autosomal dominant polycystic kidney disease (ADPKD) leads to kidney failure due to continued enlargement of the cysts in the majority of patients, typically by the sixth decade of life. Treatment focuses on slowing the progression of kidney failure and treating the associated features of the disease, such as kidney infections or kidney stones and flank or abdominal pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      High blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treating high blood pressure can have a dual benefit in people with polycystic kidney disease because it can help prevent cardiovascular disease and also reduce the likelihood of developing kidney failure.",
"    </p>",
"    <p>",
"     Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) can effectively lower blood pressure in most people with ADPKD. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Dietary protein restriction",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are conflicting findings on the benefit of a low protein diet in people with ADPKD. Given the limited evidence of benefit, we do",
"     <strong>",
"      not",
"     </strong>",
"     recommend restricting protein intake below 0.8",
"     <span class=\"nowrap\">",
"      g/kg",
"     </span>",
"     of body weight per day. In this example, a 180 pound (82 kg) man would need approximately 66 grams of protein per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      End-stage renal disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with ADPKD who progress to end-stage renal disease require either dialysis or kidney transplantation. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with ADPKD who require dialysis are usually treated with hemodialysis. People with ADPKD who have hemodialysis appear to survive longer than people with other types of end-stage renal disease.",
"    </p>",
"    <p>",
"     Peritoneal dialysis, a form of dialysis that involves infusing fluid into the abdomen and then draining the fluid, is less commonly performed due to the presence of the enlarged kidneys, but can be considered on an individual basis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"      \"Patient information: Hemodialysis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The prognosis after kidney transplantation is usually excellent.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      POLYCYSTIC KIDNEY DISEASE SCREENING",
"     </span>",
"    </p>",
"    <p>",
"     Screening tests are available to relatives of a person with autosomal dominant polycystic kidney disease (ADPKD). The decision to have a screening test for ADPKD should be discussed with an experienced healthcare provider, and should include a full discussion of the potential risks and benefits.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Screening in children",
"     </span>",
"     &nbsp;&mdash;&nbsp;The chance of a child being affected by ADPKD when one parent is affected is one in two (50 percent chance). Although a child of a person with ADPKD can be screened for the disease before symptoms develop, screening is",
"     <strong>",
"      not",
"     </strong>",
"     usually recommended during childhood unless the child has signs or symptoms of the disease. Affected children may not yet have cysts that are visible by ultrasound; even if cysts were seen, learning of the diagnosis during childhood would not change the child's medical treatment but could potentially cause the child to worry. However, children with an affected parent should see a physician regularly and have their blood pressure monitored and a urinalysis performed. Children should also be followed for kidney infections, blood in the urine, kidney stones, and the presence of hernias.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Screening for polycystic kidney disease in adults",
"     </span>",
"     &nbsp;&mdash;&nbsp;An adult with a family history of polycystic kidney disease who has no symptoms may consider being screened for the disease. It is important to realize that, at present, there are no curative or preventative treatments for ADPKD. However, a number of novel treatments are being tested including increased fluid intake that may have a beneficial effect on the rate of cyst growth, and therefore kidney size. Importantly, being diagnosed with PKD could potentially affect a person's ability to obtain life insurance. As in children, monitoring for high blood pressure should be performed regularly in adults at risk of having ADPKD.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;When screening is performed, an ultrasound of the kidneys is the most commonly used test. Imaging tests such as ultrasound can be used to screen for ADPKD. The following are ultrasound criteria used to diagnose ADPKD when it is unknown whether the affected parent has PKD1 or PKD2:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In patients 15 to 39 years of age, at least three cysts (in one or two kidneys) must be seen with ultrasound.",
"      </li>",
"      <li>",
"       In patients aged 40 to 59, at least two cysts must be seen in each kidney with ultrasound.",
"      </li>",
"      <li>",
"       In patients over age 60, four or more cysts must be seen in each kidney with ultrasound.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In someone older than 40 years, a negative ultrasound usually means that the person does",
"     <strong>",
"      not",
"     </strong>",
"     have ADPKD.",
"    </p>",
"    <p>",
"     Sometimes, the affected parent is known to have either PKD1 or PKD2. If the parent has PKD2, then a negative imaging study (ie, no cysts in the kidneys) rules out the diagnosis if the person is older than 40 years. If the parent has PKD1, then a negative imaging study rules out the diagnosis if the person is older than 30 years.",
"    </p>",
"    <p>",
"     As an example, assume a 35 year old man has a parent with ADPKD, but it is not known whether the parent has PKD1 or PKD2. He undergoes screening ultrasound, which is normal. The normal ultrasound means that he does not have PKD1, but he could still have PKD2 since PKD2 is a more mild disease that may produce cysts later in life. However, people with PKD2 have a lower risk of kidney failure compared with people who have PKD1 and typically develop kidney failure more than 20 years later than patients with PKD1. This news may be reassuring to some people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Genetic testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Genetic tests can also be done to screen for PKD1 or PKD2 mutations, although the use of genetic tests is limited by their cost and the test's inability to make a diagnosis in 15 percent of cases. Genetic tests may be used for:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A young adult with a family history of ADPKD and a negative ultrasound who is a potential kidney donor",
"      </li>",
"      <li>",
"       A person whose ADPKD diagnosis is not certain based upon imaging tests",
"      </li>",
"      <li>",
"       A person younger than 30 years of age with a family history of ADPKD and a negative ultrasound who is planning to start a family",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Cyst formation in ADPKD may begin in the fetus. However, the disease does not usually cause symptoms in young children. Genetic testing can be done during pregnancy to determine if the baby is affected, although it is not recommended for several important reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The test may fail to identify ADPKD when it is present.",
"      </li>",
"      <li>",
"       Some people with gene mutations will never develop symptoms of ADPKD.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site",
"     <span class=\"nowrap\">",
"      (www.uptodate.com/patients).",
"     </span>",
"     Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498743335\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31055642\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=see_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/46/25315?source=see_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/15/12531?source=see_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31055649\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=see_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=see_link\">",
"      Patient information: Diverticular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=see_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9433?source=see_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34009?source=see_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=see_link\">",
"      Hypertension in autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15737?source=see_link\">",
"      Prenatal sonographic diagnosis of cystic renal disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=see_link\">",
"      Screening for intracranial aneurysm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"      Urinary tract infection in autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       PKD Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.pkdcure.org/\">",
"      www.pkdcure.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Kidney Fund",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.akfinc.org/\">",
"      www.akfinc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Association of Kidney Patients",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aakp.org/\">",
"      www.aakp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/24/38277/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/24/38277?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38277/abstract/1\">",
"      Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38277/abstract/2\">",
"      Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38277/abstract/3\">",
"      Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38277/abstract/4\">",
"      Bennett WM. V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment. J Am Soc Nephrol 2005; 16:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38277/abstract/5\">",
"      Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20:205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f37_24_38277=[""].join("\n");
var outline_f37_24_38277=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           POLYCYSTIC KIDNEY DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GENETICS OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CYST FORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           EFFECTS ON THE KIDNEY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           COMPLICATIONS OUTSIDE OF THE KIDNEY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           POLYCYSTIC KIDNEY DISEASE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           POLYCYSTIC KIDNEY DISEASE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           POLYCYSTIC KIDNEY DISEASE SCREENING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/10/5286\" title=\"figure 1\">",
"           Nephron anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/35/3634\" title=\"figure 2\">",
"           Kidney anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38278="Isoniazid: Pediatric drug information";
var content_f37_24_38278=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoniazid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"    see \"Isoniazid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/5/8277?source=see_link\">",
"    see \"Isoniazid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Isotamine&reg;;",
"     </li>",
"     <li>",
"      PMS-Isoniazid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"      see \"Isoniazid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.M.;",
"     <b>",
"      Note:",
"     </b>",
"     Recommendations often change due to resistant strains and newly developed information; consult",
"     <i>",
"      MMWR",
"     </i>",
"     for current CDC recommendations. Intramuscular injection is available for patients who are unable to either take or absorb oral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children &lt;40 kg,  and Adolescents &le;14 years and &lt;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of active TB infection: CDC Recommendations: 10-15 mg/kg/day once daily (maximum dose: 300 mg/day)",
"     <b>",
"      or",
"     </b>",
"     20-30 mg/kg/dose (maximum dose: 900 mg) twice weekly as part of a multidrug regimen (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of latent TB infection (LTBI): 10-20 mg/kg/day given once daily (maximum dose: 300 mg/day)",
"     <b>",
"      or",
"     </b>",
"     20-40 mg/kg/dose (maximum dose: 900 mg) twice weekly; treatment duration: 9 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary prophylaxis for TB in HIV-exposed/positive patients: 10-15 mg/kg/day once daily (maximum dose: 300 mg/day)",
"     <b>",
"      or",
"     </b>",
"     20-30 mg/kg/dose (maximum dose: 900 mg) twice weekly; treatment duration: 9 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents &gt;40 kg or Adolescents &ge;15 years:  See Adult Dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of latent tuberculosis infection (LTBI):",
"     </b>",
"     Oral, I.M.: CDC recommendations: 5 mg/kg (maximum: 300 mg/dose) once daily or 15 mg/kg (maximum: 900 mg/dose) twice weekly by directly observed therapy (DOT) for 6-9 months in patients who do not have HIV infection (9 months is optimal, 6 months may be considered to reduce costs of therapy) and 9 months in patients who have HIV infection. Extend to 12 months of therapy if interruptions in treatment occur (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of active TB infection (drug susceptible):",
"     </b>",
"     Oral, I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Daily therapy: CDC recommendations: 5 mg/kg/day once daily (usual dose: 300 mg/day) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Directly observed therapy (DOT): CDC recommendations: 15 mg/kg (maximum: 900 mg/dose) twice weekly or 3 times/week;",
"     <b>",
"      Note:",
"     </b>",
"     CDC guidelines state that once-weekly therapy (15 mg/kg/dose) may be considered, but only after the first 2 months of initial therapy in HIV-negative patients, and only in combination with rifapentine (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment may be defined by the number of doses administered (eg, \"6-month\" therapy involves 182 doses of INH and rifampin, and 56 doses of pyrazinamide). Six months is the shortest interval of time over which these doses may be administered, assuming no interruption of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Concomitant administration of 10-50 mg/day pyridoxine is recommended in malnourished patients or those prone to neuropathy (eg, alcoholics, patients with diabetes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment needed in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 100 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 50 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer 1 hour before or 2 hours after meals with water; administration of isoniazid syrup has been associated with diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M.: Administer I.M. when oral therapy is not possible; injection solution pH: 6-7",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; avoid freezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible mycobacterial infection due to",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     and prophylactically to those individuals exposed to tuberculosis (FDA approved in infant, children, and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3271336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydra [Japan] may be confused with Hydrea brand name for hydroxyurea [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F184829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, palpitation, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, encephalopathy, fever, lethargy, memory impairment, psychosis, seizure, slurred speech, toxic encephalopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Flushing, rash (morbilliform, maculopapular, pruritic, or exfoliative)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hyperglycemia, metabolic acidosis, pellagra, pyridoxine deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, epigastric distress, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia (sideroblastic, hemolytic, or aplastic), eosinophilia,  thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubinuria, hepatic dysfunction, hepatitis (may involve progressive liver damage; risk increases with age), hyperbilirubinemia, jaundice, LFTs mildly increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hyper-reflexia, paresthesia, peripheral neuropathy (dose-related incidence), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, loss of vision, optic neuritis/atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lupus-like syndrome, lymphadenopathy, rheumatic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isoniazid or any component; acute liver disease; previous history of hepatic damage during isoniazid therapy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal impairment. Use with caution and carefully monitor patients who ingest alcohol daily, are &gt;35 years of age, currently use other medications that may interact with isoniazid, have/are at risk for peripheral neuropathy, are pregnant, are women belonging to minority groups, or have a history of adverse reactions to latent TB infection (LTBI) medications. Oral solutions may contain sorbitol (&ge;70%) which may cause diarrhea.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe and sometimes fatal hepatitis may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; usually occurs within the first 3 months of treatment, although may develop even after many months of treatment. The risk of developing hepatitis is age-related, although isoniazid-induced hepatotoxicity has been reported in children; daily ethanol consumption may also increase the risk. Patients must report any prodromal symptoms of hepatitis, such as fatigue, weakness, malaise, anorexia, nausea, abdominal pain, jaundice, or vomiting. Patients should be instructed to immediately inform prescriber and discontinue isoniazid therapy if any of these symptoms occur, even if clinical evaluation has yet to be conducted.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (moderate), CYP2C19 (strong), CYP2C9 (weak), CYP2D6 (moderate), CYP2E1 (moderate), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2E1 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Isoniazid may enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Isoniazid may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Isoniazid may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorzoxazone: Isoniazid may decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: CYP2E1 Inhibitors (Moderate) may decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethionamide: May increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Isoniazid may increase the serum concentration of Fosphenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Isoniazid may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Isoniazid may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Isoniazid may increase the serum concentration of Phenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Isoniazid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate and extent of isoniazid absorption may be reduced when administered with food; avoid foods with histamine or tyramine (cheese, broad beans, dry sausage, salami, nonfresh meat, liver pate, soya bean, liquid and powdered protein supplements, wine); increase dietary intake of folate, niacin, magnesium, and pyridoxine; the American Academy of Pediatrics recommends that pyridoxine supplementation (1-2 mg/kg/day) should be administered to patients with nutritional deficiencies including all symptomatic HIV-infected children, children or adolescents on meat- or milk-deficient diets, breast-feeding infants and their mothers, pregnant adolescents and women, and those predisposed to neuritis to prevent peripheral neuropathy.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Isoniazid was found to be embryocidal in animal studies; teratogenic effects were not noted. Isoniazid crosses the human placenta. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. The CDC recommends isoniazid as part of the initial treatment regimen (CDC, 2003). Pyridoxine supplementation is recommended (25 mg/day).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests; monitor for prodromal signs of hepatitis; ophthalmologic exam; chest x-ray",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     LTBI therapy: American Thoracic Society/Centers for Disease Control (ATS/CDC) recommendations: Monthly clinical evaluation, including brief physical exam for adverse events. Baseline serum AST or ALT and bilirubin should be considered for patients at higher risk for adverse events (eg, history of liver disease, chronic ethanol use, HIV-infected patients, women who are pregnant or postpartum &le;3 months, older adults with concomitant medications or diseases). Routine, periodic monitoring is recommended for any patient with an abnormal baseline or at increased risk for hepatoxicity.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits mycolic acid synthesis, resulting in disruption of the bacterial cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, I.M.: Rapid and complete; food reduces rate and extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; distributes into most body tissues and fluids, including the CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By the liver to acetylisoniazid with decay rate determined genetically by acetylation phenotype; undergoes further hydrolysis to isonicotinic acid and acetylhydrazine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: May be prolonged in patients with impaired hepatic function or severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fast acetylators: 30-100 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow acetylators: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 75% to 95% excreted in urine as unchanged drug and metabolites; small amounts excreted in feces and saliva",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/5/8277?source=see_link\">",
"      see \"Isoniazid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If any prodromal symptoms of hepatitis occur (abdominal pain, fatigue, weakness, tiredness, nausea, lack of appetite, vomiting, dark urine, or yellowing of the skin or eyes), discontinue therapy and report to your prescriber. Report any burning, tingling, or numbness in the extremities; avoid alcohol.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F11246195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prophylactic use is recommended for patients with &ge;5 mm positive tuberculin skin test reaction who are HIV-positive or persons with risk factors for HIV infection; close contacts of newly diagnosed person with infectious tuberculosis; persons with fibrotic changes on chest XR suggestive of previous tuberculosis or inadequate treatment; persons with organ transplants or receiving immunosuppressive therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prophylactic use is recommended for patients with &ge;10 mm positive tuberculin skin test reaction who recently arrived (&lt;5 years) from endemic areas; substance abusers; residents/employees of healthcare, correctional, or long-term care facilities; children &lt;4 years; children and adolescents exposed to high-risk adults; persons at high-risk due to certain medical conditions like silicosis, diabetes mellitus, leukemia, end-stage renal disease, chronic malabsorption syndrome, cancer of head and neck, intestinal bypass or gastrectomy, and low body weight",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F184761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (50 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be made with tablets, purified water, and sorbitol. Crush ten 100 mg tablets in a mortar and reduce to a fine powder. Add 10 mL of purified water and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a graduated cylinder, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 100 mL (do not use sugar-based solutions). Label \"shake well\" and \"refrigerate\". Stable for 21 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21:9-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/1728006/pubmed\" id=\"1728006\" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for Latent Tuberculosis Infection - United States, 2004-2008,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(8):224-9. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/20203555 /pubmed\" id=\"20203555 \" target=\"_blank\">",
"        20203555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Treatment of Tuberculosis,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-11):1-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection-United States, 2003,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2003, 52(31):735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/12904741 /pubmed\" id=\"12904741 \" target=\"_blank\">",
"        12904741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1988, 35(3):441-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/3287309/pubmed\" id=\"3287309\" target=\"_blank\">",
"        3287309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(11):785-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/2124671/pubmed\" id=\"2124671\" target=\"_blank\">",
"        2124671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Scoy RE and Wilkowske CJ, &ldquo;Antituberculous Agents: Isoniazid, Rifampin, Streptomycin, Ethambutol, and Pyrazinamide,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1983, 58(4):233-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/24/38278/abstract-text/6834890 /pubmed\" id=\"6834890 \" target=\"_blank\">",
"        6834890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13393 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38278=[""].join("\n");
var outline_f37_24_38278=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708956\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048065\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048057\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184755\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184739\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048069\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048061\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3271336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184829\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048056\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048055\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184748\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048074\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184751\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184767\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048054\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048071\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048063\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11246195\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184761\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13393|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=related_link\">",
"      Isoniazid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/5/8277?source=related_link\">",
"      Isoniazid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38279="Aortic valve sclerosis";
var content_f37_24_38279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aortic valve sclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     David S Siscovick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38279/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/24/38279/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve thickening (sclerosis) without stenosis is common in elderly adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/1\">",
"     1",
"    </a>",
"    ]. It is often detected either as a systolic murmur on physical examination or on echocardiography performed for some other reason. Aortic valve sclerosis is important clinically because it can progress to aortic stenosis and is a marker for increased cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve sclerosis is defined by the following features on echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irregular leaflet thickening and focal increased echogenicity (calcification) are the hallmarks of the condition. Focal areas of thickening are typically seen on the aortic side of the valve in the center of the valve cusp, rather than at the leaflet edges, often initially involving the noncoronary cusp.",
"     </li>",
"     <li>",
"      Leaflet excursion is not impaired and the commissures are not fused. Peak continuous wave Doppler flow velocities across the valve are normal or only minimally elevated (&lt;2.0",
"      <span class=\"nowrap\">",
"       m/sec).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduction in leaflet mobility, increase in leaflet calcification, and increase in aortic transvalvular Doppler flow velocities are signs of progression from aortic sclerosis to aortic stenosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mitral annular calcification frequently accompanies aortic valve sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=see_link&amp;anchor=H14#H14\">",
"     \"Echocardiographic evaluation of the mitral valve\", section on 'Mitral annular calcification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic sclerosis is an asymptomatic condition that is generally detected either as a systolic ejection murmur on physical examination or as an incidental finding on echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic sclerosis, in the absence of stenosis, may be associated with a midsystolic ejection murmur, which is usually best heard over the right second interspace. In general, the murmur is brief and not very loud. A normal carotid pulse and normal S2 suggest the absence of aortic stenosis (",
"    <a class=\"graphic graphic_figure graphicRef61744 \" href=\"mobipreview.htm?16/62/17391\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many patients with aortic sclerosis have no murmur on physical examination. In such patients, the diagnosis is usually made incidentally on echocardiography performed for other indications.",
"   </p>",
"   <p>",
"    The physical examination is neither sensitive nor specific for excluding aortic valve obstruction. Thus, if cardiac symptoms are present, echocardiography should be performed to evaluate the severity of valve disease and determine whether progression to aortic stenosis or other cardiac abnormalities are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosis of the aortic valve is common in the elderly, being found in 26 to 29 percent of individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/1-3,7\">",
"     1-3,7",
"    </a>",
"    ], although the rate may be higher in selected individuals of the same age such as those presenting to the emergency department with chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/8\">",
"     8",
"    </a>",
"    ]. The prevalence in the elderly is also higher in older subjects: 35 percent between 75 and 84 years of age, and 48 to 50 percent of those over age 80 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Although less common, aortic valve sclerosis also occurs in middle-aged patients (eg, prevalence of 8 percent among African-Americans in the Atherosclerosis Risk in Communities Study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/10\">",
"     10",
"    </a>",
"    ]. In the Monica-KORA among 935 European adults ages 35 to 84 years, the prevalence of aortic sclerosis increased across the age distribution from 7 percent in those age 35 to 44 years to 65 percent in those age 75 to 84 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Valvular sclerosis is more common in patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/12\">",
"     12",
"    </a>",
"    ] and in those with end-stage renal disease on maintenance dialysis. Among dialysis patients, aortic and mitral valve sclerosis have been noted in 55 to 69 percent and 40 to 60 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. When adjusted for other cardiovascular risk factors, moderate chronic kidney disease is not significantly associated with aortic valve calcification, but is associated with mitral annular calcification among patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/59/954?source=see_link&amp;anchor=H7#H7\">",
"     \"Valvular heart disease in patients with end-stage renal disease\", section on 'Valvular thickening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/59/954?source=see_link&amp;anchor=H3#H3\">",
"     \"Valvular heart disease in patients with end-stage renal disease\", section on 'Valvular and annular calcification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early lesion of aortic valve sclerosis involves an active process with some similarities to atherosclerosis. The following findings have been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/16-23\">",
"     16-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal areas of accumulation of apolipoproteins B, (a) and E, consistent with accumulation of low density lipoprotein and lipoprotein(a).",
"     </li>",
"     <li>",
"      Inflammation as evidenced by macrophage and T lymphocyte infiltration on histology and increased fluorodeoxyglucose uptake on positron emission tomography (PET) scanning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence of early valve calcification, including expression of osteopontin and other proteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for a genetic component to the development of calcific aortic valve disease comes from family studies in France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/24\">",
"     24",
"    </a>",
"    ] and genome wide linkage mapping in the Hypertension Genetic Epidemiology Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, a genome-wide association study in 6942 subjects identified a single-nucleotide polymorphism (SNP) located in an intron of the lipoprotein(a) (LPA) gene (rs10455872) that was significantly associated with the presence of aortic valve calcification (odds ratio per allele, 2.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/26\">",
"     26",
"    </a>",
"    ]. The association was confirmed in three additional cohorts of diverse ancestry. This same polymorphism was associated with circulating LPA levels, and with the development of aortic stenosis, supporting a potential causal role for Lp(a).",
"   </p>",
"   <p>",
"    The pathobiology of calcific valve disease is an area of active research and our understanding of the cellular and molecular mechanisms of disease is currently in flux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/21,27\">",
"     21,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Relation to atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these histopathologic observations, aortic sclerosis has been correlated with clinical risk factors for atherosclerosis, including smoking, hypertension, hyperlipidemia, and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/3,10,12,28-33\">",
"     3,10,12,28-33",
"    </a>",
"    ]. Despite these associations, it is not clear if lipid lowering would be beneficial. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Risk factor modification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following echocardiographic studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from the Cardiovascular Health Study (CHS) evaluated 5176 patients &ge;65 years of age: 26 percent had aortic valve sclerosis with visually apparent leaflet thickening",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcification; and 2 percent had aortic stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/3\">",
"       3",
"      </a>",
"      ]. Multivariate analysis found significant correlations of aortic valve disease with age, male gender, lipoprotein(a), LDL cholesterol, hypertension, and smoking.",
"     </li>",
"     <li>",
"      In the Monica-KORA study among 935 European adults ages 35 to 84 years, the presence of echocardiographic aortic valve calcification was related to several clinical factors measured at baseline examination 10 years before the assessment of aortic valve calcification. After adjustment for traditional cardiovascular risk factors, calcific valve disease was associated with older age, current smoking and elevated serum total cholesterol levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Framingham Heart Study offspring cohort (n = 2683, mean age 61 years), 8 percent had at least one calcified valve, 5 percent had aortic sclerosis, and 1 percent had aortic stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/32\">",
"       32",
"      </a>",
"      ]. The threshold for diagnosis of aortic sclerosis was higher in this study than in the above report and the population was younger, which could explain at least in part the lower rate of aortic sclerosis. Valvular calcification was associated with age, hypertension, and diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted when aortic valve calcification was assessed by CT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Multi-Ethnic Study of Atherosclerosis (MESA) study (n = 6780, mean age 63 years), the prevalence of aortic valve calcification was higher among those with metabolic syndrome (12 percent in women, 22 percent in men) or diabetes (17 percent in women, 24 percent in men) compared to those with neither risk factor (8 percent in women, 14 percent in men) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metabolic syndrome and diabetes also were associated with a larger number of new cases of aortic valve calcification (odds ratio [OR] 1.67 [95% CI 1.21-2.31] for metabolic syndrome and 2.06 [1.39-3.06] for diabetes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that predict incident aortic valve calcification may be similar to but different from factors that predict disease progression. In the CHS study, 9 percent of 5621 subjects progressed from aortic sclerosis to aortic stenosis at five year follow-up. Older age, male gender, and LDL cholesterol were associated with disease progression whereas taller height and black race were associated with a lower likelihood of disease progression. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these associations, it is not clear that lipid lowering would be beneficial. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Risk factor modification'",
"    </a>",
"    below.) In contrast to the CHS finding, in the MESA cohort of 5801 non-statin using participants, LDL cholesterol levels were associated with the presence of aortic valve calcification only in participants younger than 65 years, although the total cholesterol to HDL ratio was associated with a slight increase in risk for calcific disease across all ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been speculated that hypertension may cause abnormally high tensile stress on the valve leaflets. In addition, increasing stiffness and decreasing elasticity of the aortic root, a consequence of aging, leads to increased mechanical stress on the valve as more of the tension created by blood flow is transmitted to the valve leaflets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/37\">",
"     37",
"    </a>",
"    ]. These mechanical factors could then cause endothelial injury and disruption, leading to inflammatory cell infiltration and lipid deposition analogous to that seen in early atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/3\">",
"     3",
"    </a>",
"    ]. These factors may account for increased leaflet calcification in patients with a bicuspid aortic valve, although a genetic predisposition to tissue calcification may also be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13818120\">",
"    <span class=\"h2\">",
"     Relation to mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbances of mineral metabolism may also contribute to the development of aortic valve sclerosis and mitral annular calcification, as suggested by the following observations. In the Cardiovascular Health Study community-based cohort of older adults, each 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    higher serum phosphate concentration was associated with 17, 12, and 12 percent higher adjusted prevalences of aortic sclerosis, mitral annular calcification, and aortic annular calcification, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/39\">",
"     39",
"    </a>",
"    ]. Other markers of mineral metabolism, including serum calcium, parathyroid hormone, and 25 hydroxyvitamin D concentrations were not associated with either aortic or mitral calcification. Similarly, among participants with chronic kidney disease in the Multi-Ethnic Study of Atherosclerosis (MESA), each 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase in serum phosphate within the normal range (2.5 to 4.5",
"    <span class=\"nowrap\">",
"     mg/dl)",
"    </span>",
"    was associated with 25 and 62 percent higher prevalences of aortic and mitral valve calcification respectively, after adjustment for traditional risk factors for atherosclerosis, PTH, and 1,25 dihydroxyvitamin D levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve sclerosis can progress to aortic stenosis and is a marker for increased cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with progressive aortic valve calcification were identified in 5880 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/41\">",
"     41",
"    </a>",
"    ]. The incidence rate of aortic valve calcium was 1.7 percent per year. Risk factors for incident aortic valve calcium included older age, male gender, a higher body mass index, current smoking and the use of lipid-lowering and antihypertensive medications. The risk of aortic valve calcium progression was associated with the severity of baseline calcification and male gender.",
"   </p>",
"   <p>",
"    When aortic valve leaflet thickening and calcification become severe, the increased valve stiffness results in obstruction at the valve level, thus causing aortic stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/2\">",
"     2",
"    </a>",
"    ]. Prospective clinical studies suggest that aortic valve sclerosis progresses to clinically significant stenosis in approximately one of eight patients and to severe stenosis in 1 out of 64 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/6,42\">",
"     6,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of progression was assessed in a review of 2131 patients with aortic valve thickening detected on echocardiography: aortic stenosis developed in 338 (16 percent) after seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/6\">",
"     6",
"    </a>",
"    ]. The stenosis was mild to moderate in 84 percent and severe in 16 percent. Only mitral annular calcification, a pathologic process similar to aortic valve sclerosis, was significantly associated with progression in multivariable analysis. As described in the next section, both aortic valve sclerosis and mitral annular calcification may also be predictors of cardiovascular events and mortality. A similar rate of progression to aortic stenosis was observed in the CHS cohort in which 9 percent of subjects with aortic sclerosis progressed to aortic stenosis in five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Predictor of cardiovascular events and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, aortic valve sclerosis is associated with clinical factors similar to those associated with coronary heart disease (CHD). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Relation to atherosclerosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When these factors are taken into account, most studies have found that patients with aortic valve sclerosis have an increased frequency of cardiovascular events and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/2,9,10,12,43\">",
"     2,9,10,12,43",
"    </a>",
"    ]. The risk of cardiovascular events with aortic valve sclerosis has been demonstrated in patients with or without prior known cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic importance of aortic valve sclerosis was illustrated in an analysis from the Cardiovascular Health Study of 5621 men and women &ge;65 years of age who were followed for a mean of five years after baseline echocardiograms were obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/2\">",
"     2",
"    </a>",
"    ]. The all-cause and cardiovascular mortality in the 29 percent of patients with aortic valve sclerosis were 22 and 10 percent, respectively. Compared to those with a normal valve, the adjusted relative risk of cardiovascular death and myocardial infarction in those with aortic sclerosis and no clinical evidence of coronary disease at baseline were 1.5 and 1.4, respectively.",
"   </p>",
"   <p>",
"    An independent effect of aortic valve sclerosis on prognosis was also noted in a report of 1980 elderly individuals (mean age 81 years) without valvular aortic stenosis, one-half of whom had aortic valve sclerosis identified by transthoracic echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/9\">",
"     9",
"    </a>",
"    ]. At four years, there were 830 new cardiac events (fatal or nonfatal MI or sudden death). Aortic valve sclerosis was independently associated with new cardiac events (risk ratio 1.8) after adjusting for the fact that more patients with aortic valve sclerosis had preexisting clinical coronary disease.",
"   </p>",
"   <p>",
"    The mechanisms responsible for the association between aortic valve sclerosis and cardiovascular events and mortality are not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/1,44\">",
"     1,44",
"    </a>",
"    ]. A possible explanation is that aortic valve sclerosis is a marker for underlying atherosclerosis or inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. However, progression from aortic sclerosis to aortic stenosis in the CHS study was not associated with CRP levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/35\">",
"     35",
"    </a>",
"    ]. The valve lesion itself is not likely to be important, since hemodynamics are normal or near normal and the time to increased risk is short compared to the possible rate of progression to aortic stenosis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mitral annular calcification, a pathologic process similar to aortic valve sclerosis, has also been associated with adverse cardiovascular outcomes. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37801?source=see_link\">",
"     \"Mitral annular calcification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Embolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although calcific microemboli have been observed in patients with calcific aortic valve disease, these appear to be rarely associated with clinical events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/45\">",
"     45",
"    </a>",
"    ]. No significant increase in stroke risk was found in studies comparing patients with aortic stenosis or aortic sclerosis with matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/2,46,47\">",
"     2,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve sclerosis does not impede transvalvular blood flow and is not an indication for surgical intervention. However, because it is a risk factor for CHD and because it can progress to significant aortic stenosis, it does have implications for patient management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk factor modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled trials to confirm whether aggressive control of blood pressure or other non-lipid risk factors for CHD will reduce the progression of aortic valve sclerosis.",
"   </p>",
"   <p>",
"    Although histologic evidence of lipid infiltration is seen early in the disease process and small retrospective studies were promising, there is no convincing evidence for benefit of lipid lowering therapy in adults with calcific aortic valve disease. In two prospective randomized trials of statin (HMG CoA reductase inhibitor) versus placebo in adults with mild to moderate calcific aortic stenosis no difference was found in the rate of hemodynamic progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In addition, the larger, prospective, randomized SEAS trial in adults with mild to moderate aortic stenosis found no benefit of aggressive lipid lowering therapy on a combined cardiovascular endpoint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link&amp;anchor=H4#H4\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Hypercholesterolemia and statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prudent approach is to consider aortic valve sclerosis to be a marker of increased cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. Thus, all such patients should undergo a careful history and physical examination with assessment of conventional cardiac risk factors, including hypertension, smoking, diabetes, and hyperlipidemia. Risk factor reduction should be instituted in all patients based upon accepted guidelines. In addition, further diagnostic evaluation may be needed in patients with clinical signs or symptoms of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, embolic events are uncommon in patients with isolated aortic valve disease. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Embolic risk'",
"    </a>",
"    above.) No treatment has been established for prevention of calcific microemboli.",
"   </p>",
"   <p>",
"    The 2008 ACCP guidelines recommend no antithrombotic therapy in patients with isolated calcific aortic valve disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/48\">",
"     48",
"    </a>",
"    ]. In patients with calcific aortic valve disease who have had ischemic stroke or TIA not attributable to another source,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (50 to 100",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis prophylaxis is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with aortic valve sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38279/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12603696\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic sclerosis is defined as irregular aortic leaflet thickening and focal increased echogenicity without impairment of leaflet excursion and with peak Doppler velocities across the valve &lt;2",
"      <span class=\"nowrap\">",
"       m/s.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aortic sclerosis is an asymptomatic condition that is generally detected either as a systolic ejection murmur on physical examination or as an incidental finding on echocardiography. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of aortic sclerosis increases with age from less than 10 percent in middle-aged adults to over 25 percent in adults &ge;65 years old. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The early lesion of aortic valve sclerosis involves an active process with some similarities to atherosclerosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Relation to atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disturbances in mineral metabolism as reflected by elevated serum phosphate levels may also contribute to the development of aortic valve calcification. (See",
"      <a class=\"local\" href=\"#H13818120\">",
"       'Relation to mineral metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aortic sclerosis has been correlated with clinical risk factors for atherosclerosis, including smoking, hypertension, hyperlipidemia, and diabetes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Relation to atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aortic valve sclerosis can progress to aortic stenosis and is a marker for increased cardiovascular risk. Thus, careful history and physical examination for cardiovascular risk in indicated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with aortic&nbsp;valve sclerosis (including those with and without known cardiovascular disease) have an increased frequency of cardiovascular events and mortality after taking into account risk factors for coronary heart disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Predictor of cardiovascular events and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no convincing evidence for benefit of lipid lowering therapy in adults with calcific aortic valve disease separate from established cardiovascular indications for such therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Risk factor modification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/1\">",
"      Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/2\">",
"      Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/3\">",
"      Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/4\">",
"      Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011; 124:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/5\">",
"      Jeon DS, Atar S, Brasch AV, et al. Association of mitral annulus calcification, aortic valve sclerosis and aortic root calcification with abnormal myocardial perfusion single photon emission tomography in subjects age &lt; or =65 years old. J Am Coll Cardiol 2001; 38:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/6\">",
"      Faggiano P, Antonini-Canterin F, Erlicher A, et al. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003; 91:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/7\">",
"      Lindroos M, Kupari M, Heikkil&auml; J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/8\">",
"      Chandra HR, Goldstein JA, Choudhary N, et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/9\">",
"      Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol 1999; 83:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/10\">",
"      Taylor HA Jr, Clark BL, Garrison RJ, et al. Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. Am J Cardiol 2005; 95:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/11\">",
"      Stritzke J, Linsel-Nitschke P, Markus MR, et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. Eur Heart J 2009; 30:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/12\">",
"      Olsen MH, Wachtell K, Bella JN, et al. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005; 95:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/13\">",
"      Straumann E, Meyer B, Misteli M, et al. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 1992; 67:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/14\">",
"      Stinebaugh J, Lavie CJ, Milani RV, et al. Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 1995; 88:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/15\">",
"      Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/16\">",
"      Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/17\">",
"      O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995; 92:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/18\">",
"      O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/19\">",
"      Olsson M, Rosenqvist M, Nilsson J. Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol 1994; 24:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/20\">",
"      Olsson M, Dalsgaard CJ, Haegerstrand A, et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994; 23:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/21\">",
"      O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006; 26:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/22\">",
"      Owens DS, Otto CM. Is it time for a new paradigm in calcific aortic valve disease? JACC Cardiovasc Imaging 2009; 2:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/23\">",
"      Marincheva-Savcheva G, Subramanian S, Qadir S, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol 2011; 57:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/24\">",
"      Probst V, Le Scouarnec S, Legendre A, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 2006; 113:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/25\">",
"      Bella JN, Tang W, Kraja A, et al. Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study. Hypertension 2007; 49:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/26\">",
"      Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/27\">",
"      Boss&eacute; Y, Mathieu P, Pibarot P. Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 2008; 51:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/28\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001; 38:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/29\">",
"      Pohle K, M&auml;ffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/30\">",
"      Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/31\">",
"      Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/32\">",
"      Fox CS, Guo CY, Larson MG, et al. Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol 2006; 97:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/33\">",
"      Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006; 113:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/34\">",
"      Katz R, Budoff MJ, Takasu J, et al. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes 2009; 58:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/35\">",
"      Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 2007; 50:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/36\">",
"      Owens DS, Katz R, Johnson E, et al. Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med 2008; 168:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/37\">",
"      Robicsek F, Thubrikar MJ, Fokin AA. Cause of degenerative disease of the trileaflet aortic valve: review of subject and presentation of a new theory. Ann Thorac Surg 2002; 73:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/38\">",
"      Weinberg EJ, Kaazempur Mofrad MR. A multiscale computational comparison of the bicuspid and tricuspid aortic valves in relation to calcific aortic stenosis. J Biomech 2008; 41:3482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/39\">",
"      Linefsky JP, O'Brien KD, Katz R, et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol 2011; 58:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/40\">",
"      Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/41\">",
"      Owens DS, Katz R, Takasu J, et al. Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol 2010; 105:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/42\">",
"      Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with \"benign\" aortic valve thickening. Arch Intern Med 2002; 162:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/43\">",
"      Shah SJ, Ristow B, Ali S, et al. Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). Am J Cardiol 2007; 99:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/44\">",
"      Otto CM. Why is aortic sclerosis associated with adverse clinical outcomes? J Am Coll Cardiol 2004; 43:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/45\">",
"      HOLLEY KE, BAHN RC, MCGOON DC, MANKIN HT. SPONTANEOUS CALCIFIC EMBOLIZATION ASSOCIATED WITH CALCIFIC AORTIC STENOSIS. Circulation 1963; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/46\">",
"      Boon A, Lodder J, Cheriex E, Kessels F. Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis. Stroke 1996; 27:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/47\">",
"      Kizer JR, Wiebers DO, Whisnant JP, et al. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke 2005; 36:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/48\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/49\">",
"      Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/50\">",
"      Chan KL, Teo K, Dumesnil JG, et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/51\">",
"      Rosseb&oslash; AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38279/abstract/52\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8123 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38279=[""].join("\n");
var outline_f37_24_38279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12603696\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Relation to atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13818120\">",
"      Relation to mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Predictor of cardiovascular events and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Embolic risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk factor modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12603696\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8123|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/62/17391\" title=\"figure 1\">",
"      Systolic murmurs and S2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/59/954?source=related_link\">",
"      Valvular heart disease in patients with end-stage renal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38280="Transesophageal echocardiography: Indications, complications, and normal views";
var content_f37_24_38280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transesophageal echocardiography: Indications, complications, and normal views",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Joseph P Kannam, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38280/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/24/38280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although transthoracic echocardiography (TTE) remains the cornerstone of diagnostic cardiac ultrasound, transesophageal echocardiography (TEE) is a valuable complementary tool. As compared with TTE, TEE offers superior visualization of posterior cardiac structures because of close proximity of the esophagus to the posteromedial heart with lack of intervening lung and bone. This proximity permits use of high-frequency imaging transducers that afford superior spatial resolution (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69251 \" href=\"mobipreview.htm?16/4/16463\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The first practical clinical use of TEE was described in 1976 when a modified rigid endoscopic probe with single M-mode crystal was used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/1\">",
"     1",
"    </a>",
"    ]. Since that time, TEE technology has evolved rapidly with developments in flexible endoscopic probe technology, phased-array ultrasound systems, and crystal miniaturization and real time three-dimensional (3D) imaging. Current TEE probes allow for both two-dimensional (2D) and 3D imaging as well M-mode, spectral Doppler, and color Doppler. The versatility of these transducers permits improved penetration with lower frequency imaging and superior spatial resolution with higher frequency imaging. Additional developments have focused on further probe miniaturization and improvement of 3D echocardiography capability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4662?source=see_link\">",
"     \"Echocardiography essentials: Physics and instrumentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications, potential complications, and normal views associated with TEE will be reviewed here. The role for TEE in the evaluation of specific cardiac abnormalities is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13240?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of the left ventricle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42040?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31878?source=see_link\">",
"     \"Transesophageal echocardiography in traumatic rupture of the aortic isthmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9886539\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both TTE and TEE have a variety of clinical indications and applications. In most patients, TEE provides superior image quality, particularly for posterior cardiac structures which are nearer to the esophagus and less well visualized on transthoracic echocardiography. Because of its moderately invasive nature, however, TEE is generally reserved for selected indications in which the potential benefits of making a diagnosis outweigh the risks associated with the procedure. For many clinical situations, a TTE study precedes the TEE as the TTE study may obviate or help guide the TEE.",
"   </p>",
"   <p>",
"    How often TEE is used for a particular indication varies from institution to institution. However, TEE is most commonly performed to evaluate for a potential cardiac source of embolus, to assess valves for endocarditis, or to exclude left atrial appendage (LAA) thrombi in patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/2\">",
"     2",
"    </a>",
"    ]. In a large series from the 1990s, the most common clinical indications for TEE were to evaluate for cardiac source of embolism, endocarditis, prosthetic heart valve dysfunction, native valvular disease, and aortic dissection or aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/3\">",
"     3",
"    </a>",
"    ]. Thoracic magnetic resonance imaging and computed tomography have largely displaced TEE for assessment of aortic",
"    <span class=\"nowrap\">",
"     aneurysm/dissection.",
"    </span>",
"    In current practice, TEE is also performed with many cardiac surgical procedures, especially those involving congenital or valve repairs, both to verify preoperative diagnosis and to monitor the success of repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TTE remains the initial test of choice for most patients requiring an echocardiogram. However, TEE should be performed as the initial test in certain life-threatening situations or in situations where TTE is likely to be nondiagnostic. Clinical situations in which TEE should be considered as the initial test include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected acute aortic pathology (ie, dissection, transsection, intramural hematoma)",
"     </li>",
"     <li>",
"      Suspected prosthetic valve dysfunction",
"     </li>",
"     <li>",
"      Suspected complications of endocarditis (eg, fistula, abscess)",
"     </li>",
"     <li>",
"      Evaluation for left",
"      <span class=\"nowrap\">",
"       atrial/LAA",
"      </span>",
"      thrombus in a patient with atrial",
"      <span class=\"nowrap\">",
"       fibrillation/atrial",
"      </span>",
"      flutter to facilitate clinical decision making regarding anticoagulation, cardioversion, or ablation",
"     </li>",
"     <li>",
"      Evaluation of source of embolism in a young patient for whom a TEE would be performed if the TTE was normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2011 the American College of Cardiology Foundation, in conjunction with numerous professional societies, issued Appropriate Use Criteria for Echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/6\">",
"     6",
"    </a>",
"    ]. While appropriate use criteria are not intended to be an exhaustive list of TEE indications, the following indications for TEE were all considered appropriate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To diagnose infective endocarditis in patients with moderate or high pretest likelihood (ie, patients with prosthetic valves, certain pathogens) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnostic approach to infective endocarditis\", section on 'Role of TEE'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To evaluate for cardiac source of embolus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link\">",
"       \"Echocardiography in detection of intracardiac sources of embolism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To evaluate for suspected acute aortic pathology (ie, dissection) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\", section on 'TEE'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      As follow-up to prior TEE when an interval change would result in a change in therapy (eg, resolution of vegetation following antimicrobial therapy)",
"     </li>",
"     <li>",
"      To evaluate for cardiac pathology when transthoracic echocardiography is nondiagnostic",
"     </li>",
"     <li>",
"      To facilitate clinical decision making regarding anticoagulation, cardioversion, or ablation in patients with atrial",
"      <span class=\"nowrap\">",
"       fibrillation/flutter",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link&amp;anchor=H6#H6\">",
"       \"Role of echocardiography in atrial fibrillation\", section on 'Transesophageal echocardiography'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To provide guidance for noncoronary percutaneous cardiac interventions (eg, placement of closure devices, valvuloplasty, percutaneous valves)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TEE is also used frequently in the evaluation of complex congenital heart disease and may be helpful for evaluating etiologies of hypotension in the intensive care unit (",
"    <a class=\"graphic graphic_table graphicRef81156 \" href=\"mobipreview.htm?30/10/30892\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7839812\">",
"    <span class=\"h2\">",
"     TEE in critical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE is a useful test that can be performed relatively quickly at the bedside in critically ill patients. Indications for TEE in the critically ill are similar to standard TEE indications in all patients. However, certain scenarios in a critically ill patient may be more quickly and thoroughly invested with TEE as the initial diagnostic procedure, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained hypotension",
"     </li>",
"     <li>",
"      Unexplained hypoxemia",
"     </li>",
"     <li>",
"      Suspected complications following a myocardial infarction (ie, acute mitral regurgitation, ventricular septal defect, free wall rupture with cardiac tamponade)",
"     </li>",
"     <li>",
"      Uncertain volume status",
"     </li>",
"     <li>",
"      Blunt chest trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a review of 83 TEE studies performed in the critical care setting, unexpected findings were observed in 25 percent of patients, resulting in a change in management in 17 percent or a referral for invasive examination in 22 percent. In 16 percent of cases, surgical intervention was performed based on TEE without further examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2904159\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing a TEE, the suggested preprocedure assessment, preparation, and monitoring during and after the procedure is similar to gastrointestinal endoscopy. A detailed discussion of this is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SAFETY OF TEE EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for TEE competence have been published by the American College of Cardiology and American Heart Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/8\">",
"     8",
"    </a>",
"    ]. Although considered moderately invasive and generally performed with conscious sedation, TEE is safe in experienced hands and may be completed in almost all patients when performed by a trained clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to beginning the TEE, all patients should have a history and physical examination performed, focusing on factors that increase the risk of an adverse outcome (eg, medication allergies, prior difficult intubation or airway problems, odynophagia or dysphagia). While there are few absolute contraindications to TEE examination, patients with one or more of the following conditions are at increased risk of complications from TEE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mental status or an uncooperative patient",
"     </li>",
"     <li>",
"      Tenuous cardiorespiratory status (consider endotracheal intubation prior to TEE for airway protection)",
"     </li>",
"     <li>",
"      Esophageal stricture or malignancy (identify esophageal location prior to TEE)",
"     </li>",
"     <li>",
"      Surgical interposition of the esophagus",
"     </li>",
"     <li>",
"      Zenker's diverticulum (identify esophageal location prior to TEE)",
"     </li>",
"     <li>",
"      History of odynophagia or dysphagia (consider screening endoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow prior to TEE)",
"     </li>",
"     <li>",
"      Cervical spine arthritis with reduced range of motion",
"     </li>",
"     <li>",
"      Severe thrombocytopenia (less than 50k), elevated international normalized ratio (greater than 4), or prolonged partial thromboplastin time (&gt;150 seconds)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with recent or active esophageal perforation, tear, or hemorrhage should likely not undergo TEE except in extreme situations. In a patient with a difficult esophageal intubation, the assistance of a trained gastroenterologist or an anesthesiologist, who may directly visualize the glottis with a laryngoscope, can facilitate successful esophageal intubation. Careful attention to posterior pharyngeal anesthesia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    spray and patient reassurance help to facilitate the esophageal intubation and minimize the degree of sedation that is required.",
"   </p>",
"   <p>",
"    If required, TEE may be performed in uncooperative patients using a greater level of sedation and prophylactic endotracheal intubation for airway protection. For situations in which the risk of TEE is high, intracardiac echocardiography may be an alternative study which can provide the needed information.",
"   </p>",
"   <p>",
"    Serious complications are extremely rare in patients undergoing TEE, having been estimated at less than 1 in 5000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. While death during TEE has been rarely reported, complications such as esophageal perforation, gastrointestinal bleeding, pharyngeal hematoma, and methemoglobinemia are more likely to occur but only rarely are fatal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal perforation &mdash; There is a very low risk of esophageal perforation. This was illustrated in a study of 10,000 consecutive patients undergoing TEE in which there was one case of hypopharyngeal perforation, two cases of cervical esophageal perforation, and no fatalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding &mdash; An increased risk of bleeding should be considered among patients with thrombocytopenia, those who have received thrombolytic therapy or chronic anticoagulation, and patients with other bleeding diatheses. Patients with esophageal varices and no active or recent variceal bleeding do not appear to be at an increased risk of serious complications from TEE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pharyngeal hematoma &mdash; This upper respiratory tract complication occurs from direct trauma to the posterior pharynx and may result in the acute airway compromise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Methemoglobinemia &mdash; Methemoglobinemia is a rare but potentially life-threatening complication of topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"       benzocaine",
"      </a>",
"      and related agents used for posterior pharyngeal anesthesia (eg, two deaths in a review of 132 benzocaine cases reported to the United States Food and Drug Administration) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/17\">",
"       17",
"      </a>",
"      ]. In a series of over 28,000 TEEs performed at a single center, the incidence of methemoglobinemia was 0.07 percent (1 case per 1499 TEE studies) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/18\">",
"       18",
"      </a>",
"      ]. Methemoglobinemia may be suspected clinically by the development of cyanosis in the presence of a normal arterial PO2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/19\">",
"       19",
"      </a>",
"      ]. Pulse oximetry is inaccurate in monitoring oxygen saturation in the presence of methemoglobinemia, and cannot be used to make the diagnosis. Issues related to the diagnosis and treatment of methemoglobinemia are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TEE examination is rarely associated with bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/20\">",
"     20",
"    </a>",
"    ]. The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines for antibiotic prophylaxis do",
"    <strong>",
"     not",
"    </strong>",
"    recommend prophylaxis for patients undergoing transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minor complications are seen in fewer than 1 in 500 examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/3\">",
"     3",
"    </a>",
"    ]. These may include transient bronchospasm, transient hypoxia, nonsustained ventricular tachycardia, transient atrial fibrillation, minimal hemoptysis, or vomiting. Minor complications generally resolve spontaneously without specific treatment following termination of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THE NORMAL HEART AND GREAT VESSELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with TTE examinations, we believe a complete TEE examination should include imaging of all cardiac chambers, valves and great vessels, regardless of the indication for the study, as patient condition permits. In 2002, a scientific statement from the American Heart Association made recommendations for standardized segmentation and nomenclature for tomographic imaging of the heart for all modalities (",
"    <a class=\"graphic graphic_figure graphicRef55080 graphicRef64968 graphicRef65139 \" href=\"mobipreview.htm?34/36/35402\">",
"     figure 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/23\">",
"     23",
"    </a>",
"    ]. Follow-up TEE studies (eg, to monitor resolution of an atrial appendage thrombus) may be focused.",
"   </p>",
"   <p>",
"    A standard comprehensive approach to imaging is recommended, but each individual study should be modified to reflect the specific clinical indication. As an example, a patient undergoing TEE examination for evaluation of LAA thrombus should include visualization of the appendage in a continuum of imaging planes from 0&ordm; to 180&ordm;, with less focus on the mitral and aortic valves. On the other hand, an examination in a patient with suspected endocarditis should include extensive imaging of all cardiac valves with less focus on the LAA.",
"   </p>",
"   <p>",
"    This section will describe the normal cardiac anatomy as visualized sequentially during a routine multiplane TEE study. Following intubation of the esophagus, the probe is advanced in most adult patients to a depth of 28 to 30 cm from the incisors, coming to rest in the proximal-to-mid esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Horizontal plane",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Four-chamber view",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the horizontal (0&ordm;) imaging plane, a four-chamber view of the heart can be seen, demonstrating the left atrium, mitral valve, left ventricle (LV), right atrium, tricuspid valve, and right ventricle (RV) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76441 \" href=\"mobipreview.htm?22/40/23168\">",
"     image 2",
"    </a>",
"    ). Doppler examination of transmitral inflow and mitral regurgitation may be performed. The RV and LV are frequently foreshortened in this position and the true apex is rarely seen (due to foreshortening and the distance from the imaging probe). Slight withdrawal of the probe permits imaging of the left ventricular outflow tract (LVOT) and aortic valve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76441 \" href=\"mobipreview.htm?22/40/23168\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mitral valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitral valve should be evaluated in several imaging planes, particularly when mitral valve pathology is suspected. Comprehensive mitral valve imaging is essential for diagnosis and perioperative evaluation. Mitral valve mapping using TEE has excellent correlation with surgical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42040?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Left atrial appendage",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the transducer positioned in the mid-esophagus, at the base of the heart, the LAA may be examined for thrombus and for decreased contractile function. Use of left-sided contrast may aid in differentiation between normal trabeculae and thrombi. While the LAA length is similar in all imaging planes, its width, accessory lobe visualization and cross-sectional area may vary considerably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically record pulsed Doppler spectra from the mouth of the LAA and left upper pulmonary vein (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54962 \" href=\"mobipreview.htm?21/55/22399\">",
"     image 3",
"    </a>",
"    ). Normal LAA flow typically consists of prominent ejection and inflow components after the P wave on the ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/26\">",
"     26",
"    </a>",
"    ]. LAA ejection and inflow velocities are independent of transducer orientation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/25\">",
"     25",
"    </a>",
"    ]. Among patients in sinus rhythm, LAA ejection velocity is typically &gt;0.5",
"    <span class=\"nowrap\">",
"     m/s,",
"    </span>",
"    with depressed LAA ejection velocity defined as &lt;0.2",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pulmonary veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four major pulmonary veins can readily be identified during the TEE study. The left upper pulmonary vein is best identified in the horizontal plane, immediately adjacent to the LAA, while the left lower pulmonary vein is often identified with posterior rotation of the probe at 135 degree crystal orientation. The right upper pulmonary vein is easily identified running near parallel with the superior vena cava with the probe rotated anteriorly and the crystal in the 90 to 110 degree orientation. Further anterior rotation demonstrates the right lower pulmonary vein.",
"   </p>",
"   <p>",
"    As for the LAA, pulmonary vein Doppler flow is typically assessed with pulsed Doppler with the sample volume positioned approximately 1 cm within the entrance of the pulmonary vein. Normal pulmonary venous flow is biphasic with a predominant systolic flow [S wave] [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38280/abstract/28\">",
"     28",
"    </a>",
"    ]. With increasing severity of mitral regurgitation, there will be",
"    <span class=\"nowrap\">",
"     attenuation/decrease",
"    </span>",
"    in the pulmonary vein S wave and increase in the height of the diastolic flow [D wave]. With severe mitral regurgitation, there is reversal of the expected forward flow in the S wave Doppler spectra. Color Doppler is often helpful to visualize extension of the mitral regurgitation jet into the pulmonary veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pulmonary artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the transducer imaging plane in the horizontal (0&ordm;) position, the TEE probe is rotated anteriorly and withdrawn slightly to visualize the main pulmonary artery, right main pulmonary artery, and left main pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69255 \" href=\"mobipreview.htm?6/27/6591\">",
"     image 4",
"    </a>",
"    ). The patient may cough or note posterior \"irritation\" during imaging at this level in the proximal esophagus, and diligent care is required to avoid extubating the TEE probe from the esophagus. The main pulmonary artery is also seen near the study conclusion with the crystal in the 90 degree orientation while examining the aortic arch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Right and left atria",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the TEE transducer tip in a neutral position, the probe is advanced and rotated anteriorly to evaluate the body of the left atrium, interatrial septum, and the body of the right atrium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79455 \" href=\"mobipreview.htm?9/6/9327\">",
"     image 5",
"    </a>",
"    ). The interatrial septum is evaluated at various crystal orientations with color flow Doppler to assess for evidence of an atrial septal aneurysm, an atrial septal defect or patent foramen ovale. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further anterior rotation of the probe and intermediate transducer rotation to 40 to 60&ordm; permits visualization of the right pulmonary veins (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72534 \" href=\"mobipreview.htm?34/20/35151\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Aortic leaflets and aortic root",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probe is rotated slightly posteriorly to visualize the aortic root and aortic valve leaflets, following which the probe is rotated to 30&ordm; to 55&ordm; to image the aortic valve leaflets in short axis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69646 \" href=\"mobipreview.htm?36/18/37154\">",
"     image 7",
"    </a>",
"    ). Advancement and retraction of the probe in this plane will allow for imaging of the LVOT and ascending aorta, respectively. Color flow Doppler interrogation for aortic regurgitation may also be performed in this orientation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vertical plane",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the multiple maneuvers (anteflexion, retroflexion, retraction, advancement) of the TEE probe and transducer tip required for imaging in the horizontal plane, imaging in the vertical (90&ordm;) plane primarily involves simple anterior and posterior rotation of the probe. We begin imaging in the vertical (90&ordm;) plane with posterior structures and then rotate the probe anteriorly. The most posterior structure is the coronary sinus and left lower pulmonary vein (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68047 \" href=\"mobipreview.htm?0/52/833\">",
"     image 8",
"    </a>",
"    ). As the probe is slowly rotated anteriorly, we image the mitral valve and two-chamber long axis view of the left atrium and left ventricle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68047 \" href=\"mobipreview.htm?0/52/833\">",
"     image 8",
"    </a>",
"    ). Color Doppler interrogation of the mitral valve allows identification of central and eccentric jets of mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further anterior rotation of the probe allows for imaging of the LVOT and aortic valve as well as proximal ascending aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58675 \" href=\"mobipreview.htm?28/3/28724\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After imaging the LVOT and aortic valve in the vertical plane, multiplane imaging at 110 to 145&ordm; permits enhanced visualization of the LVOT, aortic valve, and the ascending aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58675 \" href=\"mobipreview.htm?28/3/28724\">",
"     image 9",
"    </a>",
"    ). Anterior rotation of the probe at this crystal position also results in a favorable orientation for assessment of the tricuspid valve, coronary sinus, right atrial appendage, and interatrial septum. Assessment of atrial septal defects or aneurysms, as well as right atrial appendage thrombi, is readily performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Returning to the vertical (90&ordm;) orientation, further rotation of the probe anteriorly allows for imaging of the pulmonic valve, main pulmonary artery, right pulmonary artery, and left pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57980 \" href=\"mobipreview.htm?31/60/32719\">",
"     image 10",
"    </a>",
"    ). With further anterior rotation, the right ventricle, tricuspid valve, and right atrium are well seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57980 \" href=\"mobipreview.htm?31/60/32719\">",
"     image 10",
"    </a>",
"    ). Continuous-wave Doppler may allow for velocity assessment of the tricuspid regurgitation jet from this orientation.",
"   </p>",
"   <p>",
"    With further anterior rotation, the superior vena cava, right atrial appendage, body of the right atrium, interatrial septum, and inferior vena cava and Eustachian valve may be seen (the bicaval view) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71051 \" href=\"mobipreview.htm?29/39/30335\">",
"     image 11",
"    </a>",
"    ). Color flow Doppler evaluation of the interatrial septum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the injection of agitated saline contrast may allow for identification of an atrial septal defect or patent foramen ovale in this orientation, or such examination may be performed in the 135&ordm; orientation previously described. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link\">",
"     \"Identification and assessment of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, anterior rotation of the TEE probe in the vertical plane permits imaging of the right upper pulmonary vein, a vessel important to identify as it is the pulmonary vein most commonly associated with anomalous pulmonary venous return (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81803 \" href=\"mobipreview.htm?37/20/38222\">",
"     image 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Imaging at the gastroesophageal junction",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the transducer imaging plane in the horizontal (0&ordm;) position the TEE probe is advanced toward the gastroesophageal junction (38 to 40 cm) where the right atrial appendage, tricuspid valve, and coronary sinus may be seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69903 \" href=\"mobipreview.htm?26/47/27377\">",
"     image 13",
"    </a>",
"    ) as the probe approaches the gastroesophageal junction.",
"   </p>",
"   <p>",
"    During advancement of the probe through the gastroesophageal junction, the patient often experiences a slight epigastric discomfort. Particular diligence is required during probe advancement in patients with a large hiatus hernia to avoid curling of the transducer tip in the distal esophagus. Increased depth penetration is often needed and we customarily change to a lower imaging frequency upon entering the stomach. Anteflexion of the probe permits imaging of the left ventricle in a short axis view at the level of the mitral valve and papillary muscles (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73013 \" href=\"mobipreview.htm?42/40/43648\">",
"     image 14",
"    </a>",
"    ). The imaging transducer is then rotated to the vertical (90&ordm;) imaging plane to allow for visualization of the inferior and anterior left ventricular walls, mitral leaflets and left atrium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73013 \" href=\"mobipreview.htm?42/40/43648\">",
"     image 14",
"    </a>",
"    ). Slight anterior rotation of the probe will allow for visualization of the LVOT and aortic valve. This view may be especially helpful for Doppler assessment for aortic valve or LVOT gradients.",
"   </p>",
"   <p>",
"    Further anterior rotation of the probe and rotation of the multiplane imaging transducer to 100 to 120&ordm; imaging plane allows for imaging of the right atrium, tricuspid valve, right ventricle, and right ventricular outflow tract (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61239 \" href=\"mobipreview.htm?7/42/7840\">",
"     image 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gastric imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advancement of the probe to a length of 42 to 45 cm from the incisors into the fundus of the stomach with maximum anteflexion results in an \"apical four or five chamber\" equivalent view of the heart (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62623 \" href=\"mobipreview.htm?12/34/12833\">",
"     image 16",
"    </a>",
"    ). From this orientation, continuous wave, pulsed, or color Doppler examination of the LVOT and aortic valve may be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thoracic aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;After all other images are obtained, attention is turned to the descending thoracic aorta, which is located posteriorly. For optimal visualization, the imaging frequency is increased to 5 MHz to permit improved spatial resolution of the adjacent aorta and the focal point is adjusted. After identifying the descending thoracic aorta in the horizontal (0&ordm;) imaging plane, we advance the probe during continuous imaging of the aorta to approximately 45 cm from the incisors or until the aortic lumen is no longer visible (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79300 \" href=\"mobipreview.htm?15/42/16036\">",
"     image 17",
"    </a>",
"    ). The probe is then gently retracted during continuous imaging of the descending aorta. Annotations are made on the screen as to the distance from the incisors at 2 to 3 cm intervals or the specific level of any abnormalities.",
"   </p>",
"   <p>",
"    Transducer rotation to the vertical (90&ordm;) imaging plane allows for longitudinal imaging of the descending thoracic aorta. Color flow Doppler confirms the direction of blood flow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79300 \" href=\"mobipreview.htm?15/42/16036\">",
"     image 17",
"    </a>",
"    ). Further retraction is made with imaging in the horizontal (0&ordm;) imaging plane.",
"   </p>",
"   <p>",
"    As the probe is withdrawn into the proximal esophagus (28 cm from the incisors), the transverse aorta may be seen as the aortic lumen appears to elongate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54091 \" href=\"mobipreview.htm?21/14/21728\">",
"     image 18",
"    </a>",
"    ). The probe is then gently retracted with slight flexion and anterior rotation to view the ascending aorta. Color flow Doppler demonstrates normal aortic flow and, in some cases, flow within the superior vena cava may be seen. Transducer rotation into the vertical (90&ordm;) plane at this level may allow for imaging of the pulmonary valve and main pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80660 \" href=\"mobipreview.htm?3/24/3471\">",
"     image 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) have a variety of clinical indications and applications, in most patients TEE provides superior image quality, particularly for posterior cardiac structures that are nearer to the esophagus and often less well visualized on TTE. Because of its moderately invasive nature, however, TEE is generally reserved for selected indications in which the potential benefits of making a diagnosis outweigh the risks associated with the procedure. For many indications, a TTE study is performed first as it may obviate the need for TEE",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      help to guide the TEE. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TTE remains the initial test of choice for most patients requiring an echocardiogram. However, TEE should be performed as the initial test in certain life-threatening situations or in situations where TTE is likely to be nondiagnostic, including (see",
"      <a class=\"local\" href=\"#H9886539\">",
"       'Indications for TEE'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Suspected acute aortic pathology (ie, dissection, transsection, intramural hematoma)",
"     </li>",
"     <li>",
"      Suspected prosthetic valve dysfunction",
"     </li>",
"     <li>",
"      Suspected complications of endocarditis (eg, fistula, abscess)",
"     </li>",
"     <li>",
"      Evaluation for left",
"      <span class=\"nowrap\">",
"       atrial/left",
"      </span>",
"      atrial appendage thrombus in a patient with atrial",
"      <span class=\"nowrap\">",
"       fibrillation/atrial",
"      </span>",
"      flutter to facilitate clinical decision making regarding anticoagulation, cardioversion, or ablation",
"     </li>",
"     <li>",
"      Evaluation of source of embolism in a young patient for whom a TEE would be performed if the TTE was normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are few absolute contraindications to TEE examination. However, patients with altered mental status, tenuous cardiorespiratory status, recent or active esophageal tear or hemorrhage, coagulopathies, esophageal stricture, Zenker&rsquo;s diverticulum, or severe cervical spine arthritis with reduced range of motion are at increased risk of complications from TEE. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Safety of TEE examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious complications are extremely rare in patients undergoing TEE, having been estimated at less than 1 in 5000. While death during TEE has been rarely reported, complications such as gastrointestinal bleeding, esophageal perforation, and methemoglobinemia are more likely to occur but only rarely are fatal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Safety of TEE examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with TTE examinations, we believe a complete TEE examination should include imaging of all cardiac chambers, valves and great vessels, regardless of the indication for the study, as patient condition permits. A standard comprehensive approach to imaging is recommended, but each individual study should be modified to reflect the specific clinical indication. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'The normal heart and great vessels'",
"      </a>",
"      above.) Focused TEE studies are appropriate for follow-up studies (eg, monitoring of atrial appendage thrombi).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/1\">",
"      Frazin L, Talano JV, Stephanides L, et al. Esophageal echocardiography. Circulation 1976; 54:102.",
"     </a>",
"    </li>",
"    <li>",
"     Oh JK, Seward JB, Tajik AJ. Transesophageal and Intracardiac Echocardiogrphy. In: The Echo Manual, 3rd edition, Lippincott Williams &amp; Wilkins, 2007. p.29-30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/3\">",
"      Khandheria BK, Seward JB, Tajik AJ. Transesophageal echocardiography. Mayo Clin Proc 1994; 69:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/4\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     Otto CM. Clinical Indications and Quality Assurance. In: Textbook of Clinical Echocardiography, 4th edition, Saunders Elsevier, 2009. p.117-118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/6\">",
"      American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011; 57:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/7\">",
"      Foster E, Schiller NB. The role of transesophageal echocardiography in critical care: UCSF experience. J Am Soc Echocardiogr 1992; 5:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/8\">",
"      Qui&ntilde;ones MA, Douglas PS, Foster E, et al. ACC/AHA clinical competence statement on echocardiography: a report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. J Am Coll Cardiol 2003; 41:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/9\">",
"      Daniel WG, Erbel R, Kasper W, et al. Safety of transesophageal echocardiography. A multicenter survey of 10,419 examinations. Circulation 1991; 83:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/10\">",
"      Ofili EO, Rich MW. Safety and usefulness of transesophageal echocardiography in persons aged greater than or equal to 70 years. Am J Cardiol 1990; 66:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/11\">",
"      Pearson AC, Castello R, Labovitz AJ. Safety and utility of transesophageal echocardiography in the critically ill patient. Am Heart J 1990; 119:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/12\">",
"      Min JK, Spencer KT, Furlong KT, et al. Clinical features of complications from transesophageal echocardiography: a single-center case series of 10,000 consecutive examinations. J Am Soc Echocardiogr 2005; 18:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/13\">",
"      Spier BJ, Larue SJ, Teelin TC, et al. Review of complications in a series of patients with known gastro-esophageal varices undergoing transesophageal echocardiography. J Am Soc Echocardiogr 2009; 22:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/14\">",
"      Suriani RJ, Cutrone A, Feierman D, Konstadt S. Intraoperative transesophageal echocardiography during liver transplantation. J Cardiothorac Vasc Anesth 1996; 10:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/15\">",
"      Vedrinne JM, Duperret S, Bizollon T, et al. Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest 1997; 111:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/16\">",
"      Saphir JR, Cooper JA, Kerbavez RJ, et al. Upper airway obstruction after transesophageal echocardiography. J Am Soc Echocardiogr 1997; 10:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/17\">",
"      Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med 2004; 164:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/18\">",
"      Kane GC, Hoehn SM, Behrenbeck TR, Mulvagh SL. Benzocaine-induced methemoglobinemia based on the Mayo Clinic experience from 28 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors. Arch Intern Med 2007; 167:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/19\">",
"      Henry LR, Pizzini M, Delarso B, Ridge JA. Methemoglobinemia: early intraoperative detection by clinical observation. Laryngoscope 2004; 114:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/20\">",
"      Steckelberg JM, Khandheria BK, Anhalt JP, et al. Prospective evaluation of the risk of bacteremia associated with transesophageal echocardiography. Circulation 1991; 84:177.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/22\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/23\">",
"      Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/24\">",
"      Zaroff JG, Picard MH. Transesophageal echocardiographic (TEE) evaluation of the mitral and tricuspid valves. Cardiol Clin 2000; 18:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/25\">",
"      Chan SK, Kannam JP, Douglas PS, Manning WJ. Multiplane transesophageal echocardiographic assessment of left atrial appendage anatomy and function. Am J Cardiol 1995; 76:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/26\">",
"      Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus. Circulation 1991; 84:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/27\">",
"      Subramaniam B, Riley MF, Panzica PJ, Manning WJ. Transesophageal echocardiographic assessment of right atrial appendage anatomy and function: comparison with the left atrial appendage and implications for local thrombus formation. J Am Soc Echocardiogr 2006; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38280/abstract/28\">",
"      Tanabe K, Yoshitomi H, Oyake N, et al. Effects of supine and lateral recumbent positions on pulmonary venous flow in healthy subjects evaluated by transesophageal Doppler echocardiography. J Am Coll Cardiol 1994; 24:1552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5320 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38280=[""].join("\n");
var outline_f37_24_38280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9886539\">",
"      INDICATIONS FOR TEE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7839812\">",
"      TEE in critical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2904159\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SAFETY OF TEE EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THE NORMAL HEART AND GREAT VESSELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Horizontal plane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Four-chamber view",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mitral valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Left atrial appendage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pulmonary veins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Right and left atria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Aortic leaflets and aortic root",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vertical plane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Imaging at the gastroesophageal junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gastric imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5320|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/4/16463\" title=\"diagnostic image 1\">",
"      Lateral CXR barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/40/23168\" title=\"diagnostic image 2\">",
"      TEE 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/55/22399\" title=\"diagnostic image 3\">",
"      TEE left upper pulmonary vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/27/6591\" title=\"diagnostic image 4\">",
"      TEE pulmonary arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/6/9327\" title=\"diagnostic image 5\">",
"      TEE right left atria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/20/35151\" title=\"diagnostic image 6\">",
"      TEE right pulmonary veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/18/37154\" title=\"diagnostic image 7\">",
"      TEE aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/52/833\" title=\"diagnostic image 8\">",
"      TEE coronary sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/3/28724\" title=\"diagnostic image 9\">",
"      TEE right left outflow tracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/60/32719\" title=\"diagnostic image 10\">",
"      TEE pulmonic valve and pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/39/30335\" title=\"diagnostic image 11\">",
"      TEE vena cavae bicaval view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/20/38222\" title=\"diagnostic image 12\">",
"      TEE right pulmonary vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/47/27377\" title=\"diagnostic image 13\">",
"      TEE right atrial appendage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/40/43648\" title=\"diagnostic image 14\">",
"      TEE short axis view LV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/42/7840\" title=\"diagnostic image 15\">",
"      TEE right sided structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/34/12833\" title=\"diagnostic image 16\">",
"      TEE modified apical 4 chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/42/16036\" title=\"diagnostic image 17\">",
"      TEE descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/14/21728\" title=\"diagnostic image 18\">",
"      TEE transverse aorta and aortic arch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/24/3471\" title=\"diagnostic image 19\">",
"      TEE pulmonic valve and pulmonary artery color Doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5320|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/41/8850\" title=\"figure 1A\">",
"      Cardiac plane definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/55/26487\" title=\"figure 1B\">",
"      LV segmentation I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/9/16533\" title=\"figure 1C\">",
"      Coronary artery territories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5320|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/10/30892\" title=\"table 1\">",
"      Evaluation hypotension by TEE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42040?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13240?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of the left ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31878?source=related_link\">",
"      Transesophageal echocardiography in traumatic rupture of the aortic isthmus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38281="Management of refractory cutaneous dermatomyositis";
var content_f37_24_38281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of refractory cutaneous dermatomyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38281/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38281/contributors\">",
"     Ruth Ann Vleugels, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38281/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38281/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/24/38281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19331632\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic dermatomyositis (DM) is an idiopathic inflammatory myopathy that most commonly presents with progressive, symmetric proximal muscle weakness and a group of characteristic cutaneous findings. The cutaneous manifestations of DM may also develop in the absence of detectable muscle disease, and can persist after the successful treatment of DM-associated myositis.",
"   </p>",
"   <p>",
"    Skin lesions of DM are often resistant to photoprotection and topical therapies alone, necessitating the initiation of systemic therapy. Patients who fail to respond to antimalarials and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or who relapse during therapy with these agents require more aggressive immunosuppressive or immunomodulatory drugs.",
"   </p>",
"   <p>",
"    The management of patients with refractory cutaneous DM will be discussed here. The initial treatment of cutaneous DM, as well as the clinical manifestations, diagnosis, and management of the extracutaneous manifestations of DM and juvenile DM are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15513?source=see_link\">",
"     \"Initial management of cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331639\">",
"    <span class=\"h1\">",
"     APPROACH TO REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM is associated with characteristic cutaneous findings, most notably a pruritic, violaceous to erythematous eruption involving the scalp face, neck, upper trunk, arms, and dorsal hands (",
"    <a class=\"graphic graphic_picture graphicRef56879 graphicRef68649 graphicRef54230 graphicRef77822 graphicRef79924 graphicRef63383 graphicRef75246 \" href=\"mobipreview.htm?43/3/44090\">",
"     picture 1A-G",
"    </a>",
"    ). Pruritus associated with DM can be severe, leading to significant detrimental effects on patient quality of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15513?source=see_link&amp;anchor=H377365#H377365\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Classification of cutaneous DM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For a subset of patients with skin manifestations of DM, trials of multiple therapies (in combination or sequentially) are required to identify the treatment regimen that produces satisfactory disease control. Because many patients fail to improve adequately with photoprotection, antipruritics, and topical corticosteroids or topical calcineurin inhibitors, the addition of systemic antimalarials or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is often necessary. Patients who fail to respond to these conventional interventions or who relapse after an initial response require the initiation of more aggressive therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15513?source=see_link&amp;anchor=H13069029#H13069029\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Approach to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H676881\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a wide variety of immunomodulatory and immunosuppressive medications have been used in the treatment of refractory cutaneous DM, few formal studies have investigated the efficacy and safety of these agents in this disorder.",
"   </p>",
"   <p>",
"    We typically treat patients who have failed conventional therapy (photoprotection, topical agents, antimalarials,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) or intravenous immunoglobulin (IVIG) based upon the availability of small, uncontrolled studies that support their efficacy. The relatively favorable side effect profile of MMF leads us to favor this drug slightly over IVIG. In addition, the intravenous route of administration and high cost of IVIG may be prohibitive in some clinical settings. Despite the fact that evidence that supports the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    for skin disease in DM is limited to a few case reports, the oral route of administration and well-tolerated nature of this drug make it another reasonable therapeutic option for patients with refractory skin manifestations of DM. (See",
"    <a class=\"local\" href=\"#H9149463\">",
"     'Mycophenolate mofetil'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19331646\">",
"     'Intravenous immunoglobulin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2345188\">",
"     'Dapsone'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Like MMF and IVIG,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has shown efficacy for refractory cutaneous DM in a small, uncontrolled study. However, conflicting results have been reported, and further studies are necessary to determine the ideal regimen and patient population for rituximab therapy. (See",
"    <a class=\"local\" href=\"#H9149216\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional treatments that may be tried in patients with refractory cutaneous DM include systemic immunosuppressants, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , as well as biologic TNF inhibitors. Due to the limited availability of evidence in support of the efficacy of these agents and the risks for severe adverse effects associated with many of these drugs, we generally reserve the use of these agents to patients who have failed or who are poor candidates for other therapies for refractory disease. The need for treatment of concomitant refractory muscle disease can also influence the choice of therapy. (See",
"    <a class=\"local\" href=\"#H2342037\">",
"     'Other therapies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9149463\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is an immunosuppressive agent that reversibly inhibits inosine monophosphate dehydrogenase, an enzyme required for de novo purine synthesis. The dependency of T and B lymphocytes on this pathway for the production of DNA and RNA is responsible for the selective immunosuppressive properties of MMF. MMF is effective for the treatment of myositis in DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], and the drug also appears to be beneficial for skin disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345251\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of MMF for the cutaneous manifestations of DM is supported by uncontrolled studies and a case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. In a retrospective study of 12 patients with cutaneous DM that was refractory to other systemic drugs, MMF given alone or as an adjunctive therapy resulted in improvement in 10 patients (83 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/6\">",
"     6",
"    </a>",
"    ]. Most responses occurred within four to eight weeks, and all responses were attained at doses of 2 to 3",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    MMF also was effective in a series of four patients with skin lesions of DM that failed to respond to systemic glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In patients who are transitioning from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to MMF due to an inadequate response to methotrexate, we often continue methotrexate at a reduced dose (usually 10 to 15",
"    <span class=\"nowrap\">",
"     mg/",
"     <strong>",
"      week",
"     </strong>",
"     )",
"    </span>",
"    for several weeks to several months after starting MMF. This may reduce the risk for disease flares while awaiting the drug&rsquo;s onset of action and during titration of the MMF dose. We taper and eventually discontinue methotrexate once clinical improvement is noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345314\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMF has a favorable toxicity profile when compared to many other systemic immunosuppressants. Gastrointestinal distress is the most common adverse effect of the drug; additional side effects include teratogenicity and reversible cytopenias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     \"Mycophenolate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether MMF leads to an increased risk for malignancy. In the retrospective study described above, one patient with a history of breast cancer developed cancer in the contralateral breast during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/6\">",
"     6",
"    </a>",
"    ]. Another patient in the study developed an Epstein Barr virus-related B-cell lymphoma of the central nervous system that resolved without further intervention following the discontinuation of MMF and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link&amp;anchor=H11#H11\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331646\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) is a product derived from pooled donor plasma that contains numerous immunoregulatory substances. IVIG has been used successfully for refractory extracutaneous manifestations of adult and juvenile DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/7-13\">",
"     7-13",
"    </a>",
"    ] and appears to be beneficial in some patients with cutaneous manifestations of DM that have failed to respond adequately to other therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345428\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in cutaneous DM was reported in a randomized trial of IVIG for DM. In this trial, IVIG was added to the treatment regimens of 15 patients with myositis and cutaneous DM who had failed to improve with immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients were given IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    or placebo once monthly for three consecutive months, and had the option to cross over to the alternative therapy after the initial treatment period. Marked improvement in skin disease (assessed through clinical photographs) occurred in 8 out of 12 patients treated with IVIG in either the initial or crossover phase. Improvements in cutaneous disease preceded or coincided with muscle improvement, which was evident approximately 15 days after the first infusion of IVIG and peaked between the second and third infusions. The effect of placebo treatment on skin disease was not reported. &nbsp;",
"   </p>",
"   <p>",
"    Case reports and case series offer additional support for the use of IVIG in refractory DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In a series of patients with inflammatory myopathy that included four patients with refractory adult DM, dramatic improvement in cutaneous DM occurred in three patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/16\">",
"     16",
"    </a>",
"    ]. Low dose IVIG may also be effective for some patients; in one woman with cutaneous manifestations of DM refractory to systemic glucocorticoids, five day courses of IVIG (0.1",
"    <span class=\"nowrap\">",
"     g/kg/day)",
"    </span>",
"    given twice over the course of two weeks led clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse of muscle weakness occurs soon after the discontinuation of IVIG in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/14,18\">",
"     14,18",
"    </a>",
"    ], and based upon clinical experience, the duration of response in cutaneous disease also may be variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatment may need to be continued to maintain improvement, and the high expense of IVIG makes this treatment option less favorable for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345615\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of IVIG include hypersensitivity reactions, headaches, vasculitis, aseptic meningitis, renal failure, myocardial infarction, and thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345188\">",
"    <span class=\"h2\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is a sulfonamide drug commonly used for the treatment of neutrophilic dermatoses. Dapsone also is an effective therapy for some patients with cutaneous lupus erythematosus, and limited evidence suggests that dapsone may be of benefit in cutaneous DM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=see_link&amp;anchor=H14890811#H14890811\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\", section on 'Dapsone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345363\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports support the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    for recalcitrant cutaneous DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one report, two patients with cutaneous DM unresponsive to combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , quinacrine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and other immunosuppressive medications had rapid improvement in skin lesions with the addition of dapsone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/21\">",
"     21",
"    </a>",
"    ]. The responses to dapsone correlated with treatment; skin disease worsened upon withdrawal of dapsone and improved after reinitiation.",
"   </p>",
"   <p>",
"    In contrast, failures to respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    have been documented in a patient with drug-induced amyopathic DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/22\">",
"     22",
"    </a>",
"    ] and a patient with postmyopathic DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15513?source=see_link&amp;anchor=H2068610#H2068610\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Amyopathic DM'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15513?source=see_link&amp;anchor=H2068718#H2068718\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Postmyopathic DM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is usually initiated at a dose of 25 mg twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/24\">",
"     24",
"    </a>",
"    ]. The dose can be increased to a total dose of 200 to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    when necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345382\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis and methemoglobinemia may occur in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy. Patients with glucose-6-phosphate dehydrogenase deficiency are at greater risk for hemolysis than the general population. Peripheral neuropathy, agranulocytosis, and a hypersensitivity syndrome are additional adverse effects of dapsone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug eruptions\", section on 'Hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9149216\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B lymphocytes. Case reports have documented improvement in the muscular, pulmonary, cardiac,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cutaneous manifestations of DM with rituximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/25-34\">",
"     25-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, formal studies have yielded conflicting results on the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for the cutaneous manifestations of DM. Data on the effects of rituximab on extracutaneous manifestations of DM are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345695\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beneficial effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    on the cutaneous manifestations of DM were reported in an open label study in which seven patients with DM were treated with four weekly infusions of rituximab (100 or 375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /infusion)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/35\">",
"     35",
"    </a>",
"    ]. Among the five patients in whom the presence of a cutaneous eruption of DM was documented at the start of the study, all exhibited improvement in skin disease with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, hair regrowth occurred in two patients with alopecia secondary to DM. Treatment with rituximab was also beneficial as an adjunctive therapy in a retrospective study of juvenile DM; three out of four patients exhibited improvement in cutaneous and muscle disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, an open label study in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (two 1 g doses separated by two weeks) was added to the treatment regimens of eight adults with DM did not detect improvements in skin disease following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/37\">",
"     37",
"    </a>",
"    ]. Although all eight patients demonstrated sustained depletion of peripheral B cells on rituximab, a statistically significant change in the mean Dermatomyositis Skin Severity Index (DSSI) score was not detected. &nbsp;",
"   </p>",
"   <p>",
"    Although no randomized trials have specifically evaluated the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    on cutaneous DM, a 44-week multicenter randomized trial (Rituximab in Myositis [RIM] trial) of 200 adults and children with refractory DM or polymyositis that compared patients treated with rituximab on weeks zero and one to patients treated with rituximab on weeks eight and nine found results that suggested rituximab may be beneficial for myositis in this population. Despite a failure to identify a significant difference in the time to treatment response in the two groups, 83 percent of patients met criteria for improvement in myositis by the end of the trial. Neither of the two validated indices for the assessment of disease severity in cutaneous DM (DSSI nor the Cutaneous Dermatomyositis Disease Area and Severity Index [CDASI]) was utilized to evaluate skin disease, limiting the ability of this trial to assess the effects of rituximab on cutaneous disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional studies are necessary to determine the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    specifically for cutaneous DM, the ideal treatment regimen, and the patient population that might benefit most from rituximab. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345721\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    usually is well tolerated. However, the drug has been associated with nausea, serum sickness-like reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/38\">",
"     38",
"    </a>",
"    ], and infusion-related events, including hypotension, fevers, and rigors. In addition, a boxed warning on the drug label has been mandated by the US Food and Drug Administration (FDA) due to reports of fatalities from infusion reactions, severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy due to JC virus in patients treated with rituximab. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342037\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on other therapies for cutaneous DM are limited. This lack of data and the potential for serious adverse effects with many of these alternative agents generally limits their use to patients who have failed or who cannot receive other treatments for refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342426\">",
"    <span class=\"h2\">",
"     Immunosuppressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    have been used for the treatment of refractory noncutaneous manifestations of DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/30,39-57\">",
"     30,39-57",
"    </a>",
"    ]. However, the evidence for the efficacy of these agents for cutaneous disease is primarily limited to case reports and documentation of clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/24,58-62\">",
"     24,58-62",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331716\">",
"    <span class=\"h2\">",
"     Biologic TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports document benefit from TNF-alpha inhibitors for extracutaneous manifestations of adult and juvenile DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/63-73\">",
"     63-73",
"    </a>",
"    ], and cases in which these agents improved refractory skin disease in DM have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/64,73\">",
"     64,73",
"    </a>",
"    ]. In one patient, combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    led to improvement in cutaneous and muscle disease after failure to respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , MMF, and methotrexate plus systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/64\">",
"     64",
"    </a>",
"    ]. Improvement was maintained for at least six months with etanercept as monotherapy.",
"   </p>",
"   <p>",
"    The potential for adverse consequences of TNF-alpha inhibitor therapy also must be considered in patients with DM. Disease progression or exacerbations have occurred during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/74-76\">",
"     74-76",
"    </a>",
"    ], and it is unknown whether the baseline risk for malignancy associated with adult DM is augmented with the use of TNF-alpha inhibitors. Moreover, cases in which DM-like disorders, including the cutaneous manifestations of DM, have developed in patients treated with biologic anti-TNF-alpha therapy for inflammatory arthritides have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2342513\">",
"    <span class=\"h2\">",
"     Other systemic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    , an immunomodulatory agent used in the treatment of rheumatoid arthritis, may be effective in some patients with cutaneous DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/23,80\">",
"     23,80",
"    </a>",
"    ]. Leflunomide led to improvements in skin disease in a series of three patients with DM refractory to multiple other systemic therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases in which patients with DM improved during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , an agent believed to exert antiinflammatory effects through inhibition of TNF-alpha, have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/22,81\">",
"     22,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiestrogens (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or anastrazole) appeared to contribute to improvements in skin disease in two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/82\">",
"     82",
"    </a>",
"    ]. The mechanism through which antiestrogens could contribute to resolution of DM is unknown; a relationship between estrogen and the production of proinflammatory cytokines, such as TNF-alpha, has been postulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1822005\">",
"    <span class=\"h2\">",
"     Total body irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body irradiation was associated with improvements in myositis and skin disease in two patients with refractory DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/83\">",
"     83",
"    </a>",
"    ]. Due to the potential for short and long term complications and the availability of other therapeutic options, total body irradiation generally is not recommended for the treatment of cutaneous DM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H4#H4\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Total body irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4764538\">",
"    <span class=\"h3\">",
"     Hematopoietic stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cell transplantation has been used in the treatment of severe and refractory autoimmune diseases, including DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/84-90\">",
"     84-90",
"    </a>",
"    ]. In a child with juvenile DM, autologous peripheral hematopoietic stem cell transplantation was associated with improvements in muscle disease and the cutaneous manifestations of DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/86\">",
"     86",
"    </a>",
"    ]. Resolution of DM-associated calcinosis cutis has also been reported following hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19331772\">",
"     'Calcinosis cutis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331772\">",
"    <span class=\"h1\">",
"     CALCINOSIS CUTIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcinosis of the skin, soft tissues, muscle, or bone is a challenging complication of DM that is estimated to occur in at least 30 percent of patients with juvenile DM, and occasionally develops in patients with adult DM. In juvenile DM, early therapeutic intervention may decrease the incidence or severity of calcinosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/91-97\">",
"     91-97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\", section on 'Calcinosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases in which calcinosis responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , intralesional corticosteroids, intravenous immunoglobulin, or electric shock wave lithotripsy have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/91,98-113\">",
"     91,98-113",
"    </a>",
"    ]. However, none of these therapies have been shown to be consistently effective for calcinosis secondary to DM.",
"   </p>",
"   <p>",
"    Resolution of calcinosis has also been reported in patients receiving treatment for DM with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , IVIG, or hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/69,84,114,115\">",
"     69,84,114,115",
"    </a>",
"    ]. Surgical excision can be used to remove cutaneous or subcutaneous lesions that are symptomatic and unresponsive to medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/116\">",
"     116",
"    </a>",
"    ]. Occasionally, calcinosis cutis regresses spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38281/abstract/113\">",
"     113",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331779\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatomyositis (DM) is an idiopathic inflammatory disorder that is associated with a set of characteristic cutaneous findings. Patients who fail to respond to conventional therapies or who experience recurrence of disease with standard therapies require more aggressive immunosuppressive or immunomodulatory therapies for disease control. (See",
"      <a class=\"local\" href=\"#H19331639\">",
"       'Approach to refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data are limited on treatments for refractory cutaneous DM. The limited availability data on efficacy and concerns over drug safety, tolerability, and cost influence the selection of the most appropriate therapy. For patients with cutaneous manifestations of DM that are refractory to topical therapies, antimalarials, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil based on evidence supporting the efficacy and relative safety of this drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In patients who do not tolerate or fail to improve with MMF and for whom the cost of IVIG is not prohibitive, we suggest treatment with IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Additional studies are necessary to clarify the effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      on cutaneous DM. (See",
"      <a class=\"local\" href=\"#H19331639\">",
"       'Approach to refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      , have also been used for cutaneous DM. The lack of strong evidence in support of these therapies and the risks of serious adverse effects generally relegate the use of these agents to patients who have failed or cannot tolerate other therapies. The role of biologic TNF-alpha inhibitors in refractory cutaneous DM remains uncertain. (See",
"      <a class=\"local\" href=\"#H2342037\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcinosis cutis is a common cutaneous manifestation in patients with juvenile DM. Although a variety of agents have been used for this indication, none have shown consistent benefit in patients with calcinosis cutis. (See",
"      <a class=\"local\" href=\"#H19331772\">",
"       'Calcinosis cutis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/1\">",
"      Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/2\">",
"      Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/3\">",
"      Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001; 202:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/4\">",
"      Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep 2006; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/5\">",
"      Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000; 27:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/6\">",
"      Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006; 142:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/7\">",
"      Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/8\">",
"      Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/9\">",
"      Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/10\">",
"      Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/11\">",
"      Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/12\">",
"      Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. Arch Dis Child 1995; 72:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/13\">",
"      Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol 2012; 30:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/14\">",
"      Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/15\">",
"      Peake MF, Perkins P, Elston DM, et al. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis 1998; 62:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/16\">",
"      Barbasso Helmers S, Dastmalchi M, Alexanderson H, et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007; 66:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/17\">",
"      Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol 1999; 26:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/18\">",
"      Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol 2006; 6:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/19\">",
"      Callen JP. Immunomodulatory treatment for dermatomyositis. Curr Allergy Asthma Rep 2008; 8:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/20\">",
"      Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol 1994; 19:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/21\">",
"      Cohen JB. Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. Int J Dermatol 2002; 41:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/22\">",
"      Flores-Su&aacute;rez LF, Morales H, Angeles A, Kraus A. Drug-induced amyopathic dermatomyositis. J Clin Rheumatol 2002; 8:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/23\">",
"      Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008; 58:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/24\">",
"      Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother 2004; 5:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/25\">",
"      Rios Fern&aacute;ndez R, Callejas Rubio JL, S&aacute;nchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/26\">",
"      Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/27\">",
"      Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005; 11:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/28\">",
"      Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/29\">",
"      Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/30\">",
"      Kaposztas Z, Etheridge WB, Kahan BD. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant Proc 2008; 40:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/31\">",
"      Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008; 75:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/32\">",
"      Feist E, D&ouml;rner T, S&ouml;rensen H, Burmester GR. Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008; 35:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/33\">",
"      Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/34\">",
"      Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/35\">",
"      Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/36\">",
"      Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/37\">",
"      Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/38\">",
"      Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/39\">",
"      Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/40\">",
"      Grau JM, Herrero C, Casademont J, et al. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 1994; 21:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/41\">",
"      Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/42\">",
"      Vencovsk&yacute; J, Jarosov&aacute; K, Mach&aacute;cek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/43\">",
"      Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/44\">",
"      Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/45\">",
"      Kim HJ, Hong YK, Yoo WH. Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature. Rheumatol Int 2009; 29:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/46\">",
"      Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005; 23:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/47\">",
"      Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/48\">",
"      Ando M, Miyazaki E, Yamasue M, et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 2010; 29:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/49\">",
"      Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 2005; 44:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/50\">",
"      Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003; 32:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/51\">",
"      Meyer O, Hayem G, Palazzo E, et al. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol 2005; 23:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/52\">",
"      Takashi S, Okubo Y, Yamazaki Y, et al. [Amyopathic dermatomyositis with interstitial pneumonia: effective treatment with cyclophosphamide pulse therapy]. Nihon Kokyuki Gakkai Zasshi 1999; 37:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/53\">",
"      Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/54\">",
"      Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/55\">",
"      Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol 1991; 9:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/56\">",
"      Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum 1985; 28:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/57\">",
"      Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005; 52:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/58\">",
"      Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med 2008; 47:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/59\">",
"      Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008; 27:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/60\">",
"      Mart&iacute;n Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. [Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases]. Med Clin (Barc) 2006; 127:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/61\">",
"      Yamada A, Ohshima Y, Omata N, et al. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004; 163:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/62\">",
"      Shimojima Y, Ishii W, Kato T, et al. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med 2003; 42:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/63\">",
"      Hengstman G, van den Hoogen, van Engelen B, et al. Anti-TNF blockage with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheum 2000; 43:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/64\">",
"      Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006; 54:S139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/65\">",
"      Selva-O'Callaghan A, Mart&iacute;nez-Costa X, Solans-Laque R, et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004; 43:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/66\">",
"      Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004; 43:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/67\">",
"      Korkmaz C, Temiz G, Cetinbas F, B&uuml;y&uuml;kkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford) 2004; 43:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/68\">",
"      Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/69\">",
"      Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/70\">",
"      Miller M, Mendez E, Klein-Gitelman M. Use of etanercept in juvenile dermatomyositis. Arthritis Rheum 2002; 46:S306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/71\">",
"      Saddeh CK. Entanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum 2000; 43:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/72\">",
"      Nzeusseu A, Durez P, Houssiau H, Devogelaer J. Successful use of infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2000; 43:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/73\">",
"      Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007; 26:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/74\">",
"      Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/75\">",
"      Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/76\">",
"      Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/77\">",
"      Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7:R666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/78\">",
"      Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006; 55:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/79\">",
"      Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010; 146:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/80\">",
"      Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008; 67:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/81\">",
"      Sebastiani M, Puccini R, Manfredi A, et al. Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report. Ther Apher Dial 2009; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/82\">",
"      Sereda D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006; 142:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/83\">",
"      Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve 1988; 11:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/84\">",
"      Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010; 39:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/85\">",
"      Saccardi R, Di Gioia M, Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol 2008; 15:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/86\">",
"      Wu FQ, Luan Z, Lai JM, et al. [Treatment of refractory rheumatism among preschool children with autologous peripheral blood hematopoietic stem cell transplantation]. Zhonghua Er Ke Za Zhi 2007; 45:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/87\">",
"      Oryoji K, Himeji D, Nagafuji K, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol 2005; 24:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/88\">",
"      Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/89\">",
"      van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/90\">",
"      Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001; 60:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/91\">",
"      Pachman LM. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy. Arthritis Rheum 1994; 37:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/92\">",
"      Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/93\">",
"      Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/94\">",
"      Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/95\">",
"      Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 1987; 26:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/96\">",
"      Shehata R, al-Mayouf S, al-Dalaan A, et al. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 1999; 17:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/97\">",
"      Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/98\">",
"      Shahani L. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep 2012; 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/99\">",
"      Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol 1998; 25:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/100\">",
"      Harel L, Harel G, Korenreich L, et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol 2001; 28:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/101\">",
"      Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol 1988; 124:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/102\">",
"      Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001; 138:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/103\">",
"      Ambler GR, Chaitow J, Rogers M, et al. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005; 32:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/104\">",
"      Downey EC Jr, Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 1988; 123:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/105\">",
"      Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg 2008; 34:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/106\">",
"      Chan AY, Li E. Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery. Clin Rheumatol 2005; 24:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/107\">",
"      Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol 2005; 15:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/108\">",
"      Oliveri MB, Palermo R, Mautalen C, H&uuml;bscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996; 23:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/109\">",
"      Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford) 2000; 39:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/110\">",
"      Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010; 28:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/111\">",
"      Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010; 77:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/112\">",
"      Fuchs D, Fruchter L, Fishel B, et al. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986; 5:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/113\">",
"      Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis 2010; 13:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/114\">",
"      Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol 2008; 144:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/115\">",
"      Pe&ntilde;ate Y, Guillermo N, Melwani P, et al. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 2009; 60:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38281/abstract/116\">",
"      Shearin JC, Pickrell K. Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis. Ann Plast Surg 1980; 5:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13774 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38281=[""].join("\n");
var outline_f37_24_38281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19331779\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19331632\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19331639\">",
"      APPROACH TO REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H676881\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9149463\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345251\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345314\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331646\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345428\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345615\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2345188\">",
"      Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345363\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345382\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9149216\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345695\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345721\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2342037\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342426\">",
"      Immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331716\">",
"      Biologic TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2342513\">",
"      Other systemic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1822005\">",
"      Total body irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4764538\">",
"      - Hematopoietic stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19331772\">",
"      CALCINOSIS CUTIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19331779\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13774|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/6/29793\" title=\"picture 1A\">",
"      Dermatomyositis - heliotrope eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/10/29860\" title=\"picture 1B\">",
"      Dermatomyositis - heliotrope eruption on eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/58/13217\" title=\"picture 1C\">",
"      Dermatomyositis - neck and chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/41/13969\" title=\"picture 1D\">",
"      Dermatomyositis - upper back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/41/27284\" title=\"picture 1E\">",
"      Dermatomyositis - hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/45/44754\" title=\"picture 1F\">",
"      Gottron papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/48/6915\" title=\"picture 1G\">",
"      Gottron sign",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15513?source=related_link\">",
"      Initial management of cutaneous dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=related_link\">",
"      Management of refractory discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=related_link\">",
"      Mycophenolate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38282="Normal aging";
var content_f37_24_38282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal aging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38282/contributors\">",
"     George E Taffet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38282/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/24/38282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/24/38282/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/24/38282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H937028\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Time modifies many biologic processes. Aging is characterized by progressive and broadly predictable changes that are associated with increased susceptibility to many diseases. Aging is not a homogenous process. Rather, organs in the same person age at different rates influenced by multiple factors, including genetic make-up, lifestyle choices, and environmental exposures. A Danish twin study found that genetics accounted for about 25 percent of the variation in longevity among twins, and environmental factors accounted for about 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/1\">",
"     1",
"    </a>",
"    ]. However, with greater longevity (to age 90 or 100), genetic influences became more important.",
"   </p>",
"   <p>",
"    This topic will present an overview of normal aging. Effects of aging on the endocrine and immune systems are discussed in more detail separately, as is abnormal aging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/22/12650?source=see_link\">",
"     \"Endocrine changes with aging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810845\">",
"    <span class=\"h1\">",
"     AGE-ASSOCIATED PHYSIOLOGIC CHANGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178571021\">",
"    <span class=\"h2\">",
"     Physiologic rhythms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organization of rhythmic physiologic processes is altered by aging. Age impacts the circadian pattern of body temperature, plasma cortisol, and sleep, and can cause desynchronization or \"internal phase drift.\" Phase advances can lead to the occurrence of some rhythmic functions (eg, the 24-hour body temperature trough and sleep onset) one to two hours earlier in older adults. The pulsatile secretion of gonadotropins, growth hormone, thyrotropin, melatonin, and adrenocorticotropic hormone (ACTH) are attenuated with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/2\">",
"     2",
"    </a>",
"    ]. One source of this dysfunction appears to be neuronal loss in the suprachiasmatic nucleus in the hypothalamus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, age may delay the ability to reset physiologic rhythms to a new photoperiod.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97310021\">",
"    <span class=\"h2\">",
"     Loss of complexity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of complexity, a concept derived from the field of nonlinear dynamics, may be a general principle of all aging systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/4\">",
"     4",
"    </a>",
"    ]. This loss of complexity may result in decreased heart-rate variability, blood-pressure variability, electroencephalographic frequencies, response to auditory frequencies, and response to stress. Age-related loss of complexity may not be immutable, however; as an example, senior athletes show greater heart rate variability than sedentary age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810854\">",
"    <span class=\"h2\">",
"     Homeostenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homeostenosis refers to the concept that, from maturity to senescence, diminishing physiologic reserves are available to meet challenges to homeostasis. This concept was first recognized by Walter Cannon in the 1940s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/6\">",
"     6",
"    </a>",
"    ]. Homeostenosis leads to the increased vulnerability to disease that occurs with aging.",
"   </p>",
"   <p>",
"    A figure graphically displays the traditional thinking about homeostenosis (",
"    <a class=\"graphic graphic_figure graphicRef58907 \" href=\"mobipreview.htm?35/21/36178\">",
"     figure 1",
"    </a>",
"    ). The endpoint of this process is frailty, where even the smallest challenge overwhelms the available reserves and results in disaster. The &ldquo;precipice&rdquo; may be variably defined: death, cardiac arrest, hospital admission, or onset of a symptom such as confusion or incontinence. Aging itself brings the individual closer to the precipice by the loss of physiologic reserves. With aging, the area in which the older person can bring themselves back to homeostasis by invoking their reserves narrows or becomes stenotic.",
"   </p>",
"   <p>",
"    Evidence for this model is plentiful. As an example, the APACHE severity of illness scales, used to predict prognosis for patients in intensive care, have a correction for age. The Acute Physiologic Assessment, a component of the APACHE score, indicates deviation from homeostatic values for 12 variables, including vital signs, oxygenation, pH, electrolytes, hematocrit, white blood count, and creatinine. A zero score indicates homeostasis, and a greater point total indicates a larger deviation from homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a comparison of young and old patients who had a cardiac arrest, the younger group (mean age 59) had significantly higher Acute Physiologic Assessment scores in the 24 hours pre-arrest than the older group (mean age 75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/9\">",
"     9",
"    </a>",
"    ]. These data indicate that the deviation from homeostasis needed to cross a critical threshold (cardiac arrest) is less in the old. In practical terms, the creators of the APACHE scales recognize this by giving &ldquo;age points&rdquo; so that total scores are equalized between the groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=see_link&amp;anchor=H5#H5\">",
"     \"Predictive scoring systems in the intensive care unit\", section on 'Acute Physiologic and Chronic Health Evaluation (APACHE)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintaining homeostasis is a dynamic, active process. Frailty is the state when physiologic reserves are maximally invoked just to maintain homeostasis and any challenge will cross some threshold. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=see_link\">",
"     \"Frailty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The &ldquo;family of precipices&rdquo; concept is useful in understanding altered presentations of disease in older adults. As an example, delirium is a common presentation of a wide variety of illness in the older individual, a marker of the uneasy truce that the old brain maintains with the environment. A given older person may have the same presentation (confusion) for a urinary tract infection, gastrointestinal bleeding, or a myocardial infarction. The systemic responses to these differing illnesses may be similar, involving catecholamines and mediators of inflammation. The &ldquo;anti-confusion reserves&rdquo; are exhausted so the distance from homeostasis to this &ldquo;precipice&rdquo; is easily crossed.",
"   </p>",
"   <p>",
"    In summary, an apparent loss of physiologic reserves in older adults leads to intolerance to challenges to their homeostasis. This increased vulnerability is in part because the older person is continually expending reserves to compensate for primary age changes, as well as other processes that are absent or trivial in the younger individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810861\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of additional challenges, the hematopoietic system maintains adequate function throughout an individual&rsquo;s lifespan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/10\">",
"     10",
"    </a>",
"    ]. Red cell life span, iron turnover, and blood volume are unchanged with age. However, bone marrow mass decreases and fat in the bone marrow increases with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Therefore, functional reserves are reduced with age. Thus, advanced age may be an important consideration for determining suitability as a donor for hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/13\">",
"     13",
"    </a>",
"    ] or tolerance of chemotherapy.",
"   </p>",
"   <p>",
"    The compensatory hematopoietic response to phlebotomy, hypoxia, and other challenges is delayed and less vigorous in the healthy older person [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/14\">",
"     14",
"    </a>",
"    ]. This is due to changes in both populations of progenitor cells and the bone marrow environmental matrix. When young mice are transfused with a cellular mixture of marrow from older and younger mice, the young marrow assumes the bulk of the repopulation burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies comparing the bone marrow of healthy older and younger patients found a 35 percent decrease in the colony size of the stimulated erythroid progenitor cells (CFU-E) in older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/16\">",
"     16",
"    </a>",
"    ]. Another study suggests that inability to produce critical stimulatory hormones (stem cell factor, GM-CSF and IL-3) is the major factor accounting for functional difference between bone marrow from older and younger people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/17\">",
"     17",
"    </a>",
"    ]. The presence of abnormalities both intrinsic to older progenitor cells, as well as the milieu, is consistent with findings from a study that progenitor cells isolated from young animals demonstrated a decreased ability to repopulate bone marrow in old animals, while cells from old animals had a decreased ability to repopulate young animals; the donor age effect was about equal in magnitude to the host age-effect and the worst yield was when old marrow was given to an old host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total circulating white cells counts do not change with age in healthy older people, but the function of several cell types is reduced. Age-related changes in the immune system are discussed separately. (See",
"    <a class=\"local\" href=\"#H23811008\">",
"     'Immune system'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age is a significant risk factor for myelotoxicity due to chemotherapy regimens for malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/19\">",
"     19",
"    </a>",
"    ]. However, consistent with many other changes, heightened sensitivity to chemotherapy and impaired recovery of the bone marrow is not a uniform finding in all older adults. This underscores the importance of heterogeneity among older people in their functional status as well as their homeostatic reserves. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Though the number of platelets is unchanged with age, platelet responsiveness to a number of thrombotic stimulators is increased. This results in a small but consistent decrease in bleeding time with age. Old age should be considered a procoagulant state. Fibrinogen, factor V, factor VII, factor VIII, factor IX, high molecular-weight kininogen, and prekallikrein increase with age in healthy humans, possibly related to the low grade inflammation that is part of normal aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/20\">",
"     20",
"    </a>",
"    ]. Fibrin degradation fragments (D-dimers) are elevated two-fold in healthy older subjects with no evidence of thrombosis and may be even higher in hospitalized older adults such that an age incorporating formula for D-dimer interpretation has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/21\">",
"     21",
"    </a>",
"    ]. Plasminogen activator inhibitor-1, the major inhibitor of fibrinolysis, increases dramatically with aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Overall, age is an important risk factor for deep venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810868\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL TRACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall effects of aging on the gastrointestinal system are modest; aging itself does not cause malnourishment. Nonetheless, age-related changes in gastrointestinal systems affect the incidence and presentation of multiple gastrointestinal problems in older adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810875\">",
"    <span class=\"h2\">",
"     Oropharynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epithelial lining of the oral mucosa thins with age. The gums recede, exposing the tooth cementum, which is more prone to decay, and predisposing older persons to root caries and incomplete mastication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ]. Edentate patients are at greater risk for inadequate nutritional intake compared with those with partial or full retention of their teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modest age-associated changes occur in the salivary glands, including a small decrease in the number of acinar cells and slightly decreased saliva production from parotid salivary glands, although accessory salivary gland production is unchanged. Up to 50 percent of older patients have subjective complaints of dry mouth, which can impact chewing and swallowing. However, some of these complaints may be attributed to medication side-effects rather than aging itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transfer of the food bolus to the pharynx is altered in the majority of older patients. Loss of esophageal muscle compliance results in increased resistance to flow across the upper esophageal sphincter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/28\">",
"     28",
"    </a>",
"    ]. Up to 60 percent of older patients without dysphagia have abnormal transfer to the pharynx on videofluoroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/29\">",
"     29",
"    </a>",
"    ]. Less effective mastication and decreased food clearance from the pharynx lead to increased aspiration risk in older adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810882\">",
"    <span class=\"h2\">",
"     Esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic changes in the esophagus include hypertrophy of the skeletal muscle at the upper third, decrease in myenteric ganglion cells that coordinate peristalsis, and perhaps increased smooth muscle thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ]. The amplitude of esophageal contractions during peristalsis decreases, but the movement of food is not impaired. Abnormal peristalsis after swallowing and non-peristaltic repetitive contractions, at one time attributed to old age and called &ldquo;presbyesophagus,&rdquo; are now thought to be due to disease processes.",
"   </p>",
"   <p>",
"    Secondary esophageal contractions (induced by esophageal distention) appear to be greatly reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ]. Secondary contractions contribute to clearance of refluxed acid. Diminution of these contractions, combined with decreased lower esophageal sphincter tone, results in increased gastric acid exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ]. Sensation of distention, and possibly tissue damage, in the distal esophagus is also impaired with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus many older patients with severe reflux esophagitis seen at endoscopy have surprisingly little symptomatology. Nevertheless, indigestive symptoms can impair nutritional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810889\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies suggested that gastric acid production decreased dramatically with age, with a decrease in parietal cells and an increase in interstitial leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequent studies challenge those findings and suggest that 90 percent of people aged 65 and over are able to acidify gastric contents in the basal unstimulated state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Helicobacter pylori infection may account for the discrepancies between early and more recent work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/34\">",
"     34",
"    </a>",
"    ]. Over 50 percent of older people are infected with H. pylori, with the prevalence increasing with advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43271?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacteriology and epidemiology of Helicobacter pylori infection\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased rates of gastritis and increased sensitivity to gastric irritants, such as non-steroidal anti-inflammatory medications or bisphosphonates, in older adults may be related to several age-related physiologic changes: decreased prostaglandin synthesis, decreased bicarbonate and nonparietal fluid secretion, and delayed gastric emptying. Gastric motility is determined by the combined effects of the enteric nerves, smooth muscle, and the interstitial cells of Cajal. The number and volume of the interstitial cells of Cajal bodies decreases by over 10 percent per decade in normal people without motility complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/36\">",
"     36",
"    </a>",
"    ]. In aging rat models, gastric blood flow and sensory neural function are decreased, delaying recognition of experimentally induced mucosal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810896\">",
"    <span class=\"h2\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small intestine undergoes modest anatomic changes, including moderate villus atrophy and coarsening of the mucosae. The absorption of several micronutrients (eg, xylose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , B12, copper) may decrease with age but remain adequate for homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/37\">",
"     37",
"    </a>",
"    ]. The efficiency of calcium absorption from the gut lumen decreases because of decreased vitamin D receptors in the gut and decreased levels of circulating 25(OH) vitamin D. Typically, women over age 75 absorb 25 percent less of a given dose of calcium than younger women, especially if there is reduced acid secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/38\">",
"     38",
"    </a>",
"    ]. Iron may also be less well absorbed, but overall aging impacts the absorption of macronutrients minimally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consumed carbohydrates result in significantly more hydrogen excretion in the older adults, suggesting malabsorption and subsequent bacterial metabolism of the carbohydrate in the aging gut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/39\">",
"     39",
"    </a>",
"    ]. Up to 15 percent of residents in senior congregate housing have evidence of bacterial overgrowth as assessed by breath hydrogen testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/40\">",
"     40",
"    </a>",
"    ]. Bacterial overgrowth and associated malabsorption can affect nutritional status and micronutrient absorption.",
"   </p>",
"   <p>",
"    Decreases in sensory and myenteric neurons contribute to the increased frequency of painless ulcers with increased age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25,41\">",
"     25,41",
"    </a>",
"    ]. Interestingly, in several animal studies, caloric restriction has been shown to decrease myenteric neuronal loss with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810903\">",
"    <span class=\"h2\">",
"     Large intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic changes with aging in the large intestine include mucosal atrophy, cellular and structural abnormalities in the mucosal glands, hypertrophy of the muscularis mucosa, and atrophy of the muscularis externa. Functional changes include altered coordination of contraction and increased opioid sensitivity that may predispose the older person to drug-induced constipation.",
"   </p>",
"   <p>",
"    Studies have not been consistent regarding alterations in colonic motility, but the general consensus is that colonic propulsive motility is reduced with age and about one-fourth of those over 65 years suffer from chronic constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/26\">",
"     26",
"    </a>",
"    ]. One factor contributing to reduced motility is an age-related reduction in myenteric plexus neurons and a decline in the interstitial cells of Cajal similar to that seen in the stomach. Intrinsic sensory neurons that respond to physicochemical changes may degenerate disproportionately compared with motor enteric neurons. The loss of sensory input into local reflex pathways could contribute to reduced propulsive motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link\">",
"     \"Etiology and evaluation of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The loss of intrinsic sensory neurons may also contribute to the decreased visceral response to bowel perforation or ischemia that is classically observed in the older patient. As an example, the rigid surgical abdomen after appendiceal perforation is a less frequent finding in those over 75, leading to delayed diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older women may be more predisposed to fecal incontinence than older men as the resting pressure and squeeze pressure decrease with age, resulting in decreased anal sphincter tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/45\">",
"     45",
"    </a>",
"    ]. In one study, both male and female patients aged greater than 70 years had 30 to 40 percent decreases in sphincter pressures compared to controls less than 30 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/46\">",
"     46",
"    </a>",
"    ]. The internal anal sphincter of continent older people is thickened, perhaps to compensate for decreased resting and maximum pressures in the anal canal with age. However, thinning of the external sphincter correlated with fecal incontinence more than age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diverticuli are common in western populations over age 65, with prevalence &ge;65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/48\">",
"     48",
"    </a>",
"    ]. The prevalence of diverticuli is lower in other populations, presumably with other diets, but nonetheless there remains a strong age-dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/49\">",
"     49",
"    </a>",
"    ]. The formation of colonic diverticuli is attributed to decreased muscle wall strength, decreased bowel wall compliance, and increased intra-abdominal pressure required for stool excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/48\">",
"     48",
"    </a>",
"    ]. Slower large bowel transit and increased segmental contractions (as opposed to propulsive contractions) result in increased water reabsorption, leaving harder stools and increasing the likelihood of wall failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36854?source=see_link\">",
"     \"Epidemiology and pathophysiology of colonic diverticular disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The risk of colon cancer increases with age. In addition to prolonged exposure to potential carcinogens, aging is associated with increased proliferation and decreased apoptosis in the colonic mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/50\">",
"     50",
"    </a>",
"    ]. The biology of these changes is a rich area for exploration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810910\">",
"    <span class=\"h2\">",
"     Hepatobiliary system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver mass decreases between 20 and 40 percent with age, and perfusion and blood flow decreases up to 50 percent between the third and tenth decades of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/51\">",
"     51",
"    </a>",
"    ]. Lipofuscin accumulates in hepatocytes with age and is also seen in young patients with severe malnutrition, accounting for an appearance that has been described as &ldquo;brown atrophy.&rdquo; Older livers have more macrohepatocytes (large cells), and increased polyploidy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings are relevant to liver function in older adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although many liver functions decline (diminished",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      demethylation, galactose elimination, and reduced caffeine clearance), standard &ldquo;liver function tests&rdquo; (transaminases, alkaline phosphatase) are minimally affected by age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25,53\">",
"       25,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Findings are contradictory regarding albumin synthesis in older livers; animal studies found reductions consistent with a loss of liver mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/54\">",
"       54",
"      </a>",
"      ], although this was not confirmed in a study in healthy older people [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/55\">",
"       55",
"      </a>",
"      ]. Serum albumin declines slightly with normal human aging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/56\">",
"       56",
"      </a>",
"      ]. Interestingly, studies have shown that mortality of nursing home residents correlates with albumin levels, even within the normal range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The metabolism of LDL cholesterol decreases with a reduction in LDL receptors in older patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/58\">",
"       58",
"      </a>",
"      ], which could contribute to the higher serum LDL levels in older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytochrome P450 content decreases with age, with one study finding a 32 percent decrement comparing individuals over 70 years with a group 20 to 29 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/59\">",
"       59",
"      </a>",
"      ]. This may account for the finding that metabolic clearance of many drugs is 20 to 40 percent slower in older people [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link\">",
"       \"Drug prescribing for older adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The lower amounts of vitamin K antagonists needed to anticoagulate older people are consistent with age-related decreased synthesis of vitamin-K-dependent clotting factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although function and anatomy of the gall bladder are well preserved in old age, the bile composition has a higher lithogenic index, predisposing the older person to cholesterol gallstone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Younger livers show a robust regenerative response to liver injury characterized by mitogen-activated protein kinase activity. This declines with age in animals and people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810917\">",
"    <span class=\"h2\">",
"     Exocrine pancreas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exocrine pancreas undergoes only modest alterations with age. Minor atrophic and fibrotic changes have essentially no impact on pancreatic exocrine function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/39\">",
"     39",
"    </a>",
"    ]. Aged animals showed decreased output of lipase and amylase in response to meals that were high in fat or carbohydrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810924\">",
"    <span class=\"h1\">",
"     THE RENAL SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple effects of aging on the renal system (",
"    <a class=\"graphic graphic_table graphicRef68244 \" href=\"mobipreview.htm?38/31/39419\">",
"     table 1",
"    </a>",
"    ). Renal mass decreases by 25 to 30 percent between the ages of 30 and 80 years, with the steepest decline after age 50. In addition, fat and fibrosis replace some of the remaining functional parenchyma. Loss occurs primarily in the renal cortex and preferentially affects those nephrons most important to maximal urine concentration.",
"   </p>",
"   <p>",
"    Normal aging is associated with diffuse sclerosis of glomeruli such that 30 percent of glomeruli are destroyed by age 75 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/63\">",
"     63",
"    </a>",
"    ]. The remaining glomeruli have impaired filtering ability. Intrarenal vascular changes include spiraling of the afferent arterioles, narrowing of the larger arteries, intimal fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/64\">",
"     64",
"    </a>",
"    ], and shunts between afferent and efferent arterioles allowing blood flow to bypass the glomeruli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/65\">",
"     65",
"    </a>",
"    ]. Nephrosclerosis (global glomerulosclerosis, interstitial fibrosis, and arteriosclerosis) was identified in donor kidneys to be used for transplantation in 3 percent of donors 18 to 29 years old and 73 percent of donors 70 to 77 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At baseline, renal plasma blood flow is 40 percent lower in healthy normotensive older men than in young men and this difference is magnified under conditions that stimulate renal vasodilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/67\">",
"     67",
"    </a>",
"    ]. Studies suggest that older kidneys may be maintained in a state of vasodilation to compensate for loss of vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Vasodilating prostaglandins are increased at baseline in normal older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/69\">",
"     69",
"    </a>",
"    ], and this contributes to the increased (roughly doubled) risk of renal injury with use of nonsteroidal anti-inflammatory drugs in older people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creatinine clearance decreases with age (7.5 to 10 mL per minute per decade), although there is wide variability in decline seen in longitudinal studies of healthy elders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/72\">",
"     72",
"    </a>",
"    ]. As many as one-third have no change at all in the glomerular filtration rate (GFR), one-third have a slight decline, and one-third have a more marked decline. Creatinine production also decreases with age and tubular secretion of creatinine increases, so that the serum creatinine may remain stable despite decreases in the GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/73\">",
"     73",
"    </a>",
"    ]. All of the commonly used equations for estimating creatinine clearance factor age into the formulae, however, the EGFR provided by some EHRs need to be utilized cautiously especially with those over 90 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/74\">",
"     74",
"    </a>",
"    ]. Cystatin C based estimates of renal function may be useful when accurate assessment in an older person is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/75\">",
"     75",
"    </a>",
"    ]. In healthy older people, an increase of roughly 50 percent in Cystatin C levels is seen from age 40 to age 80 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid and electrolyte homeostasis are maintained relatively well with aging, in the absence of challenges. However, the ability to maximally dilute urine and excrete a water load is impaired and compromises volume regulation under conditions of stress. In the setting of dehydration, the minimum urine flow rate is twice as great in those over 70 compared to those under 40, and the maximum urine osmolality is also reduced with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition to this impaired ability to retain water and solute, the older kidney also is impaired in its ability to retain amino acids and glucose.",
"   </p>",
"   <p>",
"    Other functional changes in the renal system are a reduction of urine acidification and impairment in excreting an acid load. The older kidney is more prone to nephrotoxicity related to medications or intravenous contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Additionally, the injured older kidney is less likely to recover from acute insult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/80\">",
"     80",
"    </a>",
"    ]. The older kidney is also more vulnerable to ischemic insult, with a greater number of cells undergoing apoptosis following ischemia than in the young kidney. Tubular cells appear to have diminished ability to entirely repopulate the tubules after an acute ischemic insult.",
"   </p>",
"   <p>",
"    In animal studies, hormonal functions of the kidney are affected by aging, such as decreasing hydroxylation of vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/81\">",
"     81",
"    </a>",
"    ] and down regulation of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/82\">",
"     82",
"    </a>",
"    ]. The production of erythropoietin in response to hemoglobin, however, appears to be unchanged with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810931\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advancing age increases the risk for hypertension and coronary artery disease. The prevalence of coronary artery disease at autopsy may reach 75 percent after the sixth decade in men and two decades later in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/84\">",
"     84",
"    </a>",
"    ]. Therefore, to isolate age-related cardiovascular change from disease-related change, studies must carefully select older individuals with no underlying cardiovascular condition. The Baltimore Longitudinal study studied highly screened older individuals and found only a minimal impact of aging on resting cardiovascular function such as left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/85\">",
"     85",
"    </a>",
"    ]. This reflects the adequacy of the compensatory strategies used by the old heart (and vascular system) to counteract subtle and gradual age-associated physiologic, molecular, and biochemical changes. However, by invoking available compensatory mechanisms to maintain resting function, the older person is less able to compensate for subsequent challenges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23810854\">",
"     'Homeostenosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many older people perform little physical activity. Typical age changes may therefore also reflect the impact of factors related to lifestyle and comorbidity, and the contribution of age alone may be difficult to determine.",
"   </p>",
"   <p>",
"    Minimal anatomic changes occur in the right side of the heart. In contrast, the left atrium enlarges and the left ventricle stiffens with aging. Left atrial volume, corrected for body size, increases roughly 50 percent from the third decade to the eighth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/87\">",
"     87",
"    </a>",
"    ]. The left ventricle also hypertrophies with age, with an average increase in left ventricular wall thickness of 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the aortic valve and mitral annulus thicken and develop calcific deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/89\">",
"     89",
"    </a>",
"    ]. Mitral annular calcification may predispose the older person to cardiac conduction problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=see_link\">",
"     \"Valvular heart disease in elderly adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventricular cardiomyocytes hypertrophy, in part as a response to the increased afterload produced by large artery stiffening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. The largest myocytes are also the most vulnerable to challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/91\">",
"     91",
"    </a>",
"    ]. Loss of myocytes with age has been reported to occur by both apoptosis and necrosis; the total number of cardiomyocytes may be reduced significantly in healthy human hearts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/90,92,93\">",
"     90,92,93",
"    </a>",
"    ]. As well, substantial cellular dropout occurs in the sinoatrial (SA) node and more modest cellular loss at the atrioventricular node. This may underlie increased sensitivity of the older SA node to calcium channel blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a negligible age-related decrease in the resting heart rate, but a marked decrease in the maximum heart rate in response to exercise or other stressors. The intrinsic heart rate (the rate without sympathetic or parasympathetic input to the heart) decreases by five to six beats per minute each decade. The response to both parasympathetic antagonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ) and beta-adrenergic agonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ) is decreased in healthy older people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heart rate reflects the combined effects of sympathetic and parasympathetic tones. The target maximum heart rate is calculated as &lsquo;220 &ndash; age.&rsquo; Women may have a more gradual decline and a correction factor of 0.90-0.85 may adjust the target heart rate for women, although this is not always applied. Exercise training does not modify the age-associated decline in maximum heart rate. Heart rate variability, perhaps due to decreased parasympathetic tone and decreased sympathetic responsiveness, also decreases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of atrial premature beats increases with age, but is not associated with increased cardiac risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/97\">",
"     97",
"    </a>",
"    ]. An increase in isolated ventricular ectopic beats is also seen in healthy older individuals and is part of the normal aging process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The culmination of age-associated cardiovascular changes is a decrease in maximum work, measured as maximum oxygen utilization (VO2max) on exercise testing. Exercise training in sedentary older individuals can improve this parameter, but a decline with age is seen even in highly-trained individuals.",
"   </p>",
"   <p>",
"    Resting left ventricular ejection fraction (LVEF) is not changed in healthy older people, but there are smaller increases in LVEF in response to exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/99\">",
"     99",
"    </a>",
"    ]. At maximum effort, LVEF in the young is above 80 percent while by age 80 it is 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/85\">",
"     85",
"    </a>",
"    ]. Older hearts also have impaired early left ventricular filling with a compensatory greater contribution from atrial systole than younger hearts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/100\">",
"     100",
"    </a>",
"    ]. This may in part explain why atrial fibrillation is more likely to precipitate heart failure in older adults. An atrial gallop (S4) is a normal finding on physical examination in individuals in sinus rhythm over 75, a manifestation of the increased contribution of left atrial systole to ventricular filling.",
"   </p>",
"   <p>",
"    The old heart is a vulnerable heart. For example, mortality and the probability of developing heart failure after a myocardial infarction increase dramatically with age. While myocardial infarction is not a part of normal aging, response to this systemic challenge is impaired because of the aging process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810938\">",
"    <span class=\"h1\">",
"     RESPIRATORY SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging, in the absence of additional challenges, does not result in hypoxia or pneumonia. However, age-related anatomic and functional changes in the respiratory system contribute to the increased frequency of pneumonia, increased likelihood of hypoxia, and decreased maximum oxygen uptake in the older person.",
"   </p>",
"   <p>",
"    The lung undergoes a number of anatomic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/101\">",
"     101",
"    </a>",
"    ]. Alveolar ducts enlarge due to loss of elastic tissue, resulting in a decreased surface area for gas exchange. Overall about one-third of the surface area per volume of lung tissue is lost over the life span, and anatomic dead space increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/102\">",
"     102",
"    </a>",
"    ]. The loss of lung elastic tissue decreases recoil and results in modest reduction in the expiratory boundary of the maximal flow-volume envelope. During maximal exercise, this may limit expiratory airflow and produce dynamic lung hyperinflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/103\">",
"     103",
"    </a>",
"    ]. Surfactant composition is also altered by age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/104\">",
"     104",
"    </a>",
"    ]. Carbon monoxide diffusion studies find that diffusion capacity decreases approximately 5 percent per decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age increases ventilation-perfusion mismatching because airways",
"    <strong>",
"    </strong>",
"    in dependent portions of the older lung, areas that are better perfused than elsewhere, are closed during all or part of the respiratory cycle. This is a critical factor in the declining arterial P02 with age. Alveolar PO2 does not change with age, but age increases the alveolar-arterial (A-a) oxygen gradient. The effect of the ventilation-perfusion mismatch is more marked in the supine than sitting position because of positional changes in thoracic mechanics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/106\">",
"     106",
"    </a>",
"    ]. The decrease in arterial PO2 (PaO2) may not be linear, but appears to decline from age 30 until 70 or 75, and thereafter remains almost constant. While age-related changes do not result in hypoxia at sea level, older adults may approach hypoxia at altitude [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/107\">",
"     107",
"    </a>",
"    ]. The fall on PaO2 is slightly greater in women than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/106,108\">",
"     106,108",
"    </a>",
"    ]. Older people may have little reserve for further decrements in pulmonary function before important hemoglobin desaturation occurs.",
"   </p>",
"   <p>",
"    In contrast to the decrease in PaO2 and increase in alveolar-arterial oxygen gradient, carbon dioxide excretion is not impaired with age; changes in PaCO2 are due to disease and should not be attributed to age alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chest wall also changes with age; increased stiffness of the chest wall predominates over an increase in compliance of the lung parenchyma. Overall chest wall compliance decreases by one-third from age 30 to 75 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/110\">",
"     110",
"    </a>",
"    ]. Intercostal muscle contraction accounts for less chest expansion in older individuals, with a relatively greater contribution from abdominal muscles. Abdominal muscles are only partially effective in ventilating in the seated (or supine) position. Thus, full airway expansion occurs only in the standing position in older adults. Atelectasis can result in an increased A-a gradient.",
"   </p>",
"   <p>",
"    As the chest remodels with age, the diaphragm flattens and becomes less efficient. The diaphragmatic changes likely contribute to the increase in the work of breathing during exercise, which can increase 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of age on traditional pulmonary function tests is shown in the graph (",
"    <a class=\"graphic graphic_figure graphicRef67608 \" href=\"mobipreview.htm?38/6/39021\">",
"     figure 2",
"    </a>",
"    ). With advancing age, functional reserves decrease. In nonsmoking men, forced vital capacity (FVC) decreases between 0.15 and 0.3 liters per decade, and forced expiratory volume in 1 second (FEV1) decreases by 0.2 to 0.3 liters per decade, with steeper decline in the seventh and eight decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. Age-related changes in women decline less steeply. Total lung capacity (proportional to height) does not change significantly with age; however, the residual volume (air left in the lung at the end of full expiration) increases by as much as 10 percent per decade because of a higher closing volume.",
"   </p>",
"   <p>",
"    The Cardiovascular Health Study population experienced age-related decreases in maximal inspiratory force and a smaller decrement in maximal expiratory force parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/114\">",
"     114",
"    </a>",
"    ]. Both the inspiratory force and expiratory force are significantly greater in physically active older people. Diaphragm thickness was also greater in the active old group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/115\">",
"     115",
"    </a>",
"    ]. Thus, some of the decrements described above are due to sedentary lifestyle.",
"   </p>",
"   <p>",
"    Older persons have decreased responses to hypoxemia, hypercapnia, and mechanical loading, such as breathing through a small-diameter endotracheal tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/116\">",
"     116",
"    </a>",
"    ]. The central drive to the respiratory muscles is decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/117\">",
"     117",
"    </a>",
"    ]. Many of these changes are minimized with exercise; the implication is that central or peripheral receptor hyporesponsiveness may be due in part to deconditioning, and that exercise training can induce compensation for age-related changes.",
"   </p>",
"   <p>",
"    Cough is less vigorous in the older person because of the age effects on respiratory muscle strength and greater closing volumes that prevent clearing of increasing proportions of the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/114\">",
"     114",
"    </a>",
"    ]. Mucociliary clearance is slower and less effective, and recovery of mucociliary clearance after insult (typically viral infection) is slowed with age. In addition to impaired clearance from large airways, clearance of inhaled particles from the small conducting airways is also impaired with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of decline in the peak aerobic capacity in healthy older persons with age, especially men, is not constant. The Baltimore Longitudinal Study of Aging found a 3 to 6 percent decrease in peak aerobic capacity per decade in the 30s and more than 20 percent decrease in peak aerobic capacity per decade in the 70s and beyond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/119\">",
"     119",
"    </a>",
"    ]. The decrease in FEV1 with age correlates strongly with the worsening peak aerobic performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810945\">",
"    <span class=\"h1\">",
"     GENITOURINARY SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging changes in the genitourinary system increase the older person's risk of urinary incontinence, urinary tract infection, erectile dysfunction, and dyspareunia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810952\">",
"    <span class=\"h2\">",
"     Bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of urinary incontinence increases with age. Until age 80, incontinence is more common in women than men, but the prevalence differences by gender subside after age 80 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/121\">",
"     121",
"    </a>",
"    ]. Urinary incontinence is related to decreases in detrusor muscle contractility, maximum bladder capacity, maximum flow rate, and the ability to withhold voiding, with an increase in postvoid residual (PVR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/122\">",
"     122",
"    </a>",
"    ]. These functional changes are due in part to decreased innervation of the detrusor muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/123\">",
"     123",
"    </a>",
"    ] and in part due to changes in the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41737?source=see_link\">",
"     \"Urinary incontinence in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Withdrawal of estrogen in women results in decline in urethral length as well as decreased maximal urethral closure pressure. The urethra becomes a less effective barrier from bacterial contamination with age, especially in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810959\">",
"    <span class=\"h2\">",
"     Male reproductive system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys of sexual activity among older men have found varying rates of activity. In one multinational survey, over 80 percent of men aged 60 to 69 and 70 percent of those aged 70 to 79 reported that they were sexually active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/126\">",
"     126",
"    </a>",
"    ]. In contrast, two representative samples from the United States found that 39 percent of men aged 75 to 85 years reported sexual activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/127\">",
"     127",
"    </a>",
"    ]. The older penis needs greater stimulation to attain an erection, spontaneous erections are less frequent, erections are less firm, refractory times between erections (or ejaculations) become prolonged and ejaculation is less forceful with smaller ejaculate volumes. These changes are the sum of age-related neurological, vascular, and endocrinological changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/128\">",
"     128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A gradual decline in male reproductive ability occurs with age. Germ cells are formed continually, but sperm production decreases. The sperm from older testes have an increased frequency of chromosomal abnormalities and impaired motility and decreased ability to fertilize even when administered by intrauterine artificial insemination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/129\">",
"     129",
"    </a>",
"    ]. The seminiferous tubules also degenerate and Leydig cell number decreases. Changes in the epididymis and seminal vesicles are characterized by deposition of pigmented granules in the epithelial walls and amyloid in the seminal vesicle wall, which may be associated with amyloid deposition elsewhere in the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enlargement of the prostate gland occurs with age. Prostate gland hyperplasia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=see_link\">",
"     \"Epidemiology and pathogenesis of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810966\">",
"    <span class=\"h2\">",
"     Female reproductive system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovary ages with a decline in oocyte numbers as women enter their late fourth decade, and menopause (amenorrhea for 12 months after the final menstrual period) ensues at an average age of 51 years. In women of advanced age undergoing IVF treatment, (defined here as after 45) the implantation, clinical pregnancy, and live birth rates, all occur at reduced frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/131\">",
"     131",
"    </a>",
"    ]. Changes related to menopause and estrogen-depletion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once menopause has occurred, more gradual age-related post menopausal processes are seen. The vagina loses elasticity. The clitoris, like the older penis, needs greater stimulation and becomes less engorged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/132\">",
"     132",
"    </a>",
"    ]. Subcutaneous fat in the pelvis is lost. Vaginal dryness and atrophy are mostly estrogen dependent, but may be compounded by age-related diminished blood flow to the vagina. Cervicovaginal secretions, especially during arousal, become sparser. Vaginal pH rises, allowing colonization by enteric microflora. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810973\">",
"    <span class=\"h1\">",
"     MUSCULOSKELETAL SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584138046\">",
"    <span class=\"h2\">",
"     Muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is great variability, muscle mass decreases in relation to body weight by about 30 to 50 percent in both men and women. The loss is not linear, but accelerates with increasing age. Sarcopenia, age-related loss of muscle mass and strength, is defined as a decrease in appendicular muscle mass two standard deviations below the mean for young healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/133\">",
"     133",
"    </a>",
"    ]. In many sites, muscle quality decreases with infiltration of fat and connective tissue into the old muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The loss of muscle mass is not uniform; in general, the loss from the legs is greater than from the arms. Type I slow-twitch fibers are less affected by age than fast-twitch fibers. In any muscle bundle, the size of the myofibrils decreases, followed by the number of myofibrils. Innervation of skeletal muscle decreases in men over 50; the number of motor units in any given muscle decreases with a compensatory increase in motor unit size. While this synaptic remodeling occurs at all ages, the &ldquo;new&rdquo; neuromuscular innervations are unstable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/135\">",
"     135",
"    </a>",
"    ]. Some have implicated motor neuron changes as the primary cause of sarcopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/136\">",
"     136",
"    </a>",
"    ]. The loss of muscle contributes to age-related insulin resistance, age-related changes in body composition, and volumes of distribution for water soluble drugs.",
"   </p>",
"   <p>",
"    The presence of atrophied or partially or completely denervated muscle fibers can be seen on cross-section of muscle from an older person. Time to peak tension with ankle dorsiflexion is slowed, as is time to muscle relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/137\">",
"     137",
"    </a>",
"    ]. Strength also decreases dramatically with age, partially explained by loss in muscle mass. From age 30 to age 80, a typical person's grip strength decreases 60 percent; however, activity plays an important mitigating role. Overall, lower extremity strength is lost at a relatively faster rate than upper extremity strength; activity may decrease the rate of decline, but will not completely prevent it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/134\">",
"     134",
"    </a>",
"    ]. The older muscle is more easily fatigued as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recovery of older muscle after injury is slowed and frequently incomplete. At least some of this impairment is locally mediated, perhaps by nerve regeneration, as old muscles transplanted into young animals regenerate fairly well, while muscles taken from young animals and transplanted into old ones do not regain mass and generate force as effectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skeletal muscle from older adults shows altered energetics. The decrease in enzyme activity of glycolytic enzymes is greater than that of oxidative enzymes. Physical activity plays a significant role in the decrease in these enzyme activities. In older animals, an acute bout of exercise is associated with relative hypoperfusion of the most oxidatively active exercising muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age-related hormonal changes in growth hormone, androgen, and possibly others may contribute to the age-associated alterations muscle mass and function. Additionally, proinflammatory cytokines increase with age and stimulate the rate of skeletal muscle protein degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/134\">",
"     134",
"    </a>",
"    ]. The effects of these agents, especially IGF-1, may be mediated by neuromuscular effects, suggesting that both hormonal and neuronal approaches to preventing sarcopenia may be efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584138090\">",
"    <span class=\"h2\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging in both men and women increases the probability of fracture and the rate of repair is slowed, once fracture occurs. The increased proinflammatory environment in healthy elders promotes bone loss. Anatomically, the weight-bearing cortical bones lose substance from the endosteal surface. CT or MRI images indicate that the marrow lumen of the femur is larger, the cortex thins, and fat fills much of the marrow cavities. The aging loss of mineral occurs in both cortical (peripheral skeleton) and trabecular (axial skeleton) bone. There is a progressive decline in osteoblast number and activity but osteoclasts remain unchanged with age Overall, the decline in bone mass is approximately 0.5 percent per year in healthy older people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/141\">",
"     141",
"    </a>",
"    ]. Age-related changes in women are compounded by menopausal changes in bone mass and function. Vitamin D deficiency, common in older people, further accelerates bone loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight bearing exercise is frequently reduced in older adults, contributing to a negative calcium balance and loss of bone mineral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/142\">",
"     142",
"    </a>",
"    ]. Increasing weight bearing time or increasing loading forces may result increase bone mineral and prevent age-related bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once bones fracture, the repair mechanisms are impaired in aging. In older animals, fractures produce less local blood vessel formation, less osteogenic differentiation of progenitor cells, and require at least twice as long to regain prefracture biomechanical properties, including strength, than in younger adult animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/144\">",
"     144",
"    </a>",
"    ]. Cells isolated from old bones are less responsive to vitamin D than young ones. The matrix in old individuals may stimulate less bone formation than matrix from younger people. This suggests that growth factors (eg, IGF-1) may be deficient or inhibitory factors may be present in the old matrix. Supplementation with VEGF, parathyroid hormone, vitamin D and calcium, statins, and some of the bone morphogenic proteins have all shown promise in facilitating bone healing in various experimental paradigms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810980\">",
"    <span class=\"h1\">",
"     SKIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal aging of the skin leads to atrophy, decreased elasticity, and impaired metabolic and reparative responses. These changes are separate from those due to sun exposure, so-called &ldquo;photoaging.&rdquo;",
"   </p>",
"   <p>",
"    The epidermis becomes thinner, and the dermoepidermal junction flattens, resulting in increased fragility of the skin to shear stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/146\">",
"     146",
"    </a>",
"    ]. Removing an adhesive dressing from an older person may dislodge the epidermis because the dermoepidermal junction is weaker than the bond between the skin and the dressing. Bleeding into the space between the dermis and epidermis occurs more frequently.",
"   </p>",
"   <p>",
"    Loss of undulations at the dermoepidermal junction decreases the area available for nutrient transfer, including protective lipids in the stratum corneum. This results in dry skin (xerosis) and a compromise in the barrier function of the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/147\">",
"     147",
"    </a>",
"    ]. Epidermal turnover is slowed due to decreased division of keratinocytes and longer migration from the basal layer to the skin surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/148\">",
"     148",
"    </a>",
"    ]. The epidermal cellular composition changes, with decreases in melanocytes, immunologically active Langerhans' cells, and a 50 percent overall reduction in nail growth and reductions in sweat and sebaceous gland activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional changes associated with age rather than sun damage include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dermis thins with decrease in vascularity and in the biosynthetic capacity of the resident fibroblasts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/150\">",
"       150",
"      </a>",
"      ]. These changes contribute to delayed wound healing.",
"     </li>",
"     <li>",
"      The elastic fiber network degenerates as elastin biosynthesis declines significantly after the fourth decade. Changes in the glycosaminoglycan macromolecules in the dermis lead to loss of hydration and decreased skin resilience [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/151\">",
"       151",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ability to deliver heat to the skin for excretion is impaired. With the loss of rete pegs at the dermoepidermal junction and loss of dermal capillarity, the area for heat transfer to the epidermis is decreased. Loss of subdermal fat decreases insulation and the ability of older people to conserve heat. Tonic vasoconstriction in many older adults, as well as decreases in both number and production of sweat glands, also contribute to impaired thermoregulation with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/152,153\">",
"       152,153",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sensory perception of the skin decreases, particularly in the lower extremities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/154\">",
"       154",
"      </a>",
"      ]. Decreased sensation involves both touch, due to decreased Meissner&rsquo;s corpuscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/155\">",
"       155",
"      </a>",
"      ], and low frequency vibration, mediated by the Pacinian corpuscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/156\">",
"       156",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The skin plays a critical role in vitamin D synthesis. Ultraviolet rays convert 7-dehydrocholesterol to pre-vitamin D3 in the epidermis. Levels of 7-dehydrocholesterol decreased with age, thus decreasing the older person's capacity for vitamin D synthesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/157\">",
"       157",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a decrease in subdermal fat. This loss of support contributes to the skin wrinkling and sagging, as well as to increased susceptibility to trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/158\">",
"       158",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical administration of all-trans-retinoic acid (tretinoin) appears to reverse many of the age-related changes in sun-protected skin (inner thigh). After nine months of daily treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    cream 0.025 percent, the epidermis thickens, rete ridges become deeper, capillaries reappear, matrix proteins are redeposited, and collagen and elastin increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/159\">",
"     159",
"    </a>",
"    ]. Thus, these age-related changes appear to be mutable.",
"   </p>",
"   <p>",
"    Photoaging is the result of chronic sun exposure and recurrent damage by the sun's ultraviolet light. Photoaging, not physiologic aging, produces most of the cosmetically undesirable changes in skin. Cellular dysplasia, atypical cells, a loss of polarity of the keratinocytes, and a significant disorganization in the epidermis are the result of photoaging. In the dermis, photoaging leads to elastosis, aggregates of amorphous elastic fibers, a decrease in collagen content, an increase in glycosaminoglycans, and a modest inflammatory infiltrate localized to the perivascular areas. The photoaged skin looks wrinkled, lax, yellowed, rough, and sometimes leathery. Photoaged skin has a higher tendency toward telangiectasias, and it is spottily hyperpigmented and hypopigmented. Photoaging changes are also partially reversible by topical treatment with retinoic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810987\">",
"    <span class=\"h1\">",
"     SENSORY SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584138016\">",
"    <span class=\"h2\">",
"     Eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure of the eye changes with age. Periorbital tissues atrophy; eyelids become more relaxed. The lower lid flaccidity may lead to ectropion (eyelid turns outward) or entropion (eyelid turns inward). Lacrimal gland function, tear production, and goblet cell function all decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/160\">",
"     160",
"    </a>",
"    ]. Even though tear production decreases, watering eyes becomes more common because tissue atrophy leads to displacement of the lacrimal punctum and less effective drainage.",
"   </p>",
"   <p>",
"    The conjunctiva atrophies and yellows. The sensitivity of the cornea to touch declines by 50 percent. Deposition of cholesterol esters, cholesterol, and neutral fat in the cornea causes arcus senilis, an annular yellow-white deposit on the peripheral cornea. The presence of arcus senilis correlated with shorter life spans in women in the Copenhagen City Heart Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/161\">",
"     161",
"    </a>",
"    ]. The iris becomes more rigid, yielding a smaller, more sluggishly responsive pupil. The lens yellows, in part because of photo-oxidation in lens protein and an accumulation of insoluble protein. The yellowing of the lens causes decreased transmission of blue light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Production of aqueous humor decreases and the vitreous humor and body also shrink. Separation between the liquid and solid components of the vitreous may be due to collagen changes and manifest as flashes of light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/163\">",
"     163",
"    </a>",
"    ]. The retina becomes thinner because of a loss of neurons.",
"   </p>",
"   <p>",
"    The changes in lens and iris lead to &rdquo;presbyopia.&rdquo; The distance needed to focus near objects increases because of decreased lens elasticity and, to a lesser extent, weakening and loss of an effective angle of the ciliary muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/164\">",
"     164",
"    </a>",
"    ]. Presbyopia has gradual onset in the fourth decade with steady deterioration in static acuity (object at rest) and a more pronounced loss of dynamic visual acuity (ie, objects in motion). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=see_link\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The older eye adapts more slowly to changes in lighting conditions; the pupil becomes rigid and the lens more opaque. The rate of synthesis of photopigment slows with age, adding to slowed adaptation to lower light conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/165\">",
"     165",
"    </a>",
"    ]. Lens alterations increase light scattering, making the older person more sensitive to glare. After lens removal, the glare threshold becomes normal.",
"   </p>",
"   <p>",
"    Finally, contrast sensitivity declines, so older persons need increased color contrast to discriminate between target and background. This factor should be taken into account in the design of living environments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23810994\">",
"    <span class=\"h2\">",
"     Hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-related changes in the auditory system produce decrements in high frequency hearing acuity and impaired speech recognition in noisy environments. The loss of hearing acuity may result in social isolation and increases risk for delirium during hospitalization. The cumulative effects of environmental or occupational noise confound interpretation of age effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With age, the walls of the external auditory canal thin. The cerumen becomes drier and more tenacious, increasing the risk of cerumen impaction in older people. Although the ossicular joints degenerate with age, sound transmission by the ossicles is well preserved.",
"   </p>",
"   <p>",
"    The inner ear experiences at least five distinct changes that occur to varying degrees:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hair cells in the organ of Corti are lost, initially affecting those in the basal end of the cochlea that respond to the highest frequencies",
"     </li>",
"     <li>",
"      Neurons innervating the cochlear and in the auditory centers of the brain are lost",
"     </li>",
"     <li>",
"      The basilar membrane underlying the sensory apparatus stiffens and may calcify",
"     </li>",
"     <li>",
"      The capillaries of the stria vascularis (the source of endolymph) thicken",
"     </li>",
"     <li>",
"      The spiral ligament degenerates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Which of these five changes is dominant will define subgroups of age-related hearing. The net results are loss of hearing acuity, especially at higher frequencies (presbycusis), difficulty with speech discrimination, and problems localizing the sources of sound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/166,167\">",
"     166,167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some older individuals who say they cannot hear in fact are having difficulty understanding what is said. Many of the consonant sounds are in the higher frequencies (t, k, ch), and patients may not comprehend speech if they cannot appreciate those sounds. Strategically and practically, it may be better to rephrase a question that is not understood by an older person rather than repeat it in a louder voice, especially because pitch (frequency) is often raised when volume is increased. Additionally older people may have difficulty discriminating target sound from background noise, adding to challenges of communicating in social situations or noisy emergency rooms. In these patients, amplification of sound alone is not effective because both target and background are amplified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23811001\">",
"    <span class=\"h2\">",
"     Taste and smell",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are visible changes in the taste buds with age, though they have modest impact on the sense. Although the number of papillae on the tongue decreases with aging, neurophysiologic responses of individual papillae are minimally altered, and there is no relation between gustatory acuity and number of taste buds.",
"   </p>",
"   <p>",
"    Loss of taste in older patients is in large part due to decreased olfaction rather than taste itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"     25",
"    </a>",
"    ]. However, taste sensitivity also decreases with age, as shown by a study in which older patients required 30 percent higher concentrations of aspartame to detect this artificial sweetener [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/168,169\">",
"     168,169",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly more salt (two- to three-fold) needs to be added to tomato soup before it can be appreciated by an older person [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/170\">",
"     170",
"    </a>",
"    ]. The effects of age on the tongue need not be uniform with regions of deficient gustatory sense becoming more common with age.",
"   </p>",
"   <p>",
"    The acuity of olfaction declines significantly with age. Detection thresholds are increased by more than 50 percent in healthy people by age 80; recognition of familiar smells decreases similarly, including the recognition of spoiled food and of a gas stove left on. The cause of the decreased olfactory sense is unclear, but the sensation area decreases, the number of sensing neurons decreases, and the ability of the older person to replenish dying olfactory receptor neurons is compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased taste and smell sensation may result in decreased enjoyment of food and an age-related difficulty in sorting tastes of mixed or combined foods. The role of olfaction in maintaining appetite is critical; for example, some people with anosmia forget to eat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23811008\">",
"    <span class=\"h1\">",
"     IMMUNE SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the changes that occur with age, decrements in immune functions are among the most critical, contributing to the increased frequency of infections, malignancies, and autoimmune disorders. These changes are mentioned briefly here and reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunosenescence, or the aging of the immune system, does not impact all immune processes equally. Some of the responses that are most affected by age include the ability of lymphocytes (both B and T cells) to work in concert to generate effective immune responses upon exposure to new antigens, in the form of either infections or vaccinations.",
"   </p>",
"   <p>",
"    An important concept in immunosenescence is that of loss of precise regulation of inflammatory processes. Older adults display cytokine profiles that are consistent with a chronic, low-level inflammatory state, which is sometimes referred to as &ldquo;inflammaging&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/171\">",
"     171",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189995853\">",
"    <span class=\"h1\">",
"     MOLECULAR BASIS OF AGING",
"    </span>",
"   </p>",
"   <p>",
"    The molecular basis for age-related physiologic changes is a subject of intense active investigation. The process of natural selection (in which genes that promote beneficial conditions in early or reproductive years are selected for, and genes associated with harmful conditions are selected against), does not play a significant role in later life. Despite the lack of selection for late life genes, some processes that may provide benefit early in life could be detrimental later in life, so called antagonist pleiotropy. For more than fifty years, the most robust means to increase survival and modify many age-related changes was to use caloric restriction. Reducing caloric intake by 20 to 40 percent in laboratory mice and rats of the most common strains increased median and maximum lifespan by 20 to 50 percent. Studies with non-human primates have been less promising, and despite having lower cholesterol, better insulin sensitivity, etc., survival has not been increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/172,173\">",
"     172,173",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Several findings implicate that shortening of the telomere (nucleoprotein end caps on chromosomes) is involved in increased vulnerability of aging cells to DNA damage and dysregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/174-176\">",
"     174-176",
"    </a>",
"    ]. The shortened telomeres, as well as other replicative dysregulation, may lead to inadequate replacement of damaged or dead cells from their respective precursor cell populations. Interestingly, many of these resting precursors cells start to differentiate along adipocyte-like pathways, rather than into other tissue types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other hypotheses implicate the p53 gene that is activated when DNA is damaged. This gene activation may mediate several molecular processes affecting cell function and viability: normal cell growth and division is halted, with apoptosis for cells that rapidly turnover; peroxisome proliferator-activated receptor gamma with coactivators PGC",
"    <sub>",
"     1-alpha",
"    </sub>",
"    and PGC",
"    <sub>",
"     1-beta",
"    </sub>",
"    are repressed and lead to loss of muscle mitochondria, and buildup of free radicals with loss of antioxidant defenses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/177\">",
"     177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mammalian target of rapamycin (mTOR) pathway regulates nutrient distribution and is believed to play an important role in the ability of caloric restriction to extend lifespan. Rapamycin has been shown to produce longevity in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23811022\">",
"    <span class=\"h1\">",
"     LONGEVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longevity predictions are important in many aspects of medical care. Limited survival will impact the benefits of initiating medications or performing procedures or screening tests. Decision making regarding the appropriateness of a specific intervention (eg, &rdquo;Should this older person be given a bisphosphonate to prevent osteoporosis?&rdquo;) requires recognition of both the likely survival time for an individual and how long it may take for the intervention to have effect.",
"   </p>",
"   <p>",
"    One classic study provides survival data on individuals in the United States, stratified into quartiles by survival for each five year period above age 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/179\">",
"     179",
"    </a>",
"    ]. The absence of significant comorbid conditions, or the presence of superior functional status for age, identifies older adults who are likely to live longer than average. Conversely, individuals with functional dependencies in activities of daily living",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    significant comorbidity (eg, heart failure, end-stage renal disease, oxygen-dependent chronic obstructive lung disease) have a life expectancy substantially below the average for",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    age.",
"   </p>",
"   <p>",
"    Age-related modification of risk-benefit relationships has broad applicability. In addition to the documentation of the broad range of life-expectancy for a given age, a table has been developed to measure the likely benefit against the potential risk (",
"    <a class=\"graphic graphic_table graphicRef53094 \" href=\"mobipreview.htm?33/56/34700\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For example, a typical 85 year old man who has a symptomatic inguinal hernia is likely to have the problem for another 4.7 years and thus may warrant a discussion of surgical repair. Note that the tables are based on a US Caucasian population, and may not be generalizable to other groups. Also, the tables do not account quality of life for the specified years. Both of these issues may critically modify the interpretation of the tabular data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189996508\">",
"    <span class=\"h2\">",
"     Successful aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;successful aging&rdquo; is used to identify older individuals who are free from chronic disease and continue to function well into old age, both physically and cognitively. The term &ldquo;essentially healthy&rdquo; identifies those with no acute disease, no recent history of cancer, normotensive, and with well-controlled chronic disease. &ldquo;Exceptionally healthy&rdquo; identifies older adults who take no medications, have no chronic disease, are normotensive and have a normal body weight. Psychosocial and genetic factors contribute to successful aging as well as to longevity.",
"   </p>",
"   <p>",
"    Predictors of high functional status in both physical and cognitive domains were evaluated in the longitudinal Cardiovascular Health Study, following 1677 participants for 14 years (median age 85, range 77 to 102, at study endpoint) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/180\">",
"     180",
"    </a>",
"    ]. Although all participants showed functional decline over time, 53 percent remained functionally intact and this group had a higher baseline health profile and lower vascular disease risk. Greater physical impairment was found in women and in those with greater weight. Cardiovascular disease and hypertension were predictors for both cognitive and physical impairment.",
"   </p>",
"   <p>",
"    In another longitudinal study of nearly 6000 British civil service employees followed for 17 years, successful aging was identified in 12.8 percent of men and 14.6 percent of women at followup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/181\">",
"     181",
"    </a>",
"    ]. The strongest predictor of successful aging was socioeconomic position at midlife. After adjustment for socioeconomics, not smoking, diet, exercise, moderate alcohol intake (in women), and work support (in men) predicted healthy aging.",
"    <br/>",
"   </p>",
"   <p>",
"    The effect of genetics on longevity and life expectancy has been explored in observational studies and in animal experiments. As noted above, twin studies suggest that 25 percent of longevity is genetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the importance of genetics is substantially larger at the extremes of longevity and may be greater for men than for women. In the New England Centenarian Study, male siblings of centenarians had a 17 times greater chance of living to age 100 compared with birth cohorts, compared to 8 times greater for females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/182\">",
"     182",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A polymorphism in the Cholesterol Ester Transfer Protein gene has been identified that is associated with successful aging, increased longevity, preserved cognition, less cardiovascular disease, and larger sized HDL particles in Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/183\">",
"     183",
"    </a>",
"    ]. Animal models suggest the potential for gene manipulation to prolong longevity. For example, the median and maximum survival of the nematode, C. elegans can be increased three-fold by mutating the daf-16 gene, a key regulator of",
"    <span class=\"nowrap\">",
"     insulin/IGF-like",
"    </span>",
"    pathways in the worm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/184\">",
"     184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Environmental factors are likely to interact with genetics. In Italy, the ratio of female to male centenarians is quite variable, ranging from 2:1 in Sardinia to 7:1 in Northern Italy, suggesting a gene-environment interaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/185\">",
"     185",
"    </a>",
"    ]. Okinawa, Japan, has the highest concentration of centenarians in the world. The longevity there has been attributed to a &ldquo;caloric restriction with optimal nutrition&rdquo; diet, similar to diets that increase longevity by 50 percent in mice and rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/186\">",
"     186",
"    </a>",
"    ]. A genetic component is also possible, based on family studies of Okinawan centenarians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/187\">",
"     187",
"    </a>",
"    ]. Extreme female longevity may be less dependent on genetics than male longevity, and more related to a healthier life style and more favorable environmental conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/24/38282/abstract/185\">",
"     185",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/20/16706?source=see_link\">",
"       \"Patient information: Sex as you get older (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189995544\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aging, characterized by progressive changes associated with increased susceptibility to many diseases, is influenced by genetic factors, life style choices, and environmental exposures. Several overarching physiologic principles characterize aging: loss of complexity as seen in less variability in heart rate responses, altered circadian patterns, and loss of physiologic reserves needed to cope with challenges to homeostasis. (See",
"      <a class=\"local\" href=\"#H23810845\">",
"       'Age-associated physiologic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional bone marrow reserves are reduced, with delayed response to blood loss or hypoxia. White blood cell function is impaired and myelotoxicity from chemotherapy is often increased. Advancing age leads to a procoagulant state, with increased platelet responsiveness and levels of clotting factors. (See",
"      <a class=\"local\" href=\"#H23810861\">",
"       'Hematopoietic system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reflux esophagitis, due to altered contractions and sphincter tone, is common with age and may affect nutrition. H. pylori infection is common, and sensitivity to gastric irritants such as NSAIDs is increased. Colonic changes include motility changes resulting in constipation, decreased visceral response to bowel perforation or ischemia, colon diverticuli, and increased risk for colon cancer. (See",
"      <a class=\"local\" href=\"#H23810868\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal mass and function decline, with decrease in creatinine clearance and ability to maximally dilute urine or excrete an acid load. The older kidney is more prone to nephrotoxicity related to medications or intravenous contrast. (See",
"      <a class=\"local\" href=\"#H23810924\">",
"       'The renal system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is difficult to isolate the impact of age alone on the cardiovascular system, since age increases risk for hypertension, coronary artery disease, and a more sedentary lifestyle. There is an age-related decrease in maximum heart rate, as well as the compensatory response of left ventricular ejection fraction to exercise. The annulus of both the aortic and mitral valve thicken, with development of valvular calcific deposits. (See",
"      <a class=\"local\" href=\"#H23810931\">",
"       'Cardiovascular system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About one-third of surface area per volume of lung tissue is lost over the life span, with increase in anatomic dead space increases and decrease in functional reserves. Age increases the alveolar-arterial (A-a) oxygen gradient, more marked in the supine than sitting position. Cough is less vigorous in the older person and mucociliary clearance is slower. (See",
"      <a class=\"local\" href=\"#H23810938\">",
"       'Respiratory system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aging changes in the genitourinary system increase the older person's risk of urinary incontinence, urinary tract infection, erectile dysfunction, and dyspareunia. (See",
"      <a class=\"local\" href=\"#H23810945\">",
"       'Genitourinary system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With aging, muscle mass decreases in relation to body weight, leading to impaired motility and balance, as well as age-related increased insulin resistance and changes in the volume of distribution for water soluble drugs. Aging increases the probability of fracture and slows the rate of fracture repair. Increasing weight bearing may result increase bone mineral and prevent age-related bone loss. (See",
"      <a class=\"local\" href=\"#H23810973\">",
"       'Musculoskeletal system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal aging of the skin leads to atrophy, decreased elasticity, and impaired metabolic and reparative responses. Photoaging, not physiologic aging, produces 90 percent of the cosmetically undesirable changes in skin. (See",
"      <a class=\"local\" href=\"#H23810980\">",
"       'Skin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presbyopia is due to age-related changes in the lens and iris. Age-related changes in the auditory system produce decrements in high-frequency hearing acuity and impaired speech recognition in noisy environments. Loss of taste in older patients is in large part due to decreased olfaction rather than taste itself. Decreased taste and smell sensation may result in decreased enjoyment of food and result in nutritional deficiencies. (See",
"      <a class=\"local\" href=\"#H23810987\">",
"       'Sensory system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decrements in immune functions with aging are among the most critical changes, contributing to the increased frequency of infections, malignancies, and autoimmune disorders. Immunosenescence is associated with loss of regulation of inflammatory processes. Older adults display cytokine profiles that are consistent with a chronic, low-level inflammatory state, sometimes referred to as &ldquo;inflammaging.&rdquo; (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=see_link\">",
"       \"Immune function in older adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/1\">",
"      vB Hjelmborg J, Iachine I, Skytthe A, et al. Genetic influence on human lifespan and longevity. Hum Genet 2006; 119:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/2\">",
"      Veldhuis JD. Altered pulsatile and coordinate secretion of pituitary hormones in aging: evidence of feedback disruption. Aging (Milano) 1997; 9:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/3\">",
"      Hofman MA, Swaab DF. Living by the clock: the circadian pacemaker in older people. Ageing Res Rev 2006; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/4\">",
"      Lipsitz LA, Goldberger AL. Loss of 'complexity' and aging. Potential applications of fractals and chaos theory to senescence. JAMA 1992; 267:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/5\">",
"      Galetta F, Franzoni F, Femia FR, et al. Lifelong physical training prevents the age-related impairment of heart rate variability and exercise capacity in elderly people. J Sports Med Phys Fitness 2005; 45:217.",
"     </a>",
"    </li>",
"    <li>",
"     Cowdry EV. Problems of ageing: biological and medical aspects, 2nd ed, Williams &amp; Wilkins, Baltimore 1942.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/7\">",
"      Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/8\">",
"      Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/9\">",
"      Beer RJ, Teasdale TA, Ghusn HF, Taffet GE. Estimation of severity of illness with APACHE II: age-related implications in cardiac arrest outcomes. Resuscitation 1994; 27:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/10\">",
"      Sansoni P, Cossarizza A, Brianti V, et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993; 82:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/11\">",
"      Kirkland JL, Tchkonia T, Pirtskhalava T, et al. Adipogenesis and aging: does aging make fat go MAD? Exp Gerontol 2002; 37:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/12\">",
"      French RA, Broussard SR, Meier WA, et al. Age-associated loss of bone marrow hematopoietic cells is reversed by GH and accompanies thymic reconstitution. Endocrinology 2002; 143:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/13\">",
"      Artz AS. From biology to clinical practice: aging and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/14\">",
"      Boggs DR, Patrene KD. Hematopoiesis and aging III: Anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am J Hematol 1985; 19:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/15\">",
"      Harrison DE. Long-term erythropoietic repopulating ability of old, young, and fetal stem cells. J Exp Med 1983; 157:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/16\">",
"      Lipschitz DA, Udupa KB, Milton KY, Thompson CO. Effect of age on hematopoiesis in man. Blood 1984; 63:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/17\">",
"      Bagnara GP, Bonsi L, Strippoli P, et al. Hemopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network. J Gerontol A Biol Sci Med Sci 2000; 55:B61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/18\">",
"      Albright JW, Makinodan T. Decline in the growth potential of spleen-colonizing bone marrow stem cells of long-lived aging mice. J Exp Med 1976; 144:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/19\">",
"      Pinto A, De Filippi R, Frigeri F, et al. Aging and the hemopoietic system. Crit Rev Oncol Hematol 2003; 48:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/20\">",
"      Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 2006; 60:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/21\">",
"      Isaia G, Greppi F, Ausiello L, et al. D-dimer plasma concentrations in an older hospitalized population. J Am Geriatr Soc 2011; 59:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/22\">",
"      Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/23\">",
"      Yamamoto K, Takeshita K, Kojima T, et al. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 2005; 66:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/24\">",
"      Yamamoto K, Takeshita K, Shimokawa T, et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 2002; 99:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/25\">",
"      Hall KE, Proctor DD, Fisher L, Rose S. American gastroenterological association future trends committee report: effects of aging of the population on gastroenterology practice, education, and research. Gastroenterology 2005; 129:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/26\">",
"      Dunn-Walters DK, Howard WA, Bible JM. The Aeging Gut. Mech Ageing Dev 2004; 125:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/27\">",
"      Nagler RM, Hershkovich O. Age-related changes in unstimulated salivary function and composition and its relations to medications and oral sensorial complaints. Aging Clin Exp Res 2005; 17:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/28\">",
"      Fulp SR, Dalton CB, Castell JA, Castell DO. Aging-related alterations in human upper esophageal sphincter function. Am J Gastroenterol 1990; 85:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/29\">",
"      Frederick MG, Ott DJ, Grishaw EK, et al. Functional abnormalities of the pharynx: a prospective analysis of radiographic abnormalities relative to age and symptoms. AJR Am J Roentgenol 1996; 166:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/30\">",
"      Lasch H, Castell DO, Castell JA. Evidence for diminished visceral pain with aging: studies using graded intraesophageal balloon distension. Am J Physiol 1997; 272:G1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/31\">",
"      Kekki M, Samloff IM, Iham&auml;ki T, et al. Age- and sex-related behaviour of gastric acid secretion at the population level. Scand J Gastroenterol 1982; 17:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/32\">",
"      Feldman M, Cryer B, McArthur KE, et al. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 1996; 110:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/33\">",
"      Hurwitz A, Brady DA, Schaal SE, et al. Gastric acidity in older adults. JAMA 1997; 278:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/34\">",
"      Haruma K, Kamada T, Kawaguchi H, et al. Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 2000; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/35\">",
"      Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89:S116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/36\">",
"      Gomez-Pinilla PJ, Gibbons SJ, Sarr MG, et al. Changes in interstitial cells of cajal with age in the human stomach and colon. Neurogastroenterol Motil 2011; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/37\">",
"      Saltzman JR, Russell RM. The aging gut. Nutritional issues. Gastroenterol Clin North Am 1998; 27:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/38\">",
"      Salles N. Basic mechanisms of the aging gastrointestinal tract. Dig Dis 2007; 25:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/39\">",
"      Drozdowski L, Thomson AB. Aging and the intestine. World J Gastroenterol 2006; 12:7578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/40\">",
"      Parlesak A, Klein B, Schecher K, et al. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc 2003; 51:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/41\">",
"      Hilton D, Iman N, Burke GJ, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001; 96:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/42\">",
"      Cowen T, Johnson RJ, Soubeyre V, Santer RM. Restricted diet rescues rat enteric motor neurones from age related cell death. Gut 2000; 47:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/43\">",
"      Wade PR, Hornby PJ. Age-related neurodegenerative changes and how they affect the gut. Sci Aging Knowledge Environ 2005; 2005:pe8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/44\">",
"      Lyon C, Clark DC. Diagnosis of acute abdominal pain in older patients. Am Fam Physician 2006; 74:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/45\">",
"      Gundling F, Seidl H, Scalercio N, et al. Influence of gender and age on anorectal function: normal values from anorectal manometry in a large caucasian population. Digestion 2010; 81:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/46\">",
"      Bitar KN, Patil SB. Aging and gastrointestinal smooth muscle. Mech Ageing Dev 2004; 125:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/47\">",
"      Lewicky-Gaupp C, Hamilton Q, Ashton-Miller J, et al. Anal sphincter structure and function relationships in aging and fecal incontinence. Am J Obstet Gynecol 2009; 200:559.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/48\">",
"      Comparato G, Pilotto A, Franz&egrave; A, et al. Diverticular disease in the elderly. Dig Dis 2007; 25:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/49\">",
"      Commane DM, Arasaradnam RP, Mills S, et al. Diet, ageing and genetic factors in the pathogenesis of diverticular disease. World J Gastroenterol 2009; 15:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/50\">",
"      Xiao ZQ, Moragoda L, Jaszewski R, et al. Aging is associated with increased proliferation and decreased apoptosis in the colonic mucosa. Mech Ageing Dev 2001; 122:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/51\">",
"      McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/52\">",
"      Schmucker DL. Aging and the liver: an update. J Gerontol A Biol Sci Med Sci 1998; 53:B315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/53\">",
"      Rahmioglu N, Andrew T, Cherkas L, et al. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS One 2009; 4:e4435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/54\">",
"      Anantharaju A, Feller A, Chedid A. Aging Liver. A review. Gerontology 2002; 48:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/55\">",
"      Fu A, Nair KS. Age effect on fibrinogen and albumin synthesis in humans. Am J Physiol 1998; 275:E1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/56\">",
"      Tietz NW, Shuey DF, Wekstein DR. Laboratory values in fit aging individuals--sexagenarians through centenarians. Clin Chem 1992; 38:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/57\">",
"      Rudman D, Feller AG, Nagraj HS, et al. Relation of serum albumin concentration to death rate in nursing home men. JPEN J Parenter Enteral Nutr 1987; 11:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/58\">",
"      Schmucker DL. Age-related changes in liver structure and function: Implications for disease ? Exp Gerontol 2005; 40:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/59\">",
"      Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/60\">",
"      Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/61\">",
"      Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/62\">",
"      Valdivieso V, Palma R, W&uuml;nkhaus R, et al. Effect of aging on biliary lipid composition and bile acid metabolism in normal Chilean women. Gastroenterology 1978; 74:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/63\">",
"      Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 1992; 232:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/64\">",
"      Tracy RE, Velez-Duran M, Heigle T, Oalmann MC. Two variants of nephrosclerosis separately related to age and blood pressure. Am J Pathol 1988; 131:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/65\">",
"      Long DA, Mu W, Price KL, Johnson RJ. Blood vessels and the aging kidney. Nephron Exp Nephrol 2005; 101:e95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/66\">",
"      Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med 2010; 152:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/67\">",
"      Fuiano G, Sund S, Mazza G, et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int 2001; 59:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/68\">",
"      Esposito C, Plati A, Mazzullo T, et al. Renal function and functional reserve in healthy elderly individuals. J Nephrol 2007; 20:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/69\">",
"      Ungar A, Cristofari C, Torrini M, et al. Changes in renal autacoids in aged human hypertensives. J Physiol Pharmacol 2000; 51:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/70\">",
"      Field TS, Gurwitz JH, Glynn RJ, et al. The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc 1999; 47:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/71\">",
"      Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106:13S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/72\">",
"      Lindeman RD. Overview: renal physiology and pathophysiology of aging. Am J Kidney Dis 1990; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/73\">",
"      Giannelli SV, Patel KV, Windham BG, et al. Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc 2007; 55:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/74\">",
"      Fliser D. Assessment of renal function in elderly patients. Curr Opin Nephrol Hypertens 2008; 17:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/75\">",
"      Christensson A, Elmst&aring;hl S. Estimation of the age-dependent decline of glomerular filtration rate from formulas based on creatinine and cystatin C in the general elderly population. Nephron Clin Pract 2011; 117:c40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/76\">",
"      Odden MC, Tager IB, Gansevoort RT, et al. Age and cystatin C in healthy adults: a collaborative study. Nephrol Dial Transplant 2010; 25:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/77\">",
"      Sands JM. Urine concentrating and diluting ability during aging. J Gerontol A Biol Sci Med Sci 2012; 67:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/78\">",
"      Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv 2008; 71:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/79\">",
"      Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci 2007; 334:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/80\">",
"      Schmitt R, Cantley LG. The impact of aging on kidney repair. Am J Physiol Renal Physiol 2008; 294:F1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/81\">",
"      Ishida M, Bulos B, Takamoto S, Sacktor B. Hydroxylation of 25-hydroxyvitamin D3 by renal mitochondria from rats of different ages. Endocrinology 1987; 121:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/82\">",
"      Diz DI. Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008; 52:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/83\">",
"      Powers JS, Krantz SB, Collins JC, et al. Erythropoietin response to anemia as a function of age. J Am Geriatr Soc 1991; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/84\">",
"      White N. The relationship of the degree of coronary atherosclerosis with age in men. Circulation 1950; 1:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/85\">",
"      Fleg JL, O'Connor F, Gerstenblith G, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol 1995; 78:890.",
"     </a>",
"    </li>",
"    <li>",
"     Taffet GE, Lakatta EG. Aging of the Cardiovascular System. In: Principles of Geriatric Medicine and Gerontology, 5th ed, Hazzard WR, Blass JP, Halter JB, et al.  (Eds), McGraw-Hill, New York 2003. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/87\">",
"      Van de Veire NR, De Backer J, Ascoop AK, et al. Echocardiographically estimated left ventricular end-diastolic and right ventricular systolic pressure in normotensive healthy individuals. Int J Cardiovasc Imaging 2006; 22:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/88\">",
"      Gates PE, Tanaka H, Graves J, Seals DR. Left ventricular structure and diastolic function with human ageing. Relation to habitual exercise and arterial stiffness. Eur Heart J 2003; 24:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/89\">",
"      Kitzman DW, Scholz DG, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part II (Maturity): A quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin Proc 1988; 63:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/90\">",
"      Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/91\">",
"      Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/92\">",
"      Zhang XP, Vatner SF, Shen YT, et al. Increased apoptosis and myocyte enlargement with decreased cardiac mass; distinctive features of the aging male, but not female, monkey heart. J Mol Cell Cardiol 2007; 43:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/93\">",
"      Kajstura J, Cheng W, Sarangarajan R, et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol 1996; 271:H1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/94\">",
"      Jones SA, Boyett MR, Lancaster MK. Declining into failure: the age-dependent loss of the L-type calcium channel within the sinoatrial node. Circulation 2007; 115:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/95\">",
"      Stratton JR, Cerqueira MD, Schwartz RS, et al. Differences in cardiovascular responses to isoproterenol in relation to age and exercise training in healthy men. Circulation 1992; 86:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/96\">",
"      Parati G, Di Rienzo M. Determinants of heart rate and heart rate variability. J Hypertens 2003; 21:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/97\">",
"      Fleg JL, Kennedy HL. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects greater than or equal to 60 years of age. Am J Cardiol 1992; 70:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/98\">",
"      Busby MJ, Shefrin EA, Fleg JL. Prevalence and long-term significance of exercise-induced frequent or repetitive ventricular ectopic beats in apparently healthy volunteers. J Am Coll Cardiol 1989; 14:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/99\">",
"      Stratton JR, Levy WC, Cerqueira MD, et al. Cardiovascular responses to exercise. Effects of aging and exercise training in healthy men. Circulation 1994; 89:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/100\">",
"      Swinne CJ, Shapiro EP, Lima SD, Fleg JL. Age-associated changes in left ventricular diastolic performance during isometric exercise in normal subjects. Am J Cardiol 1992; 69:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/101\">",
"      Gillooly M, Lamb D. Airspace size in lungs of lifelong non-smokers: effect of age and sex. Thorax 1993; 48:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/102\">",
"      Janssens JP. Aging of the respiratory system: impact on pulmonary function tests and adaptation to exertion. Clin Chest Med 2005; 26:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/103\">",
"      Taylor BJ, Johnson BD. The pulmonary circulation and exercise responses in the elderly. Semin Respir Crit Care Med 2010; 31:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/104\">",
"      Tagaram HR, Wang G, Umstead TM, et al. Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/105\">",
"      Stam H, Hrachovina V, Stijnen T, Versprille A. Diffusing capacity dependent on lung volume and age in normal subjects. J Appl Physiol 1994; 76:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/106\">",
"      Hardie JA, M&oslash;rkve O, Ellingsen I. Effect of body position on arterial oxygen tension in the elderly. Respiration 2002; 69:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/107\">",
"      Crapo RO, Jensen RL, Hegewald M, Tashkin DP. Arterial blood gas reference values for sea level and an altitude of 1,400 meters. Am J Respir Crit Care Med 1999; 160:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/108\">",
"      Cerveri I, Zoia MC, Fanfulla F, et al. Reference values of arterial oxygen tension in the middle-aged and elderly. Am J Respir Crit Care Med 1995; 152:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/109\">",
"      Hardie JA, Vollmer WM, Buist AS, et al. Reference values for arterial blood gases in the elderly. Chest 2004; 125:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/110\">",
"      Estenne M, Yernault JC, De Troyer A. Rib cage and diaphragm-abdomen compliance in humans: effects of age and posture. J Appl Physiol 1985; 59:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/111\">",
"      Polkey MI, Harris ML, Hughes PD, et al. The contractile properties of the elderly human diaphragm. Am J Respir Crit Care Med 1997; 155:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/112\">",
"      Kuster SP, Kuster D, Schindler C, et al. Reference equations for lung function screening of healthy never-smoking adults aged 18-80 years. Eur Respir J 2008; 31:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/113\">",
"      Xu X, Laird N, Dockery DW, et al. Age, period, and cohort effects on pulmonary function in a 24-year longitudinal study. Am J Epidemiol 1995; 141:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/114\">",
"      Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/115\">",
"      Summerhill EM, Angov N, Garber C, McCool FD. Respiratory muscle strength in the physically active elderly. Lung 2007; 185:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/116\">",
"      Kronenberg RS, Drage CW. Attenuation of the ventilatory and heart rate responses to hypoxia and hypercapnia with aging in normal men. J Clin Invest 1973; 52:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/117\">",
"      Pack AI, Millman RP. Changes in control of ventilation, awake and asleep, in the elderly. J Am Geriatr Soc 1986; 34:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/118\">",
"      Svartengren M, Falk R, Philipson K. Long-term clearance from small airways decreases with age. Eur Respir J 2005; 26:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/119\">",
"      Fleg JL, Morrell CH, Bos AG, et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation 2005; 112:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/120\">",
"      Hollenberg M, Yang J, Haight TJ, Tager IB. Longitudinal changes in aerobic capacity: implications for concepts of aging. J Gerontol A Biol Sci Med Sci 2006; 61:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/121\">",
"      Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/122\">",
"      Elbadawi A, Diokno AC, Millard RJ. The aging bladder: morphology and urodynamics. World J Urol 1998; 16 Suppl 1:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/123\">",
"      Gilpin SA, Gilpin CJ, Dixon JS, et al. The effect of age on the autonomic innervation of the urinary bladder. Br J Urol 1986; 58:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/124\">",
"      Tadic SD, Griffiths D, Schaefer W, et al. Brain activity underlying impaired continence control in older women with overactive bladder. Neurourol Urodyn 2012; 31:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/125\">",
"      Dubeau CE. The aging lower urinary tract. J Urol 2006; 175:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/126\">",
"      Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/127\">",
"      Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ 2010; 340:c810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/128\">",
"      Seftel AD. From aspiration to achievement: assessment and noninvasive treatment of erectile dysfunction in aging men. J Am Geriatr Soc 2005; 53:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/129\">",
"      Harris ID, Fronczak C, Roth L, Meacham RB. Fertility and the aging male. Rev Urol 2011; 13:e184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/130\">",
"      Hermann M, Untergasser G, Rumpold H, Berger P. Aging of the male reproductive system. Exp Gerontol 2000; 35:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/131\">",
"      Tarlatzis BC, Zepiridis L. Perimenopausal conception. Ann N Y Acad Sci 2003; 997:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/132\">",
"      Kingsberg SA. The impact of aging on sexual function in women and their partners. Arch Sex Behav 2002; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/133\">",
"      Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/134\">",
"      Ryall JG, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology 2008; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/135\">",
"      Faulkner JA, Larkin LM, Claflin DR, Brooks SV. Age-related changes in the structure and function of skeletal muscles. Clin Exp Pharmacol Physiol 2007; 34:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/136\">",
"      Delbono O. Neural control of aging skeletal muscle. Aging Cell 2003; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/137\">",
"      Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol 1988; 404:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/138\">",
"      Degens H. Age-related skeletal muscle dysfunction: causes and mechanisms. J Musculoskelet Neuronal Interact 2007; 7:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/139\">",
"      Carlson BM, Faulkner JA. Muscle transplantation between young and old rats: age of host determines recovery. Am J Physiol 1989; 256:C1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/140\">",
"      Musch TI, Eklund KE, Hageman KS, Poole DC. Altered regional blood flow responses to submaximal exercise in older rats. J Appl Physiol 2004; 96:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/141\">",
"      Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002; 48:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/142\">",
"      Giangregorio L, Blimkie CJ. Skeletal adaptations to alterations in weight-bearing activity: a comparison of models of disuse osteoporosis. Sports Med 2002; 32:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/143\">",
"      Schwab P, Klein RF. Nonpharmacological approaches to improve bone health and reduce osteoporosis. Curr Opin Rheumatol 2008; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/144\">",
"      Meyer RA Jr, Desai BR, Heiner DE, et al. Young, adult, and old rats have similar changes in mRNA expression of many skeletal genes after fracture despite delayed healing with age. J Orthop Res 2006; 24:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/145\">",
"      Gruber R, Koch H, Doll BA, et al. Fracture healing in the elderly patient. Exp Gerontol 2006; 41:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/146\">",
"      Moragas A, Castells C, Sans M. Mathematical morphologic analysis of aging-related epidermal changes. Anal Quant Cytol Histol 1993; 15:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/147\">",
"      Montagna W, Carlisle K. Structural changes in ageing skin. Br J Dermatol 1990; 122 Suppl 35:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/148\">",
"      Ashcroft GS, Mills SJ, Ashworth JJ. Ageing and wound healing. Biogerontology 2002; 3:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/149\">",
"      Yaar M, Gilchrest BA. Skin aging: postulated mechanisms and consequent changes in structure and function. Clin Geriatr Med 2001; 17:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/150\">",
"      Varani J, Dame MK, Rittie L, et al. Decreased collagen production in chronologically aged skin: roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am J Pathol 2006; 168:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/151\">",
"      Uitto J. The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure. J Drugs Dermatol 2008; 7:s12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/152\">",
"      Anderson RK, Kenney WL. Effect of age on heat-activated sweat gland density and flow during exercise in dry heat. J Appl Physiol 1987; 63:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/153\">",
"      Inbar O, Morris N, Epstein Y, Gass G. Comparison of thermoregulatory responses to exercise in dry heat among prepubertal boys, young adults and older males. Exp Physiol 2004; 89:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/154\">",
"      Perry SD. Evaluation of age-related plantar-surface insensitivity and onset age of advanced insensitivity in older adults using vibratory and touch sensation tests. Neurosci Lett 2006; 392:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/155\">",
"      Matsuoka S, Suzuki H, Morioka S, et al. Quantitative and qualitative studies of Meissner's corpuscles in human skin, with special reference to alterations caused by aging. J Dermatol 1983; 10:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/156\">",
"      Gescheider GA, Bolanowski SJ, Hall KL, et al. The effects of aging on information-processing channels in the sense of touch: I. Absolute sensitivity. Somatosens Mot Res 1994; 11:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/157\">",
"      Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet 1989; 2:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/158\">",
"      McCullough JL, Kelly KM. Prevention and treatment of skin aging. Ann N Y Acad Sci 2006; 1067:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/159\">",
"      Griffiths CE. The role of retinoids in the prevention and repair of aged and photoaged skin. Clin Exp Dermatol 2001; 26:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/160\">",
"      Van Haeringen NJ. Aging and the lacrimal system. Br J Ophthalmol 1997; 81:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/161\">",
"      Schnohr P, Nyboe J, Lange P, Jensen G. Longevity and gray hair, baldness, facial wrinkles, and arcus senilis in 13,000 men and women: the Copenhagen City Heart Study. J Gerontol A Biol Sci Med Sci 1998; 53:M347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/162\">",
"      Salvi SM, Akhtar S, Currie Z. Ageing changes in the eye. Postgrad Med J 2006; 82:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/163\">",
"      Bishop PN, Holmes DF, Kadler KE, et al. Age-related changes on the surface of vitreous collagen fibrils. Invest Ophthalmol Vis Sci 2004; 45:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/164\">",
"      Strenk SA, Strenk LM, Koretz JF. The mechanism of presbyopia. Prog Retin Eye Res 2005; 24:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/165\">",
"      Liem AT, Keunen JE, van Norren D, van de Kraats J. Rod densitometry in the aging human eye. Invest Ophthalmol Vis Sci 1991; 32:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/166\">",
"      Gates GA, Mills JH. Presbycusis. Lancet 2005; 366:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/167\">",
"      Howarth A, Shone GR. Ageing and the auditory system. Postgrad Med J 2006; 82:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/168\">",
"      Mojet J, Christ-Hazelhof E, Heidema J. Taste perception with age: generic or specific losses in threshold sensitivity to the five basic tastes? Chem Senses 2001; 26:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/169\">",
"      Gudziol H, Hummel T. Normative values for the assessment of gustatory function using liquid tastants. Acta Otolaryngol 2007; 127:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/170\">",
"      Boyce JM, Shone GR. Effects of ageing on smell and taste. Postgrad Med J 2006; 82:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/171\">",
"      Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev 2007; 65:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/172\">",
"      Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012; 489:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/173\">",
"      Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009; 325:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/174\">",
"      Lee HW, Blasco MA, Gottlieb GJ, et al. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/175\">",
"      Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/176\">",
"      Salpea KD, Humphries SE. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010; 209:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/177\">",
"      Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011; 470:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/178\">",
"      Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/179\">",
"      Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/180\">",
"      Newman AB, Arnold AM, Sachs MC, et al. Long-term function in an older cohort--the cardiovascular health study all stars study. J Am Geriatr Soc 2009; 57:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/181\">",
"      Britton A, Shipley M, Singh-Manoux A, Marmot MG. Successful aging: the contribution of early-life and midlife risk factors. J Am Geriatr Soc 2008; 56:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/182\">",
"      Perls TT, Wilmoth J, Levenson R, et al. Life-long sustained mortality advantage of siblings of centenarians. Proc Natl Acad Sci U S A 2002; 99:8442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/183\">",
"      Atzmon G, Rincon M, Rabizadeh P, Barzilai N. Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev 2005; 126:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/184\">",
"      Libina N, Berman JR, Kenyon C. Tissue-specific activities of C. elegans DAF-16 in the regulation of lifespan. Cell 2003; 115:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/185\">",
"      Franceschi C, Motta L, Valensin S, et al. Do men and women follow different trajectories to reach extreme longevity? Italian Multicenter Study on Centenarians (IMUSCE). Aging (Milano) 2000; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/186\">",
"      Willcox DC, Willcox BJ, Todoriki H, et al. Caloric restriction and human longevity: what can we learn from the Okinawans? Biogerontology 2006; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/24/38282/abstract/187\">",
"      Willcox BJ, Willcox DC, He Q, et al. Siblings of Okinawan centenarians share lifelong mortality advantages. J Gerontol A Biol Sci Med Sci 2006; 61:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14605 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38282=[""].join("\n");
var outline_f37_24_38282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H189995544\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H937028\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810845\">",
"      AGE-ASSOCIATED PHYSIOLOGIC CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178571021\">",
"      Physiologic rhythms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97310021\">",
"      Loss of complexity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810854\">",
"      Homeostenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810861\">",
"      HEMATOPOIETIC SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810868\">",
"      GASTROINTESTINAL TRACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810875\">",
"      Oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810882\">",
"      Esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810889\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810896\">",
"      Small intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810903\">",
"      Large intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810910\">",
"      Hepatobiliary system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810917\">",
"      Exocrine pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810924\">",
"      THE RENAL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810931\">",
"      CARDIOVASCULAR SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810938\">",
"      RESPIRATORY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810945\">",
"      GENITOURINARY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810952\">",
"      Bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810959\">",
"      Male reproductive system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810966\">",
"      Female reproductive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810973\">",
"      MUSCULOSKELETAL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H584138046\">",
"      Muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H584138090\">",
"      Bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810980\">",
"      SKIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23810987\">",
"      SENSORY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H584138016\">",
"      Eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23810994\">",
"      Hearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23811001\">",
"      Taste and smell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23811008\">",
"      IMMUNE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189995853\">",
"      MOLECULAR BASIS OF AGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23811022\">",
"      LONGEVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189996508\">",
"      Successful aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189995544\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14605|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/21/36178\" title=\"figure 1\">",
"      Homeostenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/6/39021\" title=\"figure 2\">",
"      Pulmonary function with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/31/39419\" title=\"table 1\">",
"      Renal changes with aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/56/34700\" title=\"table 2\">",
"      Life expectancy by age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43271?source=related_link\">",
"      Bacteriology and epidemiology of Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/22/12650?source=related_link\">",
"      Endocrine changes with aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=related_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36854?source=related_link\">",
"      Epidemiology and pathophysiology of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/52/15178?source=related_link\">",
"      Immune function in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/20/16706?source=related_link\">",
"      Patient information: Sex as you get older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41737?source=related_link\">",
"      Urinary incontinence in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=related_link\">",
"      Visual impairment in adults: Refractive disorders and presbyopia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_24_38283="Tryptase in Ana vs masto";
var content_f37_24_38283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mature and total tryptase levels in anaphylaxis and systemic mastocytosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Clinical condition",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Tryptase levels (ng/mL)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Total/mature tryptase ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Total",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        1 to 11.4",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic anaphylaxis (acute)",
"       </td>",
"       <td>",
"        &gt; baseline",
"        <sup>",
"         *",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;1",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic mastocytosis (nonacute)",
"       </td>",
"       <td>",
"        &gt;20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        &gt;20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"     <br>",
"      * Acute total tryptase level &gt;2 + (1.2 x patient's baseline total tryptase level).",
"      <br>",
"       &bull;&nbsp;Level related to clinical severity (hypotension), timing of sample collection in relation to onset of signs and symptoms, and nature of the anaphylactic stimulus.",
"       <br>",
"        <sup>",
"         &Delta;",
"        </sup>",
"        &nbsp;Reflects primarily the total body burden of mast cells when subject is in a non-anaphylactic state. A baseline total tryptase level &gt;11.4 ng/mL should raise the possibility of an underlying clonal mast cell disorder (eg, systemic mastocytosis) or a primary mast cell activation disorder.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38283=[""].join("\n");
var outline_f37_24_38283=null;
var title_f37_24_38284="Repeat prost bx high grade PIN";
var content_f37_24_38284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of repeat prostate biopsy in men with isolated high grade PIN",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number with cancer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent with cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brawer, MK, et al.",
"       </td>",
"       <td>",
"        1991",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berner, A, et al.",
"       </td>",
"       <td>",
"        1993",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weinstein, MH, et al.",
"       </td>",
"       <td>",
"        1993",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Davidson, D, et al.",
"       </td>",
"       <td>",
"        1995",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keetch, DW, et al.",
"       </td>",
"       <td>",
"        1995",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raviv, G, at al.",
"       </td>",
"       <td>",
"        1996",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Langer, JE, et al.",
"       </td>",
"       <td>",
"        1996",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        O'Dowd, GJ, et al.",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        3,030",
"       </td>",
"       <td>",
"        697",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lefkowitz, GK, et al.",
"       </td>",
"       <td>",
"        2001",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2.3*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goeman, L et al.",
"       </td>",
"       <td>",
"        2003",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moore, C, et al",
"       </td>",
"       <td>",
"        2005",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3.2&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gokden, N, et al",
"       </td>",
"       <td>",
"        2005",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        13.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herawi, M; et al.",
"       </td>",
"       <td>",
"        2006",
"       </td>",
"       <td>",
"        791",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 12 cores on initial biopsy.",
"     <br>",
"      &bull; 10 cores on initial biopsy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38284=[""].join("\n");
var outline_f37_24_38284=null;
var title_f37_24_38285="Transient neutropenia during HD";
var content_f37_24_38285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Graph showing transient neutropenia in one patient during hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 250px; background-image: url(data:image/gif;base64,R0lGODlh1wH6ANUAAP///4CAgAAAAEBAQMDAwAAz/xAQEMDN/4CZ/3BwcCAgIFBQUP/AwEBm/7CwsNDQ0P+AgPDw8DAwMKCgoBBA/zBZ/+Dg4P8AAKCz/2CA/9DZ//Dz/5CQkGBgYHCN//9AQFBz/7DA/+Dm/yBN//+goP+QkP8wMP9gYJCm//+wsP8gIP8QEP9wcP/w8P/g4P9QUP/Q0EBNgICMvwAZfwAmv89wcEBZv48wMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADXAfoAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytroAEsbFDDgEcFrS2uEIPAQEPr8HCrQLFxUIJAhIGBrjJy80ADgIKCgIOw9nao8WyABECBgAcAgng4uQJABICDw/K2/HymsUDCwQABAID+fv6/P8AHBMogAgBXwgD4JvHsCGhBQE6hLMQ8F/FfQSFDBRyMOGAAA5DivwzQACBdxKkCViAUuUCAAYERDinxNfImzjlEJAQMVwE/wDWHCwQMAHotaFFJfoS0KEmyJxQo6KxwE4ZMAAP2BlQh1Ur1whDV/5MYlOq2bOFyqJdy3aP2rZw48Z5K7eu3TN07+rd2yUv37+Ap/gNTLgw2aeGEysuMnix47+NH0u2G3my5baVL2s2m3mzZ5EdP34evShCB5YSB4yFExox6deEkoUz5npubdi4/QxQQECBOQX86HTOTVzOAH4Jih6vM7y48zYBDKw20FT47efY40QgMNbCL+bXs4tP1Xy8eTEcYtYDf759m3DHB3CdU969/SwKwtu+z79Mb4RFWdffgGFUtZ6ABCbIxUqyXEWffgpGCEUC1WmxnYPfnFTELEvIIP+DhCBWUZIxwT0RgTVPTWCMBD+pWAyLWKlnAIZGIIBAiDhGkUB88kUR1lMxRZAMBzDJNCQAQzkwzUtJ2Jjjk2MsKQBIFw1QZUZYcpRQADZ4AOWXSjzQoIkGLEUlRhahidFAG+WzZQwNgClnEWEd2EQA+1ijwARVXslmQUnIEOechCoD4BOh+VOkkAIQGeSRSS6phKCEEtpjFXimuGKLm8ZYzIyTDlopmAQYEN98T1C0S4YYXrjhQqGOKqd6dsohQwWygrlVHgEUkOuXO44pnK+/PjlirXMRWyyOEyQUIH3KLittGr1Oay0avW5w7bZjBEDDAdyG+4W34Irb33J4kGv/bn8BlGiHuuvel8ypOvkywLeGaYACBtrGy8WxGMURGg0h/LXBAQg0UMAIIFRAQQYa+FtJADPcaJcIGHhQQQEVeBCCCENokAEFFfArsRVCDvDAAtgIV3FcB6AAAgUUNIBAuUhsgIHDEJ88RVgEnMbcy2dtEELCC2eAQcRQiEyyyT470aiV7Q5tcU4aYJDBCAU04HG/VejMM9NRK3GNlfZYfRPCM1MAAgo4c+F0yWCXXUQHzFjzrBwUe8mQCCFozLHSIJMh9sNk2y0EWOGgyjec8ei7ddc3143G3FArrkcAkAdzMNIMo5D4G4f3XHZWjb/b+SoYC97xx3pgbvm61gzA/w6Ea3Auqikxt21z3H2UPrq41wixgLtzrR6K0aArPbwgsq8bQIARMRcDrp9kPbnXIcyOiPDiAoysG75EiwnbNL8NfCTRX7sjj5cysUBMe/Lilf2pfxPWAqsdUf4lgHMd4TgBPs0RIT8SEYdRhEKUBSIFAErBU4X8Vy1JSI5rv/MeJ9pnwG9QAyvwWFJLJBUkmgyhIwj5iPkS8TmFhe55oyig4vBkkn4AxB9q4sefDLIlFSqidRt7XeFewUGfUUQBzehTDrHUJiOUT4N96B3NfjcPGYIpAb8wgAL6twQLYONEJqFJOsRYjnW0oyWHacD69MA8FzrvJkXMkQEmML9dOf9BHytChjKY4Yw9RmMa1SheGtdYB+1h8GtmsWKITKIAiCBvCbWYHhFqcYtcVJIXvqCREwOgRjygz21wk0scFdTIKe0IPJ2UQwCDOMC9KJJA5GiGb1BJSDQcYHuVS8wo+fMAC2yHi3DwRQMK9gavwdAwrzyPLJapyTf4wkluEAEFoLiYXWbHGNh8pDMDAM02eCADpEnmc7bki73ZpptsoMAxL2NNAz7zamsIwQiKI07YwO84jgsmN+Gphrdhp52fwSaJwIMAv61BBAWg5mvqKTFfHGB3aUAAOM8D0MugrjdEss5D2zACYraHoZOBBgFOqVGInuEA8+xPRRdztoNocw3/rdnoGjLAz/uANDEG4MAAHKCACbohpiYtwwYKMMQErTQwNOwGeA6AvTTIDEc3BYxOWfYukKywDCWD0lHvUgsAeKeZ5LOqGjRAATlFFQAaOIBa1bpOJGigARiAw1vjSgSvAcADQW1DfoSQNgFddQwZMKicKqqwAhi2a0c4QAFqKgTFMlYKjqVCZImAgLgqjA41BEDV/KoGdcqqnmnNQAEycICIhQAEDUCBEERrMwBgoAENAEHBJttYBIQgA8MUgghw2zMMWMy3AGDtjSqrgRttAK89E4Ft8TrbAngArxarLAAuC4DTNoC0eu3ATCTgU30C4K9h2Nmy5lZLBCxWCCEo/wAIPOBcAGxsBHFaLwK4JgLaAsC8NTOsCKRZAQTQbLrEuux741QAChjWvRRAgMPquzAFFyCthm2AgeOK2MtiQL0IAMFjy5DUzD7ouwrtAlynpbPynhcAIEgoggEwWeU2gGtqPbEQzAsu9sZstEh7aIB9NVmOCUED7U0v3M6b3psR+bwV9hUKOCZdN0zAHi0TUCrLIM0QT8u8FqPuZSPLX60VIMbwpPF9v2xemtpIBFrm8YkRy+LzOjayb3YzkuNEXaS19xQ2mTIZvukzLAthybZVb5tlq1gQ6BjMlP3ymEvLsRAcwAMaSPF6DTzogrEZABQYwQFSDGHSbgzCN4pskv8BgAIPHODCIEBFnmvpBU33WcYeMDAI+qWwsoqWZF+2r5jFHIKNcUwEGuBaw3Zc1ktr4L1xVSzXKJBsOd9o1PI07KxVDRI9i0GeHYyijAGhsl7yqtqs5oI/s70H+/7hbLgjS0zmiD87os6OjBOLU6brUTEg1Mrk1oY1BPpSJCwgAbLBRVAeOPAGRpAp80ZnGJ6ab5ysTIv0kkJJThLClYxwJYsyIRJsonAwdLThUOGTFSzwQSXeUIeAahMK7QWSjnsBpSCPSi8uCQWqgMrkNmQioLTkkZZveAs0jXlOXBQOsCLhAVq8ChnNEY5xlJEd7oDHYe778ywMtahCD4kB7uH/AAkwSWrYBMkz+AiAsf+RGkFJuGC/8Nqs4ySzm3XClhZCyVXVfQi9+M68ZRqGrLp9JBLITwLs+GG+f4Gsf78J0l8EzG2yOK9a4HPib6Khqj5eDJ6dfHtsYvguiFfzmwcJU8MwYtCfpyzgvcK9Te8QgH9bCKm3gkRZ75AO9Nu73/V4uGn/ivQcCkGxpwK2ec8QgN0+d08J/hTGTXx5iElYHwZxF67efIbU4qvsme7uo8Dw6sdDNgRYQHfZ0BohWBsLH/d+PKgjAZfWq11POb8VYK7+eJjESrbPvvyrENj6x8N2pZRR0bd/U7ABFIB1rsAAJcAAQ8AAEPCAEAiBDOh2/4unDI0XVuZXb1fQdglYAidgAhdgAicwgQDggBEYgRNogicogZpTednnclTgd6nAAB8YgiewgFSggisIASkIASTAACQoLilDVS9YdU9QZaaggCmIg2bggB/wASpwARegAk/Ig0LggD8YhJaCTVHGN08Bg1IgeaCggDUoglroBkBIAlZYghDwhFE4hVXYg1kIIlPyDRJwfGpQFhiQalmQeZxAgyAogkw4CGm4hk4IhVJIhR9giBCQAgzgAuaxU0IQd16oW2WFBZ+HCTDAhEqICYXYg0+4AhewAnFIHMcReMfRSNnnXtu3BMwnCS2QAm04hSOoCi7AALLYgzv4gGf4BP9ACIQtQAUfwAKvIFDj43hC8Fyqp2KRQINRuIgpEIzZoIMr2IOOKI1MIIVSuAK9mI0fkBtqMXqyN1GM0IklWAIwgBYMwAIfAIIhOIzdCABSCAAscAEQUIIv8IQlIAQ+WAIfcALS2IYncAHf2ALsuIirEAEc8HvRJwQHaAWuhghkGIi1eBctgItreARSCAEmoAKQCAEnMIskII8hGIUnQI8X8AIQQJAAoAIrAAEsoAKrsG/HuASStDg7QoRDGGU6NQACuHGuAQJ0NQXD9wfmCIg2OIiTIYWIeI8tUAIvAIL3yJItwJIrIJPy+I0rsAIhCYmqwCCxYHRH8GQBAwAlkQD/7IAPZ5mWmrUSQwEhb7GH/GeEcDCRNriE8SgZ80iSAGACK1ACJWCPWSkELMmSgwkDLxCFK+CVqEAhVICWAUNyCgAAKtIBkkmZCGcNFnCZUzcE0kQF1HcHSCmIeTkaUqiAUyiPKrCOgmmYLPkBF5ACJPCaPwib6ZgKRFeWdxQwOBcQO3RCPVQbFdCKRdB9cXCUSpkd2kiQ6TibBNma33iYz8iSL5CII/mVpoJPURAQOZcmJ6dzPNRzRaCMUpB+bWCXZuh/hLBXVMCdl1mZ75mZArCZH9SZQyCOTXOJajCaN1ia6skHCZAf5QQFEyAR+YELa1lDCYoPeLIAbzlvRfCQ/1DQf2awiXj5n4tgfBPCI8CwkzgJZUPQkz9JQUYglFBggAjIBbE4iypQkRjaCM8Xlqs4BHLpBBqgMWDgjATZiNj4omyRFwilBG2UNMTJBBZ6hejoo5WgoQhSBBWggSyGS92jBSnAAi+wlS/gn0raCO9zljM6BORJBOvVVlPAAi+ZpFvqCTzxpT+WUkQgoVvgAiZgAoyZpp1wInhILeHhhyzWVFS6AsRop50AMOOHgUeQAaoFpmuHBSmQAoLqCV2qXWwqBBwoBMP5qKGXM8z4mVTqqJjKCU8GP/mEjEdQejWKBWbqqZ+qCR1Wk9ChHygwUSZ6BXJKp6v6CTylDLBSif9udYlwSgUpAKi36gkWMBTsNgfllwQjkFZ+WqYroKrDqgkOEBPmUAfJigTPFaZSUKt1Gq2Z0Kq6uR9J0GuXOgXBGqjeCqr3NKqGmgQFVgWNmq6KURkgwIdQQALXKa/zijtqFQWzma/6ahj1wQT/GrCLMbBKULAGu69boLALmxgIewQO+7CGUQM1kAUTS7GFUQMXALBJUKUoeIX16LEaSxgBcAMdqwQtcKUnmIIsQLIli1QBULAt8IMNCAEr8AI9GrN6EQHNMgEXSAQ2QQInUJ1Z2oAsAK08uxfsUBIpYZNPwQAksLNLSxiSkiRQW7WTkSltiTsRq7VwwbVcG54p9BH/5HS2aJu2aru2bNu2bvu2cBu3cju3dFu3dmu3u2of6VB2jbIhPWS2dnscd9sugFu3gnu3h4u4hUu3iWu4izu3jcu4jwu56YYdktkb85m1V/C1Q8C5k1i5mru5oAuhVuC5mjW69lm6qFscE6An5kSioosFpju7qwuUslu7m3S7uru7hGK6HKK6WPC7mIK7RiC8VOC7eSsYxGsQyau8o2K6WgC9WSC907u8fWG91/u82LsF1Bu7vIp74kooxtsG40t+zWu+OnG+MKW+YNu+7vu+8Bu/8ju/9Fu/9nstPjs9QUsGFrCQAdK/AdCFYyAmk+QLsJJ3YpkFFLEaAPwsACzA/12Qd+YkJruQv0AbBg/gv2NhwatxdzjStFKnBipiKi9hAczADuzKBRYwATFxQlyoEoEEwRbSdZmFdAbQtF51wmUEBtg0H4v3FCD8tF+QTUIQxHoEDasSIVcrSFNBDatxJEHSLcYwBBThdPwAdWjkBXgEd2V0DFAsE2BQFO+wc1UBEkssw1lQFCRXEGe8dCEitnWYBuSwDH07cWbpYWLQRJjZFL8JBnbsKQ9kx38MBpwZHckAEnC8vUkwUnWYyFcCIomch0wxrfMpyHgcBk10ItHQx1/wx1SBRAhnyeyLBVj7DrXQyKisyEhAlurgyEsEInt7JHJchxOHtVBXBm3yAP9IdBUl1HRh8MdDwR3WEH7Fc8tfEAElQT0CZQtlJMu/bBKx3CgX93URcrmaqQaSOa3SoSIsU59iQBHdgAulwhQ2cXCFigXbwQ4cAAwS0QGUvMIrAUiE3LS+sJmx0M70yRvXrMU8EXDWnLkF97oJ0rrUINBlQNAKcBWDZxVk0GGILFD6Uwz8AwZbjBHxJgEts9ASkMBVUNEeNrYIbdBYQBXFoAAtE9LtlsL3u9Is3dIu/dIwHdMyPdM0XdM2fdM4ndM6vdOCGqNh+WQcvQXx4wU9QlJGYNRLgNRVoNQ8zVf8dhBJPAbhuiD80CxIUBJOYNVYoNVSk6fxKybtfBJQTZn/ASwfpqEyHHE81TpJx5NRB+EAtifA+6BTkkqZx5FR09MuE7AyEy0Nbd25A5AaZI0Mx9EBwIDV10fWM/E+IKHVPZkAUS0E3gHXKuMAl2LVbx3XXqUQm00AKnKg+aDWP/EAtrcAIr20Y4snaol28PFBS5IM1PzaZYQnplIMSfwi1tAUyZAAQ0EkL0I/7NAUsq0OsI0n/IDVQBEAgzeZWK0ijjKZSKTczF0QEoFF7XcEeFQSWqQ3d9yWtT2f+nAmyg0fDyDbC0ByPCE08ZvaCloQ4d3dbxkA1kAEQ/ETy9CW+JAMu2rRGKFFS6FD/KDaAsEP9b0O4qBFGnHcgDJSA9DC/1gdATc8DY5CHQGAoAUxFBBxvu+N1RteEAKu3+/93gET39bwDr7BAfvLs+y92v0AElhdEglBBMiN1QIu4EMQMGsioJKEEQKOETNeEDiu4C5Bw90NQcoAxitjDc3w4B1QFTLc4S3e3TVuEiFehwED4wghDQ0ewu+74t0N5eTAdRNEDgGMcVO+38GBEW/p2SDB4zWEEWQuKSXhACoi5JmSq0WOR0wyAHxSEg+A1R3AAYy8znHMEbTs3oeO3/j9DmUC4wLBG/3LIHAdNA5QKgoEv17O4YmuWftGzWUXExN95kQQ5N+AN+HQ5gH+5sGx0BOty/vg4wURAewQSEW+QMZT0lHK4eHrpg7kkMRQDuWingw9hcrtwOkSTdIM3dSKAA6T6SPnrOzZQOZScN7QXu3Wfu3Ynu3avu3c3u3e/u3gHu7iPu7kXu7mfu7onu7qvu52EQQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in the total neutrophil and band count in a patient after the onset of hemodialysis with a cuprophan membrane. There is a dramatic and rapid fall in the total neutrophil count (solid line) that reaches a nadir at 15 minutes and then gradually returns toward baseline. The initial phase of the recovery is due in part to a marked increase in the number of immature band forms (dashed line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kaplow, LS, Goffinet, JA, JAMA 1968; 203:133.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38285=[""].join("\n");
var outline_f37_24_38285=null;
var title_f37_24_38286="Umbilical granuloma";
var content_f37_24_38286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Umbilical granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary L Brandt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38286=[""].join("\n");
var outline_f37_24_38286=null;
var title_f37_24_38287="Scapular squeeze PI";
var content_f37_24_38287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scapular squeeze",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie on your back with your knees bent and feet flat. Your arms should be straight out, 6 to 12 inches (15 to 30 cm) away from the side of your body, with palms facing upward. Keeping your low back flat against the ground, squeeze your shoulder blades downward and towards each other, towards the spine. Make a conscious effort not to shrug your shoulders and keep the neck relaxed. You should feel the muscles between your shoulder blades contracting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_24_38287=[""].join("\n");
var outline_f37_24_38287=null;
